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Abstract
This thesis aims to investigate immunological and virological markers of HIV infection 
during pregnancy and to inform understanding of the impact of antenatal antiretroviral 
therapy (ART) regimens on such markers, using data from the European Collaborative 
Study (ECS). Since 1986, over 7,000 HIV infected pregnant women have been enrolled 
from 23 centres in 10 countries. Maternal information collected included timing and 
type of treatment regimen, repeated measurements on maternal CD4 counts and viral 
load (since 1987) and socio-demographic variables.
Repeated HIV RNA measurements over pregnancy in over 300 untreated women were 
examined using linear mixed effects (LME) models. Immunological (CD4) and 
virological changes over pregnancy in 162 women receiving highly-active ART 
(HAART) at conception and throughout pregnancy were examined with a piecewise 
LME model, using a conditional likelihood approach to account for left-censored 
measurements. A bivariate LME model was used to assess the correlation between the 
two markers. Viral response to initial HAART regimens in 240 ART-naive pregnant 
women was determined using interval censored regression, with a propensity score to 
reduce treatment allocation bias. A Cox regression model was used to assess the effect 
of HAART on risk of premature delivery, treating elective caesarean section deliveries 
as right-censored outcomes.
HIV RNA viral load was estimated to decrease over the second and third trimesters of 
pregnancy in untreated and treated women. Differences in levels of HIV RNA viral load 
and CD4 count by race and history of injecting drug use were identified. The rate of 
achieving undetectable viral load was greater for women initiating on nevirapine- 
containing HAART than for women on protease inhibitor-based HAART. There was no 
evidence of an increased risk of birth defects or prematurity associated with type or 
timing of HAART. These findings contribute to the evidence-base for management and 
understanding of HIV infection in pregnancy.
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Chapter 1 HIV infection in pregnancy
1.1 Introduction
By December 2006, more than 20 years into the human immunodeficiency virus-type 1 
(HIV) epidemic, an estimated 39.5 million people worldwide was living with HIV 
(UNAIDS 2006). Forty-five percent of these cases are made up of women; a 
demographic group in which the incidence of HIV infection is increasing (UNAIDS 
2006). There were an estimated 4.3 million adults and children newly infected with HIV 
in 2006, almost half a million more than in 2004, with the substantial majority of these 
new infections occurring in sub-Saharan Africa (UNAIDS 2006). A small subset, 24 
000, of these new infections relates to adults and children living in Western and Central 
Europe.
The rate of newly diagnosed cases of HIV infections reported in 2005 varied widely 
between the three sub-regions of Europe: the highest rate was observed in the East (186 
per million population), over twice that reported in the West (82 per million) and twenty 
times that in Central Europe (9.4 per million) (EuroHIV 2006). Similarly, the rates of 
new infections and prevalence of HIV varies widely between countries (EuroHIV 
2006;Hamers and Downs 2004), with estimates of newly diagnosed infections reported 
by the end of 2005 ranging from as low as 16.9 per million in Poland to as high as 242.5 
per million in Ukraine (EuroHIV 2006).
1.2 Epidemiology of HIV infection
By the time the first cases of acquired immune deficiency syndrome (AIDS) were 
reported in the early 1980s (Centers for Disease Control 1981;Barre-Sinoussi et al.
16
1983), HIV had already started to spread among homosexual and drug-user 
communities throughout Western Europe. It has been estimated that HIV incidence 
among homosexual men peaked in the period 1982-1984 and in 1987-1988 among 
injecting-drug users (Downs et al. 2000). The number of heterosexually acquired 
infections increased gradually during the late 1980s and early 1990s.
The epidemic has changed in more recent times and since the late 1990s there has been 
a gradual decrease in HIV diagnoses among injecting drug users and a substantial 
increase in people infected through heterosexual contact in Europe (Figure 1.1). 
Increasing heterosexual transmission in Western Europe has seen the proportion of new 
HIV diagnoses among women increase from 25% in 1997 to 38% in 2002; in 2005 
heterosexually-acquired infections accounted for 56% of new HIV diagnoses, with over 
half of these cases being among women (Hamers and Downs 2004;EuroHIV 2006). 
Figure 1.1 also shows the rising number of cases relating to heterosexual contact with 
people originating from countries with a generalised HIV epidemic, and in 2005 an 
estimated 60% of heterosexually-acquired infections were attributed to cases from a 
country with a serious HIV epidemic, particularly sub-Saharan Africa (EuroHIV 2006).
Although new HIV diagnoses in Central Europe are through similar routes to the West 
(albeit rarely through heterosexual contact with persons originating from countries with 
serious HIV epidemics), the story in Eastern Europe is very different; nearly 90% of all 
HIV cases in 2005 were reported from only two countries, the Ukraine and the Russian 
Federation, with injecting drug use the predominant transmission group (63%) in this 
region (EuroHIV 2006).
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Figure 1.1 HIV infections newly diagnosed by transmission group 1995-2005, 
European Union.
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The prevalence of HIV infection in pregnant women varies across Europe with 
estimates of antenatal prevalence ranging ffom a high of 0.48% in Estonia (2002 data) 
and >0.6% in Ukraine to as low as <0.03% among women in Finland (EuroHIV 2005). 
Intermediate levels (0.03-0.3%) of HIV prevalence were reported among women giving 
birth in Germany, Italy, Spain and the United Kingdom and among pregnant women in 
the Netherlands and Norway (EuroHIV 2005). A distinguishing trend in Europe has 
been the continuing increase since 2000 in prevalence among women giving birth: the 
prevalence of HIV among pregnant women living in England has increased from 0.11% 
in 2001 to 0.19% in 2004 and 0.22% in 2005, reaching levels similar to those found in 
eight regions of Spain (EuroHIV 2005;Health Protection Agency 2006). Rapid increases 
of HIV prevalence among pregnant women have been reported in Estonia (a five-fold 
increase since 2000) and Ukraine (doubling of prevalence since 2000, reaching 0.34% 
in 2004) (EuroHIV 2005). Estimates of antenatal prevalence also vary within countries, 
for example the prevalence in London (0.44%) is almost four times greater than in the
rest of the country (0.13%) (EuroHIV 2005;Health Protection Agency 2006). A large 
proportion of these are due to the larger migrant population (mostly from sub-Saharan 
Africa); in 2005 antenatal prevalence of HIV stood at 2.4% among women bom in sub- 
Saharan Africa, compared to 0.04% among UK-born women (Health Protection Agency 
2006).
The rates published by EuroHIV and the Health Protection Agency are based on 
surveillance data, a key instrument in monitoring the HIV epidemic in Europe and the 
UK. However, a major limitation is that they are based on reported HIV diagnoses and 
unlikely to be representative of HIV incidence (EuroHIV 2004;Hamers and Downs
2004). The patterns of reporting HIV diagnoses may have changed over time and may 
include infections that occurred several years previously and depend on the uptake of 
HIV testing. Additionally, comparisons made between countries based on these reported 
rates assume that the quality and coverage of national surveillance are comparable 
which may not always be the case. These factors should be taken into account when 
interpreting surveillance figures (EuroHIV 2004;Hamers and Downs 2004).
The European Collaborative Study (ECS), covering 23 regional centres in 10 countries, 
recently carried out an epidemiological analysis on 6,000 mother-child pairs to compare 
the HIV mother-to-child transmission epidemic between Western and Eastern Europe 
and found that in Western European centres between 1985-1989, the majority of HIV- 
infected women were white (93%) and mainly injecting drug users (79%) with a third 
aware of their infection before the time of conception (European Collaborative Study 
2006). The ECS results reflect the trends described above in the general HIV population 
and in the period 2000-2004 the number of black women had increased to 42% (mostly
19
originating from sub-Saharan Africa) and the number of infections acquired through 
injecting drug use (IDU) had decreased to 20% with a concurrent increase in 
heterosexually-acquired infections (European Collaborative Study 2006). Additionally, 
an increase in the median maternal age from 21.7 years to 31.7 years between these two 
periods was observed. HIV-infected pregnant women enrolling in the Ukraine ECS 
centres in the period 2000-2004 were more similar to women enrolled in the earlier 
period in Western Europe; mostly white (98%), of young maternal age (median 25.4 
years) and a large proportion acquiring HIV through injecting drug use or heterosexual 
contact with injecting drug users.
1.3 HIV infection and disease progression in adults
HIV is a Ribonucleic acid (RNA) virus, which targets the cell-associated immune 
system, particularly CD4 cells (Ho et al. 1995). Following primary infection, there is a 
period characterised by a lack of clinical symptoms, but accompanied by increasing 
virus and depleting levels of CD4 cells (Figure 1.2).
The main (M) group of HIV is responsible for most HIV infections in the global 
pandemic and is subdivided into nine subtypes (or clades) (Thomson et al. 2002). The 
most prevalent are subtypes B (found mainly in North America and Europe), A and D 
(found mainly in Africa), and C (found mainly in Africa and Asia). Increased HIV 
diversity has implications for diagnostic and treatment efficacy although data remain 
limited and most current HIV research remains focused on subtype B (Perrin et al. 
2003).
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Figure 1.2 A generalized graph of disease progression and the relationship 
between HIV RNA copies and CD4 cell counts over the average course of 
untreated HIV infection
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Without antiretroviral therapy (ART), immunosupression and the onset o f AIDS are 
inevitable and the risk o f opportunistic infection and other serious clinical symptoms 
becomes great. AIDS is diagnosed according to specific clinical and immunological 
criteria (Centers for Disease Control 1992) and left untreated the median time from 
seroconversion to the onset of AIDS is estimated to be 11 years (Collaborative Group 
on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action 
2000) and from AIDS to death around 2 years (Mocroft et al. 1997). A meta-analysis of 
38 studies of HIV-infected individuals before widespread use o f ART found time since 
seroconversion and age at seroconversion to be major determinants o f survival and 
development o f AIDS in Europe, although AIDS incidence varied significantly by mode 
o f acquisition (Collaborative Group on AIDS Incubation and HIV Survival including 
the CASCADE EU Concerted Action 2000).
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A female-to-male mortality rate ratio of 0.77 was also reported, but after restricting the 
analysis to the two main exposure categories of injecting drug use and heterosexual 
acquisition there was no longer any evidence of differences between men and women 
(Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE 
EU Concerted Action 2000). There was also no evidence of differences between men 
and women in terms of survival or of time to diagnosis of AIDS.
HIV-RNA viral load and CD4 cell counts
HIV RNA viral load represents the number of actively replicating HIV copies and is 
usually measured in blood plasma and serum. HIV RNA viral load is used as a 
biological marker of disease progression in HIV-infected individuals with high levels 
indicating primary infection or advanced disease progression (Figure 1.2) and is an 
important predictor for the risk of AIDS (Mellors et al. 1997;Sabin et al. 2000;Sterling 
et al. 2001). CD4 T-lymphocytes are the main target of HIV and hence their number 
declines as HIV infection progresses (Figure 1.2); they are therefore often used to 
monitor the extent of immune suppression in HIV-infected individuals and as an 
indicator of when to start or modify treatment.
The number of HIV RNA copies is assessed with the use of a variety of laboratory 
assays, which have a lower limit below which quantification is not possible. Assays 
today generally have a lower limit of detection between 500 and 20 copies/ml, while the 
older, less sensitive versions, had higher thresholds for detection, at between 2000-4000 
copies/ml. Viral load measurements below the specific threshold value for each assay 
are therefore left-censored at the detection limit, and the distributions of HIV RNA viral 
load over time tend to be positively skew.
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A large retrospective analysis of men with HIV carried out by the Multicenter AIDS 
Cohort Study (MACS) found higher levels of HIV RNA to be associated with larger 
decreases in CD4 count per year, with HIV RNA levels >30,000 copies/ml associated 
with a mean decrease in CD4 count of 70.5- 82.9 cells/mm3 compared to a mean 
decrease of 30.4-42.3 cells/mm3 among men with HIV RNA levels <500 copies/ml 
(Mellors et al. 1997). A study of 107 mostly untreated infected men observed for up to 
17 years in the UK found little evidence of a long-term period over which HIV RNA 
levels remain stable and in most cases levels increased soon after seroconversion; mean 
HIV RNA levels were estimated to be 3.26 logio copies/ml 1 year after seroconversion 
and estimated to increase by 0.11 logio copies/ml each year thereafter (Sabin et al. 
2000).
Studies on untreated men and women have shown lower HIV RNA viral loads to be 
associated with black ethnicity (Anastos et a l 2000;Saul et al. 2001) and the authors of 
these studies postulate ethnic differences in HIV clades, HLA haplotypes and other 
social and biologic factors as possible explanations for these findings. Some studies 
have also shown an association between persons with a history of IDU and lower viral 
load (Anastos et al. 2000;Touloumi et al. 2004), although an analysis from the Woman 
and Infant Transmission Study found no association between hard drug use (including 
IDU) and HIV RNA levels (Thorpe et al. 2004).
The aforementioned MACS (Mellors et al. 1997) compared the prognostic value of HIV 
RNA levels and CD4 lymphocytes and showed that the former marker was a better 
prognostic indicator of HIV disease progression than CD4 cell count. However, it 
concluded that a more accurate prognosis was only possible through the combination of
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the two markers. More recent studies have confirmed this through the use of bivariate 
models of these two markers, which have revealed better fits to the data than two 
separate univariate models (Boscardin et al. 1998;Thiebaut et al. 2002;Thiebaut et al.
2005).
1.4 Treatment of HIV infection with antiretroviral therapy (ART)
Zidovudine (ZDV), a nucleoside reverse-transcriptase inhibitor (NRTI) licensed in 
1987, was the first antiretroviral (ARV) drug used for the treatment of HIV infection 
(Fischl et al. 1987). Additional NRTIs and two further drug classes, non-nucleoside 
reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) were subsequently 
developed and the principal drug names for these classes are given in Table 1.1 
(AIDSinfo 2007).
Table 1.1 Principal antiretroviral agents by drug class
Nucleoside reverse transcriptase 
inhibitors (NRTI)
Non-nucleoside 
reverse transcriptase 
inhibitors (NNRTI)
Protease inhibitors (PI)
Zidovudine (AZT) Efavirenz (EFV) Ritonavir (RTV)
Didanosine (ddl) Nevirapine (NVP) Indinavir (IDV)
Lamivudine (3TC) Delavirdine (DLV) Nelfinavir (NFV)
Stavudine (d4T) Saquinavir (SQV)
Abacavir (ABC) Atazanavir (ATZ)
Zalcitabine (DDC) Amprenavir (APV)
Tenofovir (TDF) Fosamprenavir (FSV) 
Lopinavir (LPV)*
- LPV is co-formulated with low-dose RTV
These different drug classes target the viral replication cycle at different stages to
disturb replication of the virus, e.g. Pis disturb the cycle by inhibiting the activity of the
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enzyme, protease. More recently, enfiirtivide (T-20), a fusion inhibitor (FI), has been 
developed and additional new therapies for HIV-1 infection, such as the CCR5 
antagonists, are now in advanced stages of clinical development (Repik et al. 2007).
Subsequent evidence indicated that the benefits of ZDV monotherapy in HIV-infected 
individuals were small, and short-lived (Fischl et al. 1989). Consequently, two large 
randomised controlled trials carried out in 1996 demonstrated that initiation of treatment 
with a combination of two ARVs (dual therapy) delayed disease progression for longer 
than treatment with ZDV alone (Delta Study 1996;Hammer et al. 1996). Highly active 
antiretroviral therapy (HAART) generally consists of at least three potent antiretroviral 
drugs, usually involving at least one PI or NNRTI in addition to a NRTI ‘backbone’. 
HAART was introduced in 1996 and was found to delay disease progression, reduce 
HIV replication and increase CD4 cell counts further than with two drug combinations 
only (Collier et al. 1996). The use of HAART in developed countries is now widespread 
and is the standard of care for the HIV-infected population in this setting (Gazzard et al. 
2006;DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents 2006). 
Additionally, guidelines now advise that Pi-based HAART regimens (usually including 
the Pis SQV or FSV) be ‘boosted’ with the PI RTV, as they have been shown to be 
superior to Pis alone (Walmsley et al. 2002).
1.5 Mother-to-child transmission of HIV
The first cases of AIDS in children were reported in 1982 (Centers for Disease Control 
1982); in 2003 alone, 630,000 children acquired HIV, mostly through mother-to-child 
transmission (MTCT). MTCT can occur during pregnancy, at the time of delivery or 
postnatally through breastfeeding (Newell et al. 2002). Intra-uterine transmission may
25
occur as a result of fetal exposure to cell-free and/or cell-associated HIV in amniotic 
fluid and through infection of the placental cells and/or disruption of the integrity of the 
placenta (as evidenced by the association of an increased risk of MTCT with 
chorioamnionitis (Mofenson et al. 1999) and amniocentesis (Mandelbrot et al. 1996)). 
Mechanisms of intrapartum transmission include microtransfusions between maternal 
and fetal blood circulation and the ascension of HIV infection from the vagina and 
cervix to amniotic fluid and the fetus after rupture of membranes (Mwanyumba et al. 
2002;Tuomala et al. 2003). A substantial amount of intrapartum transmission may occur 
through direct contact between the infant passing through the birth canal and infective 
cervicovaginal secretions and blood. Prior to therapeutic interventions, reported MTCT 
rates ranged from 15 to 20% in Europe, 13-25% in the USA, 25-40% in Africa to 13- 
48% in South and South East Asia (European Collaborative Study 2001;The Working 
Group on Mother-To-Child Transmission of HIV 1995). These geographical differences 
can be attributed to varying infant feeding practices and underlying population 
characteristics.
1.5.1 Prevention of mother-to-child-transmission (PMTCT)
In Europe today, effective interventions used in the prevention of MTCT (PMTCT) 
include elective caesarean section (CS), antenatal ART, perinatal and neonatal 
prophylaxis and the avoidance of breastfeeding. Table 1.2 highlights the trends in 
strategies for PMTCT in Europe and the associated reductions in MTCT rates over time.
Maternal plasma HIV RNA level is the strongest individual risk factor for MTCT 
(European Collaborative Study 1999;Cooper et al. 2002;Ioannidis etal. 2001;Mofenson 
et al. 1999). The ECS showed that the risk of MTCT was doubled for every unit
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increase in logio RNA with a predicted MTCT rate of 45% at 1,000,000 copies/ml, 
compared with 8.7% at 1000 copies/ml (European Collaborative Study 1999). It has 
also been shown that primary infection during pregnancy, severe immunodeficiency and 
symptomatic HIV infection, themselves associated with high viral loads, increase the 
risk of transmission (Ioannidis et a l 2001;Cooper et al. 2002;Mofenson et al. 1999). 
For these reasons, preventative measures to reduce MTCT generally focus on, but are 
not limited to, reducing HIV RNA levels by the time of delivery using ART and 
HAART. Obstetric factors which increase the risk of MTCT include vaginal delivery 
and prolonged duration of rupture of membranes (European Collaborative Study 
1999;Intemational Perinatal HIV Group 2001;European Collaborative Study 2005b). 
The use of elective CS delivery has been associated with a two-thirds reduction in the 
risk of transmission, compared to that with vaginal deliveries (European Collaborative 
Study 1999;European Mode of Delivery Collaboration 1999). In an analysis of the ECS, 
emergency CS delivery was associated with a 25% reduction in risk, however, there 
were no cases of transmissions in children who were delivered by emergency CS with 
intact membranes (European Collaborative Study 2005b); the International Perinatal 
HIV Group estimated a 2% increase in the risk of MTCT with every hour increase of 
duration of ruptured membranes in women delivering by vaginal or emergency CS 
delivery (International Perinatal HIV Group 2001).
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Table 1.2 Prevention of MTCT in Europe
1985 • First report indicating possible MTCT through breast milk (Ziegler et al 1985)
Pre-1994 • No antiretroviral prophylaxis for the prevention of MTCT
• Limited data in the early 1990s indicate a 14% additional risk of transmission from 
breast milk, over and above that of risk in utero and during delivery (Dunn et al.
1992)
• Avoidance of breastfeeding recommended (World Health Organisation 2005)
• MTCT rates in Europe 15-18% (ECS 1996;Gabiano et al. 1992)
1994 • Results of the ACTG 076 randomised placebo-controlled trial (Connor et al 1994)
• Prophylactic three-part regimen of ZDV monotherapy
• Antenatal oral ZDV started between 14 and 26 weeks’ gestation
• Intravenous ZDV during labour
• Neonatal ZDV for 6 weeks postpartum
• MTCT rate at 18 months: 8.3% in the ZDV group and 25.5% in the placebo 
1994-1996 • Clinical practice quickly changed in developed countries
• Rapid uptake and widespread use of ZDV monotherapy for prevention of MTCT 
(ECS 1998;Cooper et al. 1996)
• MTCT rate in Europe of 5-8 % for non-breastfeeding population (European 
Collaborative Study 1998;Mayaux et al. 1997b)
1997 • More potent antiretroviral regimens (including HAART) become available and
are increasingly prescribed among adults in Western Europe
• Limited use of HAART in pregnancy at this time
1999 • Results of the European Mode of Delivery Collaboration randomised trial
(European Mode of Delivery Collaboration 1999)
• Women randomised to elective CS or vaginal delivery
• Elective CS delivery before labour and before rupture of membranes associated with a 
two-thirds reduction in the risk of MTCT
2002 • Results of the PACTG 316 placebo-controlled trial (Dorenbaum et aL 2002)
• Included women receiving any antenatal ART regimens excluding NNRTI class of 
drugs (mono, dual or HAART)
• Additionally, oral single-dose nevirapine to women after onset of labour and 
postpartum to neonate
• MTCT rate of 1.4% in nevirapine group and 1.6% in placebo group
• No additional benefit from intrapartum/neonatal nevirapine
• However, confirmed effectiveness of antenatal ART
• European consensus guidelines on pregnancy and HIV infection updated (Newell et 
al 2002)
• ZDV-containing HAART, with type and timing of regimen dependent on clinical 
status
• Intrapartum intravenous ZDV and neonatal ZDV for 4-6 weeks
• Women recommend to have an elective CS
• Avoidance of breastfeeding
2002-2005 • Antenatal HAART use widespread among Europe (Italian Register for Human
Immunodeficiency Virus Infection in Children 2002;European Collaborative Study 
2005b):
• 85% of women enrolling in the ECS in 2003 receiving HAART pre-pregnancy (ECS 
2005b)
• MTCT rates of less than 2% reported in Europe (ECS 2005b)
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On the other hand, CS is also associated with a higher rate of post-partum complications 
among HIV-infected women than vaginal deliveries (Read et al. 2001a) and it has been 
suggested that elective CS to reduce the risk of MTCT may not carry an additional 
benefit for women receiving HAART with undetectable viral load near the time of 
delivery (Boer et a l 2007). Nevertheless, findings from several observational studies 
have confirmed the independent effect of elective CS in reducing the risk of MTCT for 
women receiving HAART with low viral loads (Ioannidis et al. 2001;Cooper et al. 
2002;European Collaborative Study 2005b). European guidelines recommend that 
elective CS should be scheduled for 38 weeks gestation, rather than 39 weeks, to avoid 
the initiation of labour or the rupture of membranes (Newell et al. 2002;British HIV 
Association 2005).
1.5.2 ART in PMTCT
ART reduces the risk of MTCT by decreasing viral replication, and thus plasma viral 
load in the woman. Additionally, for drugs which cross the placenta, mostly the reverse 
transcriptase inhibitors such as ZDV, nevirapine (NVP) and lamivudine (Mirochnick 
2000;Mandelbrot et al. 2001b), they act as post-exposure prophylaxis of the neonate 
during and after exposure to the virus. The results of the AIDS Clinical Trial Group 
(ACTG) 076 trial in 1994 showed the efficacy of ZDV use in PMTCT and marked the 
beginning of the widespread use of ART during pregnancy (Table 1.2). There have 
since been many advances in the therapeutic management of HIV disease and MTCT in 
Europe (Table 1.2), notably the introduction of HAART.
Although, it has not been possible to evaluate the effectiveness of antenatal HAART in 
the prevention of MTCT in randomised placebo-controlled trials, its effectiveness has
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been confirmed with data from observational studies (Cooper et a l 2002;European 
Collaborative Study 2005b). In the Women and Infants Transmission Study, the MTCT 
rate was 20.0% for women not receiving any antenatal ART, 10.4% for women 
receiving ZDV monotherapy, 3.8% for women /eceiving dual-therapy and 1.2% for 
women on HAART (Cooper et a l 2002). The Italian Register also reported a decline in 
the transmission rate over time, from 15.5% in the period 1985-1995 to 2.4% in the 
period 1996-1999, when combination prophylactic ART and elective caesarean delivery 
were combined (Italian Register for Human Immunodeficiency Virus Infection in 
Children 2002). The ECS has reported similar trends, and with the appropriate 
prophylactic interventions in place, MTCT rates are now as low as 1% (European 
Collaborative Study 2005b;European Collaborative Study 2006).
1.6 HIV in pregnancy
Pregnancy is associated with relative immunosuppression to protect the fetus from 
maternal rejection (Wegmann et a l 1993;Castilla et a l 1989). This pregnancy- 
associated decline in immune responses has also been associated with an increased 
frequency of infectious diseases, including viral infections such as influenza and 
varicella (Rich et a l 1995;Pickard 1968;Greenberg et a l 1958) and with the 
modification of the course of diseases with an immunological component, such as 
systemic lupus erythematosus (Tincani et a l 1991). This has raised concern that 
pregnancy itself might also impact on disease progression in HIV-1-infected women.
A systematic review and meta-analysis of studies of ART-naive women between 1983 
and 1996 found a significant association between the effect of pregnancy and disease 
progression, albeit not a strong one and a further sensitivity analysis revealed this
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association to be significantly less common in developed countries (French and 
Brocklehurst 1998). More recent studies carried out have found no deleterious effect of 
pregnancy on HIV disease progression (Weisser et al. 1998;Bessinger et al. 1998;Saada 
et al. 2000), but focused mainly on clinical outcomes. Given that CD4 cell counts, are 
extremely informative of immune depression, several studies have been carried out to 
examine the impact of pregnancy on levels of CD4 counts in HIV-infected women 
(ECS and Swiss Cohort and European Collaborative Study and the Swiss HIV 
Pregnancy Cohort 1997;Ibrahim et al. 2004;Bums et al. 1996)
1.6.1 CD4 cell counts during pregnancy
A joint analysis by the ECS and the Swiss HIV Pregnancy Cohort investigated 
immunological markers of disease progression in more than 400 untreated pregnant 
women (ECS and Swiss Cohort and European Collaborative Study and the Swiss HIV 
Pregnancy Cohort 1997). The pattern of CD4 counts was shown to change non-linearly 
with time during and after pregnancy; the mean CD4 count was seen to decline to its 
lowest level six months prior to delivery and subsequently increased until delivery; a 
sharp increase in the average CD4 count was subsequently observed until three months 
post-delivery, with the average dropping to baseline six months postpartum. CD4 
percentage, expressed as a percentage of absolute lymphocyte counts, was stable during 
pregnancy, suggesting that pregnancy-related changes in total lymphocyte counts may 
be responsible for the changes seen in CD4 counts. (ECS and Swiss Cohort and 
European Collaborative Study and the Swiss HIV Pregnancy Cohort 1997). 
Additionally, a South African cross-sectional study comparing lymphocyte changes in 
pregnancy and postpartum between HIV-infected and uninfected women found that that 
CD4 counts did not decrease significantly during pregnancy; however, among the
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infected women, there was a significant increase in postpartum CD4 cell counts 
compared to those in the third trimester (Ibrahim et al. 2004). It has been suggested that 
haemodilution, an increase in the volume of cell-free solution, during a normal 
pregnancy leads to a decrease in the number of CD4 lymphocytes (Castilla et al. 1989); 
the mechanisms behind changes in the cellular immune system in pregnancy are not 
well understood and the relevance for women with HIV-infection is unclear.
1.6.2 HIV-RNA viral load during pregnancy
As the most important predictor for MTCT and disease progression, a number of studies 
have examined HIV RNA levels during pregnancy and postpartum and these have been 
summarised in Table 1.3. Most of these studies revealed stable levels of HIV RNA 
during pregnancy followed by varying degrees of increases in HIV RNA levels 
postpartum. The stable levels during pregnancy would suggest that any deleterious 
effect of a decline in certain immune responses during pregnancy is offset by other 
'immunologic changes, e.g. alterations in cytokines, which are important 
immunomodulators that reportedly play an important role in modifying HIV replication 
(Fauci 1996). Physiologic and hormonal changes during pregnancy, such as elevated 
oestrogen/progesterone levels and haemodilution, could also impact on the stimulation 
of HIV replication; such elevated hormone levels are reversed after delivery leading to 
increased levels postpartum. It has also been suggested that the observed increases in 
viral load postpartum in treated women could be due to the emergence of viral 
resistance and poorer adherence (Watts et al. 2003;Ickovics et al. 2002).
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Table 1.3 Features of studies investigating HIV RNA levels in pregnancy and postnatally
Author (yr)
Mayaux et al. (97)
Cao et al. (97)
Melvin et al. (97)
O’Shea et al. (98)
Time Data source 
period
#s with
viral
load
Statistical Methods Treated/
Prophylaxis
Summary of results Limitations
89-94 SEROGEST, 
France
320
93-97 ARIEL, 
USA
204
91-95 NW Family 
center,
Washington, US
Europe
44
38
Paired Wilcoxon 
rank-sum
Paired Wilcoxon 
rank-sum and linear 
regression
Paired Wilcoxon 
rank-sum and 
Mann-Whitney U
21% ZDV 
(removed 
from analysis 
after
initiation)
85% ZDV
61% ZDV
Paired comparisons 12.6% ZDV
-No significant variation 
during pregnancy, 
postpartum values lower 
-Highest HIV RNA level 
observed during 
pregnancy lower in 
African women
- -2 copies/ml a day 
decrease in HIV RNA 
during pregnancy 
compared to increase of 6 
copies postpartum
- did not vary during 
pregnancy in regression 
-Stable HIV RNA during 
pregnancy and at 6 weeks 
postpartum in both ZDV 
and untreated groups
-For 19 untreated 
women, relatively stable 
HIV RNA during 
pregnancy, no consistent 
pattern in direction of 
change
- Did not adjust 
for confounders
- Ignored repeated 
measures
- Mostly treated 
women
-Ignored repeated 
measures 
-only measures 
from third trim 
and delivery
- Small numbers
- Did not adjust 
for confounders 
-Ignored repeated 
measures
- Small numbers
- Did not adjust 
for confounders 
-Ignored repeated 
measures
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Table 1.3 contd.
Author (yr) Time Data source #s with Statistical Methods Treated/
'_____________ period___________________ VL_________________________ Prophylaxis
Summary of results Limitations
Bums et al. (98) 86-95 Mothers and 
Infants Cohort 
Study, USA
160
Watts et al. (03) 93-97 PACTG 185, 
USA
493
Ekpini et al. (02) 96-98 Abidjan, Cote 
d’Ivoire
49
Longitudinal 
random effects 
model
Repeated measures 
linear regression
Paired Wilcoxon 
rank-sum and 
Mann-Whitney U
4% ZDV 
during 
pregnancy, 
26% ZDV or 
DDI
postpartum
86%
69% ZDV 
between 3
- Overall HIV RNA rose 
significantly during study 
period (early pregnancy 
to 2 years postpartum)
- however, slope of HIV 
RNA during pregnancy 
and 1st year postpartum 
not different from zero
- Consistent but non­
significant decrease in 
HIV RNA during 
pregnancy, followed by 
modest significant 
increase during 12 weeks 
postpartum
-in untreated women,
HIV RNA varied 
between -0.08 to 0.23 
logio copies/ml during 
pregnancy but not 
significantly different 
from baseline
-only 213 
measurements 
during pregnancy
-mostly treated 
women
-small numbers of 
untreated women 
- Did not adjust 
for confounders 
-Ignored repeated 
measures
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However, the increases in viral load postpartum observed for both untreated and treated 
women (Cao et al. 1997;Watts et al. 2003) suggest that these are insufficient 
explanations for these increases.
Most studies of HIV RNA viral load and CD4 cell changes in pregnancy to date have 
included only small numbers of women and larger studies of both treated and untreated 
women are necessary to better understand the variation of these markers during 
pregnancy, particularly with regard to changes under HAART treatment. Importantly, 
studies of viral load during pregnancy did not report adjustment for maternal immune 
status, and as revealed in studies of non-pregnant adults (Mellors et al. 1997;Boscardin et 
al. 1998;Thiebaut et al. 2002;Thiebaut et al. 2005), the combination of HIV RNA viral 
load and CD4 cell counts is essential in understanding not only the true underlying 
relationship between the two markers, but also their association with other factors such 
as ART. However, to date there have been no studies to examine CD4 cell counts and 
HIV RNA viral load during pregnancy using appropriate bivariate statistical methods.
1.7 ARVs and adverse events in pregnant women
With increasing numbers of women becoming pregnant while receiving HAART or 
initiating treatment in the early stages of pregnancy (European Collaborative Study 
2001;Cooper et al. 2002;Watts et al. 2004a), concerns have been raised relating to the 
potential impact on pregnancy outcome and safety issues for the mother and the exposed 
infant.
1.7.1 Pregnancy and neonatal outcomes
In 1998, a Swiss study assessing the safety of ART in pregnancy reported a 33% 
prematurity (<37 weeks) rate among newborns exposed to antenatal HAART (Lorenzi et
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al. 1998). The association between antenatal HAART use and premature delivery has 
since been confirmed with data from several European observational studies (ECS and 
Swiss Cohort and European Collaborative Study and the Swiss HIV Pregnancy Cohort 
2000;European Collaborative Study 2003;Townsend et al. 2007b). These findings are 
consistent with the hypothesis that an immunological mechanism may underlie the 
association between antenatal HAART and pregnancy duration, that is that prematurity is 
caused by the early onset of labour/delivery rather than being of fetal or uteroplacental 
origin. (Fiore et al. 2006). Although some US Studies have reported similar findings of 
an increased risk of prematurity with antenatal HAART use (Cotter et al. 2006;Schulte et 
al. 2007), others have not (Cooper et al. 2002;Tuomala et al. 2002;Tuomala et al. 2005). 
The discrepancy may be partly explained by differences in study populations (in terms of 
illicit-drug use as well as HIV infection) and by the lack of detailed data on prenatal 
ART use in the American studies (Thome et al. 2003). A recent meta-analysis of 
published studies on HAART and prematurity in the US and Europe reported a 
significant degree of heterogeneity between studies confirming these differences (Kourtis 
et al. 2007); however further work is needed to ascertain the source of these differences.
In an analysis of the ECS, involving 319 infants with in utero HAART exposure out of a 
total of 2326 mother-child pairs, HAART without or with a PI was associated with a 2.66 
and 4.14-times greater risk of prematurity respectively, compared to those with no 
exposure, after adjusting for maternal CD4 count, age and IDU (European Collaborative 
Study 2003). Recent studies have reported conflicting findings on whether antenatal PI- 
based HAART regimens are associated with an increased risk of prematurity compared 
to HAART without a PI (Cotter et al. 2006;Schulte etal. 2007).
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In light of the finding of an association between HAART use during pregnancy and an 
increased risk of prematurity, some European centres have operated a policy of 
scheduling elective CS deliveries at 36-37 weeks to avoid initiation of labour or rupture 
of membranes and emergency CS delivery (Newell et al. 2002).
The use of HAART during pregnancy, particularly in the early stages when 
organogenesis is taking place, has raised concerns relating to teratogenicity. Although 
human data have shown no evidence of an increased risk of congenital abnormalities 
associated with ZDV prophylaxis (European Collaborative Study 2003), most of the 
ARV drugs in these regimens have not been tested extensively in humans for teratogenic 
potential. However, efavirenz has been associated with teratogenicity in animal studies 
(Nightingale 1998) and there have been reports of neural tube defects in children with 
neonatal exposure to efavirenz in the first trimester of pregnancy (De Santis et al. 2002). 
It has therefore been recommended that efavirenz be avoided in the first trimester of 
pregnancy and that women of childbearing age be offered pregnancy testing before 
initiating therapy with this drug, and counselling on the need to be on effective 
contraception to avoid pregnancy throughout treatment (Public Health Service Taskforce 
2006b).
Although limited to a small sample size including only few women initiating treatment in 
early pregnancy, a retrospective study found an increased risk of malformations in 
infants exposed to PneumoCystis jiroveci pneumonia (PCP) prophylaxis and 
combination of ART in the first trimester (Jungmann et al. 2001). A European study 
focusing on the health of uninfected infants exposed to ART in-utero, observed a 1.4% 
prevalence of congenital abnormalities in those infants ARV-exposed (mainly to 
mono/dual therapy), similar to the 1.6% seen in those not exposed (European
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Collaborative Study 2003). The National Study of HIV in Pregnancy and Childhood, a 
paediatric and obstetric surveillance system in the United Kingdom and Ireland, reported 
relatively higher rates of congenital abnormalities than the ECS, but did not find a 
significant difference between children exposed to ART in-utero (3.4%) and those who 
were not (2.2%). There was also no increased risk associated with exposure in the first 
trimester, compared to exposures in the second or third trimester of pregnancy 
(Townsend et al. 2006).
The Antiretroviral Pregnancy Registry (APR), based in the United States, was 
established by the pharmaceutical industry in 1988 in order to monitor exposures to ART 
during pregnancy and to assess the risk of major birth defects (Antiretroviral Pregnancy 
Registry Steering Committee 2004). The APR has not identified any specific teratogenic 
risk associated with any particular class of ARV drugs with data on 3583 live births 
reported to date (Antiretroviral Pregnancy Registry Steering Committee 2004;Covington 
et al. 2004;Watts et al. 2004b). In addition, there was no significant difference in the risk 
of congenital abnormalities between first trimester exposure to ART and later exposures 
(Watts et al. 2004b). However, data from case report registries such as the APR have 
limitations, such as sample size restrictions, potential classification and reporting bias, 
potential ascertainment bias and generalisability to the population of pregnant women 
with ART exposure worldwide; these factors need to be considered when interpreting the 
results of studies from the APR.
1.7.2 Risk for pregnant women
Results from some studies have also raised concerns about the safety of using certain 
classes of ARVs and specific drugs in pregnant woman with regard to their own health 
(Hitti et al. 2004;Sarner and Fakoya 2002;Mandelbrot et al. 2003;Food and drug
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administration 2005;British HIV Association 2005;Coll O et al. 2005;Watts et a l 
2004a).
Severe, and in some cases fatal, hepatotoxicity has been reported in non-pregnant HIV- 
infected patients receiving NVP-containing HAART (Baylor and Johann-Liang 2004). 
Symptoms range from hepatitis to hepatic failure and also include hypersensitivity skin 
reactions. Women are at a greater risk than men of developing such adverse reactions, 
which occur during the initial weeks of therapy, although the risk may continue for the 
duration of exposure (Mazhude et al. 2002;Bersoff-Matcha et al. 2001). There appears to 
be a strong association between the level of immunosuppression of the individual at the 
time of initiation of treatment and the likelihood of NVP -related hepatotoxicity (with 
women with CD4 cell counts >250 cells/mm3 and men with >350 cells/mm3 at increased 
risk than women and men with lower counts) (Stem et al. 2003). In the Pediatric AIDS 
Clinical Trials Group 1022, pregnant women were randomised to receive either NVP or 
nelfinavir, with lamivudine plus ZDV (Hitti et al. 2004), however the study was 
suspended after the enrolment of only 38 women due to greater than expected toxicity in 
the NVP group of 29% vs. 5% in the nelfinavir group; all the women with adverse events 
in the NVP arm had baseline CD4 counts >250 cells/mm3 and none had a history of 
hepatitis B or C. However, there is conflicting evidence on the relationship between 
baseline CD4 counts and NVP-related hepatotoxicity (Manfredi et al. 2005;Manfredi and 
Calza 2006). Although data are lacking on whether or not the use of NVP-containing 
HAART during pregnancy is associated with an increase in the risk of hepatotoxicity, 
US and WHO recommendations express caution in the use of long-term NVP-containing 
HAART for pregnant women with CD4 cell counts 250-350 cells/mm3 (Public Health 
Service Taskforce 2006a; World Health Organisation 2006).
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There have also been case reports of lactic acidosis in pregnant women receiving 
HAART including a combination of stavudine and didanosine from before conception; 
these included some maternal deaths (Samer and Fakoya 2002;Mandelbrot et a l 2003). 
It is therefore recommended that this drug combination is avoided during pregnancy 
(Food and drug administration 2005;British HIV Association 2005). Additionally, there 
have been reports of an increased risk of pre-eclampsia among women on HAART 
(Wimalasundera et a l 2002;Coll O et a l 2005) and also of glucose intolerance and 
gestational diabetes among women on HAART, particularly those receiving Pis (Watts 
et a l 2004a).
The risk of emergence of viral resistance to ARV drugs is increased when viral 
replication is only partially suppressed, for example, with sub-optimal therapies or with 
poor adherence to treatment regimens. The risk is also present for women who 
commence ART in pregnancy to reduce the risk of MTCT (and who do not require 
therapy for their own health) and discontinue therapy postpartum. Emergence of viral 
resistance is particularly common for those drugs where a single mutation is associated 
with resistance, such as lamivudine and NVP (Mandelbrot et a l 2001a;Lyons et a l 
2005;0verton et a l 2005). The use of NVP -containing HAART in preventing MTCT 
has been associated with high levels of resistance (Lyons et a l 2005;0verton et a l 
2005). A recent study in Ireland reported 7 primary mutations among five (13%) ART- 
naive women who received therapy during pregnancy; all of these women received NVP 
-containing HAART (Lyons et a l 2005). Another study reported the finding of an 
association between the use of ZDV plus lamivudine for more than 8 weeks in pregnancy 
and a 50% risk of developing resistance (Mandelbrot et a l 2001a).
40
1.8 Statistical methods
Observational studies of HIV-infected pregnant women with prospective follow-up 
provide repeated measurements on HIV RNA viral load and CD4 cell counts which are 
non-independent due to within-subject correlation. Random effects are often used to deal 
with repeated measures (Laird and Ware 1982), but there are several additional issues in 
the analysis of longitudinal data of HIV markers. These include left-censoring of HIV 
RNA viral load, non-uniform intervals for measurements of CD4 cell counts and HIV 
RNA viral load, correlation between these HIV markers and determination of the 
functional form of non-linear patterns over pregnancy.
HIV RNA viral load data are subject to left-censoring where the true, unknown value is 
below the lower threshold level for detection. Moreover, with the widespread use of 
antenatal HAART during pregnancy, the proportion of infected women with 
undetectable levels of HIV RNA has increased (European Collaborative Study 
2001;Read et al. 2001a;Cooper et al. 2002). Relatively crude methods used in dealing 
with left-censoring of HIV RNA measurements include taking either the quantification 
limit or half of this limit; this is more problematic with older versions of assay systems, 
which have higher thresholds for detection between 2000-4000 copies/ml. These 
methods can lead to biased parameter estimates with inflated standard errors, and more 
advanced methods to account for the presence of left-censoring are preferable (Hughes 
1999).
Observational data reflect clinical practice, in that patients are not always enrolled at the 
same time and the frequency of and interval between clinic visits may differ between and 
within patients. When there is a difference in the frequency of follow-up between 
treatment groups or other variable of interest, bias can be introduced; the use of interval-
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censored methods to account for non-uniform measurement intervals will improve the 
accuracy of treatment comparison estimates (Lindsey and Ryan 1998).
Univariate linear mixed effects models of HIV RNA and CD4 cell count data are 
extremely informative, but do not appropriately allow for the intrinsic correlation 
between the two markers; bivariate modelling of these has been shown to provide a 
better fit to such data and can also allow for the incorporation of the left-censoring of 
HIV RNA data (Thiebaut et al. 2005). Additionally, the changes in HIV RNA levels and 
CD4 cell counts over the course of infection are not necessarily linear (Mellors et a l 
1997;Sabin et al. 2000), particularly among those receiving HAART (Fitzgerald et al. 
2002;Thiebaut et al. 2005;Thiebaut et al. 2006) and the use of piecewise, polynomial and 
cubic spline models (Naumova et al. 2001;Lyles et al. 1999;Gurrin et al. 2005) may be 
essential in capturing the true underlying functional form of these markers over 
pregnancy.
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1.9 Key points
• There has been an increase in the number of heterosexually-acquired HIV 
infections in Europe with women accounting for over half of these cases in 
2005 and an increase in the number of infected women from sub-Saharan 
Africa.
• Available data on whether increasing gestation may impact on HIV RNA are 
limited, based on mostly treated women and suggest that viral load remains 
stable during pregnancy, increasing in the early postpartum period.
• In the absence of clinical trials, data from observational cohorts have 
confirmed the effectiveness of antenatal HAART in PMTCT, but data are 
lacking regarding the optimal approach to therapeutic management in 
pregnancy.
• The natural dynamics of markers of HIV RNA and CD4 cell counts during 
pregnancy are poorly understood.
• Studies of HIV RNA and CD4 levels in treated women are limited, focusing 
mainly around the time of delivery.
• There is conflicting evidence on whether the use of HAART with a PI is 
associated with an increased risk of premature delivery compared to that 
associated with NNRTI-based HAART.
• There has been no evidence to date to suggest an association between 
antenatal HAART and an increased risk of congenital abnormalities.
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C hapter 2 A im s and M ethods
2.1 Rationale for this work
There have been two major developments in the care of HIV-infected pregnant women 
in recent years. Firstly, the rate of MTCT has decreased to levels as low as 1% in 
developed countries where HAART and other interventions are available (European 
Collaborative Study 2006). Secondly, the widespread use of HAART has changed the 
clinical course of HIV/AIDS with significant improvements in AIDS-free survival and 
quality of life (Porter et al. 2003;Mocroft et al. 2003). These developments help explain 
the observed increase in likelihood of further live births in HIV-infected women in 
recent years (European Collaborative Study 2005a;Bryant etal. 2007).
In the beginning of the epidemic, the focus of studies relating to HIV infection in 
pregnancy concentrated on elucidating the rates of and risk factors for MTCT and the 
implications of pregnancy on HIV disease status in the short or longer term were 
somewhat overlooked. With the routine use of HAART for PMTCT now commonplace 
in resource-rich settings, concerns that ARVs may be teratogenic, especially when used 
in the first trimester, and that their use in pregnancy may increase the risk of prematurity 
have shifted the focus to the unborn child. However, the use of ART in pregnancy 
serves the best interest of both mother and child by reducing maternal viral load and 
thereby reducing the risk of MTCT (European Collaborative Study 2005b;Mofenson et 
al. 1999) and also slowing maternal disease progression (Mellors et al. 1997). The HIV 
epidemic is increasingly affecting women of reproductive age (UNAIDS 2006), with a 
concurrent increase in the numbers of infected women taking highly potent, complex 
combinations of drugs throughout pregnancy, often initiated before or in early
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pregnancy. The impact of these drugs and their various combinations on pregnancy 
outcome, maternal and neonatal health and immunological/virological outcomes in 
pregnancy is unclear. Over the past decade there have been major changes in the 
characteristics of the HIV infected pregnant population in Europe, with a shift in mode 
of acquisition from IDU to heterosexually acquired infection (particularly in women 
from sub-Saharan Africa) (Hamers and Downs 2004;EuroHIV 2004), and the 
interaction of these changes on treatment outcome have not been fully explored.
Few data are available to indicate whether the risk of congenital abnormalities is 
increased by first trimester exposure to ARVs and/or by the use of HAART. Clinical 
trials in humans typically exclude pregnant women and many drugs have few or no data 
available on their safety in pregnancy, including teratogenicity (Public Health Service 
Taskforce 2006b). European observational studies have shown an increased risk of 
premature delivery associated with antenatal combination ART (Lorenzi et al. 
1998;ECS and Swiss Cohort and European Collaborative Study and the Swiss HIV 
Pregnancy Cohort 2000;European Collaborative Study 2003). Recent studies from 
Brazil and the US have also examined the impact of Pi-based HAART on increased risk 
of prematurity, but mostly with reference to none or mono/dual therapy only (Szyld et 
al. 2006;Schulte et al. 2007;Cotter et al. 2006). Data are lacking on whether the use of 
Pi-based HAART increases the risk of prematurity over and above that associated with 
NNRTI-based HAART.
Since the beginning of the epidemic, the relationship of pregnancy to immune and 
physiological alterations has given rise to questions about its effect on HIV disease, 
both in the short term (during gestation itself) and the effect it may have on HIV disease
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progression subsequent to delivery. Data are lacking on the dynamics of virological and 
immunological markers during pregnancy both in the absence of treatment and in 
women on stable HAART. Understanding the dynamics of these markers in pregnancy 
will facilitate the interpretation of changes in these markers among HIV-infected 
pregnant women receiving HAART at conception, and may be useful for examining 
treatment response in pregnancy.
A substantial minority of women in developed settings are diagnosed following 
antenatal testing and started on antiretroviral drugs for delaying their own disease 
progression and/or prevention of MTCT for the first time in pregnancy (European 
Collaborative Study 2005b). To date, there have been no clinical trials in this setting to 
address the questions of when HAART should be started in pregnancy and which 
regimens are more effective for optimal viral response in this group of ARV-naive 
pregnant women.
2.2 Aims and Objectives
Aims
This thesis aims to investigate immunological and virological markers of HIV infection 
during pregnancy and to inform understanding of the impact of antenatal antiretroviral 
therapy regimens on such markers, while also assessing the presence of treatment- 
related adverse pregnancy outcomes
46
Objectives
1. To model the natural variation of HIV RNA viral load during pregnancy.
2. To examine changes in HIV RNA viral load and CD4 cell counts during 
pregnancy in women receiving HAART at conception and the impact of 
HAART and other covariates on these markers.
3. To determine whether the choice of initial HAART regimen in ARV-naive 
pregnant women is associated with the time to achieving undetectable viral load 
by the time of delivery.
4. To assess whether ART use during pregnancy is associated with an increased 
risk of birth defects and prematurity.
2.3 Data source and methods
2.3.1 European Collaborative Study
The ECS is a prospective cohort study in which HIV-infected women are enrolled 
during pregnancy and their children followed from birth according to the standard ECS 
protocol (European Collaborative Study 1988;European Collaborative Study 
1999;European Collaborative Study 2005b) (Appendix A). The ECS has been ongoing 
since 1986, and by January 2007, 7176 infected women had been enrolled from 23 
centres in 10 countries; Figure 2.1 shows the locations of the principal ECS centres.
General methodology
The ECS consists of an epidemiological coordinating centre at the Institute of Child 
Health, University College London in London, UK and a network of expert clinicians 
and researchers (Appendix B). At each ECS centre a dedicated paediatrician or
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Location of principal centres participating
Key Centre
1 Padua
2 Berlin
3 Edinburgh
4 Madrid
5 Valencia
7 Amsterdam
8 Stockholm
9 Genoa
10 London
11 Brussels
12 Barcelona
13 Copenhagen
15 Milan
16 Turin
17 Naples
18 Warsaw
19 Odessa
20 Micolaiev
obstetrician is responsible for the coordination of enrolment and follow-up, and liaison 
with the coordinating centre. Standardised data collection forms according to ECS 
protocol are used in all centres to record routinely collected data, including important 
socio-demographic details and clinical and laboratory test results; thus no extra patient 
visits or tests are required as a result of enrolment in the study (Appendix A).
Data collection
ECS centres systematically identify HIV infected pregnant women according to local 
practice; a well defined policy of routine antenatal testing exists in all centres. Women 
identified as HIV-infected before, during pregnancy or at delivery are eligible for 
inclusion. Consenting women are followed up during pregnancy, with their children 
(both infected and uninfected) followed up prospectively from birth.
Clinical and laboratory information is collected from enrolled women 1-3 times during 
pregnancy; the amount of follow-up information depending on the trimester at which the 
women were enrolled and the number of routine visits they underwent during pregnancy. 
Initial information collected includes mother’s obstetric history, marital status, ethnic 
group, likely route of HIV acquisition (injecting drug use (IDU), needle sharing, high 
risk sexual partner), HIV test history and current HIV status including treatment details.
During pregnancy and at delivery, virological and immunological data on both 
qualitative and quantitative HIV DNA PCR and HIV RNA PCR are reported with the 
assays used given, as well as the results of laboratory investigations to detect total 
lymphocytes, CD4 and CD8 cell counts.
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Required delivery information includes gestational age in completed weeks, birthweight 
in grams, the administration of prophylactic ART during labour or delivery including 
type of therapy and dose, mode of delivery and any perinatal problems after delivery, 
including the presence of congenital abnormalities.
Data management
Follow-up questionnaires from ECS centres are returned to the coordinating centre in 
London on a regular basis. The data received from the clinicians undergo a number of 
data checks for completeness before being entered into a Microsoft Access Database 
which holds all information on child and maternal follow-up since the beginning of the 
ECS in 1986. In addition to this data collection method, there are several centres that 
send their data electronically, usually in the form of a Microsoft Excel spreadsheet. Any 
additions and changes from the previous information provided by that centre are checked 
by the ECS coordinator before being merged into the ECS database.
Prior to any follow-up data being sent to the coordinating centre, the questionnaires are 
seen by the key ECS clinician at each centre and so an internal data quality check exists 
at this initial stage. Data entry in London is carried out by the ECS coordinator, ensuring 
a high level of consistency and accuracy. Any inconsistencies evident at the time of data 
entry are queried with the clinician who will return to the patient’s medical notes to 
verify the information.
Additional logical data checks were carried out before carrying out any analyses and 
included confirmation that:
• Women who were ART-naive did not have any previous pregnancies recorded in 
the ECS in which any type of antiretroviral treatment was received
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• Dates of ART initiation or HIV RNA and CD4 measurements were not from 
before the timing of first HIV diagnosis
• Unusual blips in CD4 counts and HIV RNA measurements, and undetectable 
values of HIV RNA among women who were ART-naive were corroborated 
against the original forms to rule out any data entry errors.
Ethical procedures
Approval is in place for the ECS from the coordinating centre, Institute of Child 
Health/Great Ormond Street Hospital, and conforms to current guidelines on patient 
confidentiality and anonymity of data collected and published. Each ECS centre obtains 
local ethical approval updated when necessary according to local protocol. This ensures 
the correct ethical approval and guidelines are followed, both at the point of data 
collection and at the point of data analysis and dissemination.
Information from patients enrolled in the ECS is collected at routine follow-up visits and 
all standard data would be collected by the obstetricians or paediatricians as a matter of 
course and for this reason, written informed consent is not considered necessary for the 
collection of this standard data. However, all participants are given details about the 
project when invited to enrol, informed that the data will be forwarded to the ECS 
coordinating team anonymously and the option to decline participation or withdraw from 
the study at any point without detrimental consequences on their care and management.
ECS representative survey
In 2005, a small survey was carried out in 11 of the principal ECS centres (Amsterdam, 
Barcelona, Berlin, Brussels, Madrid, Milan, Naples, Stockholm, Turin and Warsaw) to 
quantify the level of non-participation for the years 2002-2004 and the generalisability of
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the findings from ECS data. Information requested included the numbers of women 
declining to enrol and the reasons for non-participation.
Of the 724 women eligible for inclusion from the 11 ECS centres in this period, 4.4% 
(32) were not enrolled. The principal reason for this was relocation of the patient to 
another country or area. No centres cited refusal to enrol as a reason for non­
participation, therefore limiting any potential bias for the exclusion of these women, i.e. 
non-enrolment was based on exogenous factors.
2.4.1 HIV RNA viral load
HIV RNA viral load is quantified as the number of copies per millilitre (copies/ml) of 
blood plasma or serum through the use of quantitative Reverse Transcriptase Polymerase 
Chain Reaction (RT-PCR) assays, with the type of assay used recorded. The 
quantification limit of each assay system does not allow detection of viral load below the 
assay-specific cut-off value and these HIV RNA measurements are therefore left- 
censored. HIV RNA values are conventionally logio transformed to resolve non­
normality and heteroscedasticity.
In the ECS, a small number of maternal plasma and serum samples for women delivering 
before 1998, when routine HIV RNA testing was not available in most centres, were 
frozen locally and shipped in dry ice to either one of two laboratories in Padua and 
Stockholm where they were stored at -70°C until testing in 1997/1998.
For HIV RNA quantification, the Amplicor HIV-1 Monitor Tests (Standard, version 1.5 
with a quantification limit of 400 copies/ml; Ultra-sensitive with a quantification limit of 
50 copies/ml: Roche Diagnostic Systems Inc., Branchburg, NJ, USA), Organon- Teknika
(NASBA) assay (Standard NASBA with a quantification limit of 500 copies/ml; 
Nuclisens with a quantification limit of 40 copies/ml: Organon Teknika, Oss, the 
Netherlands) or Quantiplex HIV-1 RNA (b-DNA) assays (version 3.0 with a 
quantification limit of 50 copies/ml: Chiron Diagnostics, Emeryville, CA, USA) were 
used.
2.4.2 Immunological markers
Standard, locally performed laboratory tests for CD4 cell count and absolute lymphocyte 
measurements are based on flow cytometry. CD4 cell counts are recorded in units of 106 
cells/per litre, but following international reporting standards, will be presented 
throughout this thesis in cells/mm3.
CD4 cell measurements were square root or logio transformed to resolve non-normality 
and heteroscedasticity, as appropriate. CD4 cell counts are also expressed in three 
categories: severely suppressed immune status was defined as <200 cells/mm3, moderate 
immune status as 200-499 cells/mm3 and competent immune status as >500 cells/mm3.
2.S General definitions
Black women in the ECS are mostly from countries in sub-Saharan Africa. As most 
women in the ECS are either Caucasian or black, investigations of race were restricted to 
comparisons between these two groups.
The first trimester of pregnancy was defined as up to and including 12 gestational weeks, 
the second trimester as 13-27 gestational weeks and the third trimester as >28 gestational 
weeks.
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Premature delivery was defined as delivery before 37 weeks gestation and severe 
premature delivery as before 34 weeks. Low birth weight was defined as <2500 grams.
2.6 Data analysis
Data entry and management were carried out using Microsoft Access 2003 (Microsoft 
Corp., Redmond, Washington, USA). Data cleaning and analyses were carried out using 
Stata version 9.1 (StataCorp LP, College Station, Texas), SAS statistical software 
version 9 (SAS Institute, Cary, North Carolina, USA) and R version 1.90 -2.4.1 (R 
Development Core Team 2006).
2.7 Statistical methods
2.7.1 General statistical methods
Continuous variables were compared using the t-test and skewed continuous variables 
were compared using the Wilcoxon/Mann-Whitney test (Kirkwood and Sterne 2003). 
Univariate comparisons for categorical variables were tested with the %2 test or %2 test 
for linear trend (Kirkwood and Sterne 2003). Fisher’s exact test was used to test 
univariate comparisons of categorical variables when expected numbers were small. The 
exact method was used to calculate 95% confidence intervals (Cl) for binomial 
proportions.
Univariable and multivariable logistic regression were used to investigate risk factors 
associated with binary outcomes and to obtain unadjusted and adjusted odds ratios, 
respectively. Model selection was based on the analysis of deviance between nested 
models (McCullagh andNelder 1983).
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2.7.2 Methods specific to each section
When more complicated statistical methods have been used (which have not been 
covered above), detailed descriptions are given in each corresponding results chapter. A 
summary is given below:
Chapter 3 -  Univariate linear mixed effects model with nested random effects and an 
additional variance function to model heteroscedasticity (Pinheiro and Bates 2000).
Chapter 4 -  Turnbull non-parametric estimator, interval censored parametric survival 
model (Turnbull 1976;Powderly et al. 1999;Collett 1994), propensity score adjustment 
(D'Agostino, Jr. 1998).
Chapter 5 -  Univariate linear mixed effects model accounting for left-censored viral load 
measurement using a conditional likelihood approach (Thiebaut and Jacqmin-Gadda 
2004), bivariate linear mixed effects models dealing with left-censored measurements 
with imputed midpoints (Thiebaut et a l 2002) and a conditional likelihood approach 
(Thiebaut and Jacqmin-Gadda 2004;Thiebaut et al. 2005), local dependence map (Jones 
and Koch 2003)
Chapter 6 -  Weighted Cox regression model (Themeau and Grambsch 2000)
2.8 Data available for each analysis
By December 2006, the number of women enrolled in the ECS was 7,176. The analyses 
presented here focused on a specific sub-group of women in the ECS and for these 
reasons, the total number of women in each analysis varied; Table 2.1 shows the 
numbers of women/mother-child pairs used in each analysis.
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Table 2.1 Numbers used in analyses
Analysis Chapter No. of 
Women
Time of analysis
HIV RNA viral load in 
untreated women in pregnancy
3 333 2005/2006
Time to undetectable HIV 
RNA viral load
4 240 2006
Joint model for CD4 count and 
HIV RNA viral load in 
pregnancy
5 162 2007
Risk of congenital 
abnormalities
6.1 3740 2004
Risk of prematurity 6.2 1294 2005/2006
2.9 Role of researcher
As this work was carried out as part of the ongoing study, which I joined in 2004 as the 
ECS statistician, it is appropriate that my role in the research presented in this thesis is 
clarified. The clinicians within each centre were responsible for data collection, data 
verification, entry and database management was carried out by the ECS coordinator at 
the coordinating centre at the Institute of Child Health. I was given the responsibility for 
the preparation and analysis of the data relating to HIV-infected women in particular, 
with the aim to inform the understanding of HIV infection during the period of 
pregnancy.
The direction and nature of the analyses were agreed in consultation with my supervisor
Professor Marie-Louise Newell and co-supervisors Drs. Mario Cortina-Borja and Claire
Thome. The strategic and technical development of the analyses presented in this thesis
was entirely my responsibility. The work has resulted in two manuscripts for publication
in peer-reviewed journals (Appendix C); I took the lead role in preparation of these
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manuscripts, as part of the ECS team. The final rates of congenital abnormalities by type 
and timing of ART regimen were also sent to the Antiretroviral Pregnancy Registry 
(Antiretroviral Pregnancy Registry Steering Committee 2004) and were published as part 
of their interim report.
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C hapter 3 D eterm inants and trends o f  H IV  R N A  levels in A R T -naive
pregnant w om en
3.1 Introduction
Data on whether increasing gestation may impact on HIV RNA levels - the pre-eminent 
risk factor for MTCT - are limited and mostly suggest that levels remain stable during 
pregnancy, increasing in the early postpartum period (Bums et al. 1998;Mayaux et al. 
1997a;Cao et al. 1997;0'Shea et al. 1998). However these studies included only small 
numbers of untreated women, or included women who were mostly on monotherapy 
making it difficult to separate a possible gestation effect from that of a treatment effect. 
Additionally these studies either did not adjust for confounders in adjusted analyses, such 
as maternal CD4 counts or did not use appropriate methods for repeated measures data 
with the analyses mostly limited to the third trimester of pregnancy.
This analysis used pregnancy data on over 300 untreated HIV-infected women enrolled 
in the ECS with HIV RNA measurements from the second trimester of pregnancy, a 
comparatively larger number of exclusively untreated women than other published 
studies over a longer period of pregnancy. Trends in HIV RNA viral load over pregnancy 
were examined using a LME model, an appropriate statistical method and adjusted for 
factors known to be associated with the level of HIV RNA level, including CD4 cell 
counts.
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3.2 Methods specific to this chapter
3.2.1 Data
This analysis was restricted to the 333 women who were reported as untreated prior to 
and throughout pregnancy and who had at least one HIV RNA measurement during 
pregnancy. Women receiving intrapartum only zidovudine for prevention of MTCT were 
not excluded; however women receiving any antenatal ARV prophylaxis were. As 
women delivered at different gestational ages, a similar approach to that adopted by 
Watts and colleagues (Watts et al. 2003) was used with HIV RNA viral load modelled 
with respect to the time from delivery. This approach avoids the grouping of 
measurements by trimester of pregnancy and makes full use of the data; therefore time 
from delivery ranged from -35 weeks to 0 weeks, with 0 weeks representing the time of 
delivery for all women. To improve the regression estimates and to examine interactions 
between ethnicity over pregnancy (only white women had measurements in early 
pregnancy), the few measurements available between -35 and -25 weeks (roughly 
corresponding to 5 and 15 weeks gestation, respectively) were excluded; this equated to 
the removal of 23 measurements and 9 women (with only one measurement in 
pregnancy) from the regression analysis.
HIV disease progression is associated with the time from seroconversion (Collaborative 
Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted 
Action 2000) and HIV RNA levels levels have been shown to vary by CD4 cell counts 
(Mellors et al. 1997), assay type (European Collaborative Study 2002), plasma or serum 
used (European Collaborative Study 1999), race and history of injecting drug use 
(Anastos et al. 2000;Saul et al. 2001;Touloumi et al. 2004). The following variables, 
together with time from delivery (weeks), were therefore considered in regression 
models; race (white or black), first CD4 cell count measured in pregnancy (>500 200-
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499 or <200 cells/mm3), type of HIV RNA quantitative assay used (NASBA/Nuclisens 
or Roche), material used (plasma or serum), timing of first HIV diagnosis (before 
pregnancy or during) and history of IDU (Y/N).
3.2.2 Statistical methods
Modelling HIV RNA measurements over time is complicated by the repeated measures 
and left-censored nature of this type of longitudinal data, as well as the potential non­
linear pattern of HIV RNA over pregnancy. The vast majority of HIV RNA viral load 
measurements were from women enrolled before 1998, when viral load measurements 
were not routinely collected (Section 2.4.1). These earlier measurements were stored for 
longer and the extent to which this may impact the accurate quantification of HIV RNA 
is not known; therefore it is prudent to attempt to account for any resulting variation 
between samples in the regression model.
Linear mixed effects model
The repeated measures nature of the data, obtained from the two sampling periods (i.e. 
the periods before and during routine collection) require a model which can account for 
any variation within and between women and also any variation between the respective 
sampling periods. A standard linear mixed effects (LME) model (Pinheiro and Bates 
2000;Goldstein 1989) with nested grouping factors, otherwise known as a multilevel 
model, can be used to analyse these data by incorporating a random effect on the 
intercept and slope of HIV RNA viral load over gestation, according to the sampling 
period.
A multilevel LME model for the level of HIV RNA viral load y ijk at the Ath week of
pregnancy of the/th woman within the /th sampling period is
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y ijk — (/?0 + bQl +b0ij) + ( ^  + bUj)& + £tjk, i j  k
~Af(0,«P,),b, = ^  ~A^(0,T2)
s i)t ~  N ( 0 ,c r 2l ) .
where M  is the number of first level groups (two in this case, before and after routine 
collection of viral load) and Mt is the number of second level groups within the first level 
group / (in this case the number of women within each sampling period). The parameters
Po and P\ are the fixed effects for the intercept and slope in the model. The random
effects b§\ and b\u corresponding to the intercept and slope for the sampling period are 
assumed to be independent for different /wit h mean zero and variance-covariance of *Fi. 
The women-within-sampling period random effects for intercept and slope, Z>oij and b\^ 
are assumed to be independent for different / and j  and to be independent of Z>oi and b\x 
with mean zero and variance-covariance ¥ 2 , where ¥ 1  and ¥ 2  are symmetric positive- 
definite matrices from a multivariate Gaussian distribution. The within-group errors eijk
are assumed to be independent for different /, j  and k with mean zero and variance a  I,
and independent of the random effects. Using this multilevel approach, the variance 
components associated with the different levels of nesting and the within group error can 
be estimated.
All women enrolled in the ECS will be seen regularly in pregnancy as part of their 
routine antenatal care, but this will not always include testing for viral load or CD4 
counts. This analysis used all available data for a given woman, and because the timing 
of CD4 cell and HIV RNA testing was dictated by clinical indication instead of a 
predetermined schedule, there are no missing data in the classic sense in these 
measurements. Further, the LME model assumes that the different women in the model
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are the only completely independent units of observation in the study and that viral load 
measurements within each woman are representative of that woman’s viral load 
trajectory in pregnancy (Leyland and Goldstein 2001;Goldstein 1989). Assuming that 
these assumptions hold, there is no restriction in the number or spacing of measurements 
in an LME model, allowing for a single model to be fit to individuals who have one or 
several measurements (Leyland and Goldstein 2001). Therefore in the LME models 
presented here, women with only one HIV RNA measurement were included; however, 
they will contribute more to the estimate of the intercept of the model than the slope 
(Goldstein 1989).
Advanced LME modelling techniques which have been developed to account for left- 
censoring of HIV RNA viral load are not able to incorporate a nested random effects 
structure at present (Thiebaut et al. 2005). For this reason, a standard multilevel LME 
model was used to study changes in HIV RNA in pregnancy, with midpoints imputed for 
measurements which were recorded at the assay lower limit of quantification.
Scatterplots of logio transformed viral load measurements over pregnancy were used to 
examine the data. A supersmoother, a non-parametric (data-driven) smoothing function 
capable of summarising the trend of a response variable, y, as a function of a continuous 
covariate, x, provided a smooth estimate of the changes in overall viral load 
measurements over pregnancy (Friedman 1984). The supersmoother is based on a 
symmetric ^-nearest neighbour linear least squares procedure, which involves taking a 
window of size k!2 data points on each side of x and fitting a regression line to that point 
to predict the value of x  that best describes the points in that window. This local 
regression is run for three values of k, nil, n/5 and «/10, and the value of k that leads to 
the best estimate for each window is determined using cross-validation (Venables and
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Ripley 1997;Friedman 1984). The supersmoother is preferred here over a Kernel or 
lowess smoother because it is adaptive to the amount of smoothing that is required.
Polynomials and spline smoothing
LME models with orthogonal polynomials and smoothing splines in the fixed effects 
were compared in modelling the basic pattern of HIV RNA viral load on gestational 
weeks to delivery.
Orthogonal polynomials with linear, quadratic and cubic terms were used to avoid 
collinear terms resulting from use of conventional (non-orthogonal) polynomials. Spline 
smoothing of the covariate is a more appropriate approach when the association between 
a continuous covariate and the outcome changes in a more complicated way, i.e. one 
which cannot be easily summarised by low-order polynomials, and is explained briefly in 
the following section.
A LME model with a smoothing spline is able to describe the local structure of the 
relationship between the outcome and the covariate providing a good fit to the data 
across the full range of the covariate and is described below (Gurrin et al. 2005;Venables 
and Ripley 1997).
Suppose that the relationship between a continuous response Y  and a single continuous 
covariate x is to be modelled by
E0 0  = ,w(*/) + £,»> / = 
where m is an arbitrary smooth function giving the conditional mean of Y, ej, q, ... e„ are
independent, normally distributed random error terms with common mean zero and
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variance cr\ . This represents a non-parametric regression model where m can take on 
any form; splines are a popular method used for representing m, and are comprised of 
piecewise polynomials (usually linear, quadratic or cubic) joined together at points 
known as knots.
The linear spline estimator is of the form
m (*) = + A * + E L  uk { x ~ Kk)+
where
J O ,  X < K k
I x - f c k i x > /c k
and K], K2, k k  are knots. The first of the above equations describes a sequence of line
segments tied together at the knots to form a continuous function. This can be extended 
to a piecewise cubic polynomial given below, defined as
m3 (x; p, u) = fi0 + f i x  + fi2x 2 + fi3x 3 + £  *=1uk (x  -  Kk )3+
where p = (/?0 + fix + fi2 + /?3) r and u = (wp ...w;t)r denote vectors of coefficients. The
cubic spline with the given knots is then a linear combination of the basis functions
1 ,x ,. .. ,x p, ( x - k xY+ , . . . , { x  — k k Y  and is appropriate for smoothing in a LME model. A
cubic spline was preferred here as it results in a smoother fitted curve than the linear or 
quadratic spline (Gurrin et al. 2005).
3.2.3 Methods used for comparing and assessing models 
Likelihood ratio tests
The likelihood ratio test (LRT) is a general method for comparing nested models fit by
maximum likelihood such as the LME models described above. A statistical model is
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said to be nested within another model if it represents a special case of the other model. 
For example if model 1 includes a linear term for gestational age only and model 2 
includes the same linear term and an additional binary covariate for race, then model 1 is 
nested within model 2, as model 1 is a special case of when the coefficient for the binary 
covariate for race is zero. If L2 is the likelihood of the larger model (model 2) and Li is 
the likelihood of the simpler model (model 1) then we would have L2 > L\, and logZ,2 > 
logLjm The LRT statistic is then given by
A = 2 lo g (i2/Z1) = 2 [ lo g (i2)- lo g (L l) ] .
If k\ is the number of parameters estimated in model /, then the asymptotic distribution of 
the LRT under the null hypothesis that the smaller model is adequate (i.e. adding 
additional terms does not improve the fit of the model) is a %2 distribution with k,-k,.i 
degrees of freedom (d.f.); the LRT statistic and the associated p  value from the x l-k
distribution will be used here to assess improvements between nested models from 
including additional random effects terms and their covariates.
Akaike Information Criteria
The Akaike Information Criteria (AIC) (Akaike 1974) is a model comparison criterion 
evaluated as
AIC = -2  log Lik + 2p , 
where p  is the number of parameters in the model, and is a useful tool in examining two 
models which are not nested but which are based on the same dataset (Pinheiro and Bates 
2000;Akaike 1974). When comparing two models, the model with the smaller of the two 
AICs is the preferred model.
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A combination of LRTs and AIC comparisons were used to guide the model selection 
procedure. Standard errors and Wald tests, which inform the statistical significance of 
specific terms within a model, were also examined to assess individual covariates in 
fitted models.
3.2.4 Model selection procedure
In order to establish the appropriate functional form of HIV RNA changes over 
pregnancy, the orthogonal polynomial and smoothing cubic spline LME models were 
first evaluated. After determining the appropriate functional form between HIV RNA 
levels and time from delivery, the inclusion of additional potential confounders was 
tested.
The covariates listed earlier in this methods section were then considered alone in the 
model with time from delivery to assess whether their inclusion resulted in an improved 
log-likelihood (LRT~ x% ; P<0.10). Covariates which improved the fit of the model were
then included together in a subsequent model (Collett 1994). Any covariates which were 
not included at this stage were further tested for inclusion in the model with the LRT, as 
the presence of the other covariates in the model may now necessitate their addition. 
Additionally, to examine whether the fit of the model could be improved by removing 
covariates already in the model, the LRT from removal of each of these terms in turn 
(while holding the other covariates in the model constant) was assessed. The initial 
model was chosen when no improvements in the log-likelihood could be attained 
through the addition or removal of any main effects.
Main effects as explanatory factors in the initial model imply that their effect on HIV 
RNA is constant over gestation and with respect to other covariates in the model; the
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inclusion of interaction terms test the joint effects of gestational age and other covariates. 
Covariates in the model were therefore assessed for significance of interactions with 
gestational age, and where appropriate with one another, and were included if inclusion 
resulted in a significant improvement in the log-likelihood. To ensure that all important 
main effects were included, a conservative /7-value of 0.10 associated with the likelihood 
ratio test was used, however a less tolerant /?<0.05 was used for inclusion of interaction 
terms. The presence of an interaction term requires the inclusion of the main effects 
terms, regardless of the significance of the associated Wald test (Cox et al. 1984).
The LME model was carried out using the Ime function in R version 2.2.0 (R 
Development Core Team 2006).
3.3 Results
The characteristics of the 333 pregnant women in this analysis are given in Table 3.1, 
along with the number of actual HIV RNA measurements available by characteristic (e.g. 
the number of measurements on women which were quantified with a NASBA assay or 
from blood plasma). A fifth of women were black, with the majority bom in sub-Saharan 
Africa. There were no differences in CD4 cell counts between black and white women 
(median 460 [IQR 20-657] cells/mm3 vs. 460 [IQR 70-550] cells/mm3; Wilcoxon test 
/t=0. 18), but black women were more likely to have had their first HIV diagnosis during 
pregnancy (45/66 vs. 93/247; ^ 2=15.5,/7<0.0001).
Over a third (35%) of women had at least two HIV RNA measurements, with a median 
of three measurements per woman (IQR 3-4) and the remainder of women had only one 
measurement available in pregnancy. Most women with only one HIV RNA 
measurement available in pregnancy (173/218; 79%) had this taken at delivery. Women
Table 3.1 Baseline characteristics for women and measurements
Characteristic Women1
«=333
HIV RNA measurements 
on women1
«=490
Viral load values (copies/ml)
Median (IQR) - 2000 (IQR 350-11,000)
Viral load measurement
Above assay detection level - 338 (69)
Below assay detection level - 152 (31)
First CD4 cell count (cells/mm3)
Median (IQR) 437 (IQR 287-633) -
Timing of CD4 measurement (weeks -13 (IQR-19,-3)
from delivery) -
Missing 45 (14)
Race
White 249 (77) 356 (76)
Black 66 (21) 101 (21)
Asian 6(2) 14(3)
Unknown 12 19
4
Age at delivery (years)
Median (IQR) 28 (25-31)
15-26 108 (33) 158 (33)
26-31 140(43) 198 (41)
>32 78 (24) 127 (26)
Unknown 7 7
History of IDU
Non-IDU 156 (49) 248 (52)
IDU 162 (51) 224 (48)
Unknown 15 18
Timing of HIV diagnosis
Pre-pregnancy 182 (55) 287 (59)
During pregnancy 151 (45) 203 (41)
HIV RNA assay
NASBA/Nuclisens - 188 (38)
Roche - 283 (58)
Other 19(4)
- n (%) unless otherwise stated
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Table 3.1 contd.
Characteristic Womenf HIV RNA measurements 
on womenf
Sampling period
Routine collection - 98 (20)
Before routine collection - 392 (80)
Blood material
Plasma - 286 (59)
Serum - 200 (41)
Time period of delivery
1987-1993 228 (68) 350 (71)
1994-1998 40(12) 52(11)
1998-2005 65 (20) 88(18)
t  - n (%) unless otherwise stated
with only one HIV RNA measurement had similar CD4 cell counts to women with at 
least two measurements (median 433 cells/mm3 [IQR 285-647] vs. median 450 
cells/mm3 [IQR 289-610]; Wilcoxon test p=0.9), but had significantly lower levels of 
HIV RNA at delivery (median 2.30 logio copies/ml [IQR 2.00-3.55] vs. median 3.49 
logio copies/ml [IQR 3.04-4.17]; Wilcoxon test/K0.001).
Nineteen women had HIV RNA measurements taken in the first trimester, 83 in the 
second trimester, 120 in the third trimester and 241 at delivery; the median HIV RNA 
levels were, respectively for these times, 3.50 (IQR 3.35-4.01), 3.51 (IQR 3.10-4.20), 
3.52 (IQR 2.70-4.34) and 2.76 (IQR 2.00-3.75) logio copies/ml. The overall proportion 
of undetectable values was surprisingly high (31%) in this untreated group of women. Of 
the 152 undetectable values of HIV RNA, 13 (9%) were <50 copies/ml, 91 (60%) were 
<200 copies/ml, 45 (29%) were <400 copies/ml and the remaining 3 (2%) were 
measured as undetectable with assays with detection limits of <500 and <1000 
copies/ml; the majority (131/152; 86%) of the undetectable measurements were from
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blood samples taken before 1996. HIV RNA levels were measured in plasma for 59% 
(«=286) of samples and were significantly lower than those measured in serum (median 
3.15 [IQR 2.30-3.95] vs. median 3.48 [3.00-4.19]; Wilcoxon test/?<0.001).
3.3.1 HIV RNA viral load over gestational age
A supersmoother was used to reveal the structure of the logio transformed HIV RNA 
viral load data with respect to time from delivery and is shown in Figure 3.1, with 
detectable and undetectable measurements marked. A jitter of the time of HIV RNA 
measurement was added to the plot to elucidate the number of measurements at delivery 
and to aid smoothing of the curve over pregnancy. A slight linear increase in HIV RNA 
levels over pregnancy can be observed until -13 weeks, followed by a slight linear 
decrease until -5 weeks at which point viral load is seen to decrease more rapidly up to 
the time of delivery. The small numbers in the first trimester of pregnancy 
(approximately corresponding to measurements less than -25 weeks in the scatterplot) 
were apparent. Subsequent models excluded these early measurements and were based 
on 467 measurements and 324 women.
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Figure 3.1 Scatterplot of HIV RNA viral load over pregnancy with supersmoother
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3.3.2 Model selection procedure
For 86 of the 467 HIV RNA measurements available, information was missing on at 
least one of the variables considered for inclusion in the model; most of these were 
missing information on CD4 counts (45/86) and race (19/86). In order to test for an 
interaction term between race and time from delivery over the 24 weeks, the 14 
measurements on Asian women were also removed from the analysis. The remaining 367 
measurements were used in subsequent modelling. The measurements included in 
regression models were overall similar to the 100 measurements not included with 
respect to the distribution of HIV RNA (median 3.30 [IQR 2.56-4.08] vs. 3.30 [IQR 
2.43-3.94] logio copies/ml; Wilcoxon test, p=  0.41), the proportion of censored values 
(110/367 vs. 38/100; =1.84, /?=0.17) and the crude pattern of HIV RNA with respect
to gestational weeks from delivery (Figure 3.2).
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Figure 3.2 Scatterplot of HIV RNA viral load over pregnancy with a supersmoother 
by HIV RNA measurements included in the model and those that were not
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The simplest model, a LME model with a linear term in weeks from delivery was fitted 
first, with a separate random intercept term for the sampling period. The inclusion of a 
random effect term for the slope of weeks from delivery did not lead to a significant
improvement in the model (LRT X\ ~  0; an^ the associated estimated standard
deviation for the random effect term for the slope was extremely small. This suggests the 
presence of a substantial amount of variation of HIV RNA among the intercepts for
individual women, but not among their slopes for gestational weeks from delivery and
the random effects term for the slope is not required.
An orthogonal quadratic and cubic model for gestational weeks from delivery (GA) with 
the same random effects terms was also fitted in a LME model and the associated AICs 
and log-likelihoods are given in Table 3.2. The supersmoother in Figure 3.1 revealed 
fluctuations in HIV RNA levels at around -13 and -5 weeks and therefore an LME model 
with a natural cubic spline was fitted, with knots at these two time points. Adding
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additional power terms to the linear and quadratic model, respectively, did not improve 
the log likelihood of the model (LRT between linear and quadratic, and quadratic and 
cubic models was < 3.84= X\)- The AICs for the four models were very similar and 
reveal that not much more is gained through including anything more complex than a 
linear term and the linear model was therefore deemed to be the most suitable.
Table 3.2 Log-likelihood and AICS of model forms for HIV RNA over pregnancy
Model d .f.8 -21og likelihood AIC
Linear 5 1017.49 1027.49
Quadratic 6 1015.42 1027.42
Cubic 7 1015.38 1029.38
Cubic spline with knots 
at -13 and -5 weeks
7 1015.31 1029.44
a -  degrees of freedom
The inclusion of each of the main effects of race, first available CD4 cell count in 
pregnancy, blood material and IDU to the model with a linear term for gestational weeks 
from delivery only, all led to significant improvements in the log-likelihood. These 
covariates were then considered together in one model (Table 3.3, model 1).
The inclusion of assay type in model 1 was now associated with a significant 
improvement in the model (model 2). The model could not be improved further with the 
addition of other main effects or with the removal of any main effects already in the 
model. Interactions between covariates in the model were then considered and the 
associated likelihood ratio tests are also given in Table 3.3. The presence of an 
interaction term between gestational weeks from delivery and race, and between assay 
and blood sample type improved the model fit significantly. However, an interaction
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Table 3.3 Likelihood ratio tests for model selection procedure
Model no. Model LRT d.f.a P
1 Weeks from delivery 
+race+CD4+IDU+blood type
10
2 Model 1 + assay type 7.10 1 0.008
3 Model 2 + race* weeks from 
delivery
7.12 1 0.008
4 Model 3 + assay*blood type 14.84 1 <0.001
5 Model 4 + CD4*race 0.35 2 0.84
6 Model 4 + CD4*IDU 1.41 2 0.50
7 Model 4 + IDU* weeks from 
delivery
1.73 1 0.19
8 Model 4 + race*blood 2.95 1 0.09
9 Model 4 + race*assay 2.77 1 0.10
a - degrees of freedom
term between gestational weeks from delivery and CD4 measurements in pregnancy was 
not tested as these measurements were not taken at the same time for each woman, while 
an interaction between IDU and ethnicity could not be tested as there were no black 
IDUs. There was no evidence of interactions between any other covariates included in 
the model (Table 3.3).
The final model included a linear term in gestational weeks from delivery, CD4 cell 
count, race, history of IDU, blood type, assay type and an interaction term between 
gestational weeks from delivery and race, and between blood and assay type. With the 
exception of IDU, all main effects or their related interaction terms in the model also had 
significant Wald tests. The removal of the IDU term from the model was not associated 
with a significant increase in log-likelihood (LRT ^ 2=2.24; /?=0.13) and could on these 
grounds be removed from the model. However, almost two-thirds of white women were
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IDUs and excluding this factor led to a substantial increase in the estimate of the model 
intercept and the race effect (with the standard errors remaining relatively stable) and the 
IDU term was therefore retained in the final model.
3.3.3 Model residuals
A primary tool for investigating heteroscedasticity is a plot of the fixed effects 
standardised (Pearson) residuals versus the fitted values from this model and is shown in 
Figure 3.3, with residuals from undetectable HTV RNA measurements indicated. The 
plot gives some indication of within-group residual error changing with fitted values of 
HIV RNA and reveals a linear pattern in the undetectable residuals. This suggests lack of 
homoscedasticity, one of the assumptions required for LME models.
Figure 3.3 Plot of the standardised residuals versus fitted values for model without 
variance function
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In favour of accounting for the variance associated with each nested grouping in this
model, left-censoring of undetectable HIV RNA measurements were dealt with by
imputing midpoints. The residual plot indicated that the fitted values for undetectable
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values were overestimated and linearly related to the standardised residuals which 
highlight one of the disadvantages of adopting this method. In an attempt to correct for 
this within-group heteoscedasticity, a combination variance function (Pinheiro and Bates 
2000) was used to model
a) the variance structure of the within-group errors for undetectable values over the 
range of fitted values, and
b) the residual error variance (as a constant term) for both undetectable and 
detectable values.
A formal test for the lack of homoscedasticity could then be carried out by examining the 
associated improvement in the log-likelihood from this model, with a significant 
improvement implying the need for the variance function to achieve homoscedasticiy of 
the within-group errors. A power function to model the variance structure is a common 
choice for modelling the monotonic heteroscedasticity seen in Figure 3.3 (Pinheiro and 
Bates 2000). The combination variance function can be represented as:
where the absolute value of the fitted values is permitted to vary by a power (6)
parameter of the within-group errors a2, with the parameter 6 taking any value in the real
line depending on whether the measurements are undetectable or not (w= [0,1]). 
Additionally, the function allows for a different variance a  according to u (Pinheiro and 
Bates 2000).
A plot of the residuals from the model including the variance function is given in Figure
3.4 and reveals the adequacy of the variance function in representing some of the 
heteroscedasticity seen in Figure 3.3. The significant improvement in the log-likelihood
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(LRT x l  = 22.95; £><0.0001) and AIC of the model (1027.49 compared to 961.51 for the 
model without the variance function) confirm the need for the variance function.
Figure 3.4 Plot of the standardised residuals versus fitted values for model with a 
variance function to model within-error heteroscedasticity
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This combination variance function increases with the size of the fitted values for the 
within-group errors for undetectable measurements only, and remains constant for the 
within-group errors for detectable values, but is 18% larger than before (Figure 3.5).
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Figure 3.5 Estimated variance functions over gestational age, stratified by 
detectable measurements
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3.3.4 Model interpretation
The estimated coefficients of change for mean HIV RNA and the standard deviations for 
the random effects parameters from this model are presented in Table 3.4. There was a 
significant association between CD4 cell counts in pregnancy and HIV RNA level; 
although this should not be interpreted as evidence of causality, women with lower CD4 
cell counts were estimated to have higher levels of HIV RNA. HIV RNA levels were 
also dependent on both the type of assay used and the blood sample type; viral load
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Table 3.4 Adjusted coefficients of change for logio HIV RNA viral load in
pregnancy and estimated random effects
Multivariate
Coefficient 95% Cl p value
HIV RNA at delivery 3.41 2.70, 4.12 <0.001
Gestational weeks to delivery increase -0.019 -0.03, -0.007 0.002
Race
White
Black
0.00
0.45 0.08, 0.83 0.02
HIV RNA assay
NASBA/Nuclisens
Roche
0.00
-0.87 -1.22,-0.52 <0.001
CD4 count (cells/mm3) 
>500 
200-499
0.00
0.29 0.05, 0.53 0.02
<200 0.78 0.44, 1.11 <0.001
History of IDU
No
Yes
0.00
-0.20 -0.47, 0.06 0.14
Sample type
Plasma
Serum
0.00
0.20 -0.17, 0.57 0.29
Sample and assay interaction
Plasma and NASBA/Nuclisens 
Serum and Roche
0.00
1.09 0.60, 1.58 <0.001
Gestational age and race interaction
Change by GA for white women 
Change by GA for black women
0.00
0.035 0.01,0.06 0.005
Random effects parameters
a intercept between sampling periods 0.44 0.15, 1.29 -
(boi)
o intercept between women (boij) 0.69 0.60, 0.80 -
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copies/ml obtained from a serum sample with a NASBA/Nuclisens assay were 60% 
(0.20 logio copies/ml) higher than those obtained from a plasma sample with the same 
assay, while HIV RNA in a serum sample measured with a Roche assay was estimated to 
be around 2.5-fold (0.42 logio copies/ml) higher than that measured in plasma and a 
NASBA/Nuclisens assay.
From around the start of the second trimester, HIV RNA viral load over pregnancy was 
estimated to decrease by 0.019 logio copies/ml per week up to the time of delivery for 
white women. This corresponds to a 4.3% weekly decrease in copies/ml over pregnancy 
(95%CI -6.7%, -1.6%), an approximate 65% decrease in HIV RNA levels over the last 
24 weeks of gestation. The slope of the change in viral load over pregnancy for black 
women was positive and significantly different to that for white women as indicated by 
thep -value for the race and gestational weeks from delivery interaction term (Table 3.4). 
The change in HIV RNA viral load over pregnancy for black women was estimated to be 
0.016 logio copies/ml (95%CI -0.005, 0.037), which equates to a weekly increase of 
3.8% copies/ml (95%CI -1.1%, 8.9%), however this was not a significant increase 
indicated by the zero-bounded 95%CIs.
As the measure of gestation in this model was weeks to delivery, the intercept estimate 
corresponds to the mean HIV RNA level at delivery for white women, with the race 
estimate in Table 3.4 corresponding to the difference in mean levels at delivery between 
black and white women. The estimated mean HIV RNA level at delivery was 3.41 logio 
copies/ml (95%CI 2.70-3.41) for white women and 3.86 logio copies/ml (95%CI 3.16- 
4.56) for black women.
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The estimated standard deviations for the intercept’s random effects were 0.44 logio units 
for the sampling period and 0.69 logio units for the between-women intercept; both 
estimates had 95%CIs which were not bounded by zero. The magnitude of these 
estimates reveals the considerable variability in the estimated fixed effects mean 
intercept between women and also between sampling periods (mean HIV RNA at 
delivery 3.41 logio copies/ml, Table 3.4). The random effect for the between-women 
intercept was over 1.5 times larger than that for the sampling period and suggests that 
individual variability explains more of the variation around the estimated intercept than 
variability between the period of sample collection. Due to the large number of women 
with only one measurement here, the within-woman correlation coefficient is unlikely to 
result in an accurate estimate of the correlation of HIV RNA measurements within a 
woman over pregnancy; this will be estimated in the following section in the sensitivity 
analysis involving women with at least two measurements.
3.3.5 Sensitivity analysis
The majority of women (65%) in this analysis had only one measurement in pregnancy, 
limiting any inferences which can be made on the shape of HIV RNA curves in 
pregnancy and on the accuracy of the within-woman correlation estimate. Additionally, 
79% (173/218) of women with only one measurement in pregnancy had their 
measurement taken at delivery; the resulting estimate of the slope of change in HIV 
RNA may therefore be confounded by factors influencing when in pregnancy this 
measurement was made.
Therefore a sensitivity analysis including only the 80 women with at least two HIV RNA 
measurements in pregnancy and with available information on all variables was carried 
out. The model included the same covariate and interaction terms but did not include a
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random effect term for the sampling period as the estimate for this term was extremely 
small (a<0.05) and its inclusion led to a variance-covariance matrix for the random
effects which was not positive-definite. The mean HIV RNA at delivery was estimated to 
be 3.86 logio copies/ml (95%CI 3.44-4.28), higher than in the model which included all 
women, while the magnitude of the estimated change in HIV RNA over pregnancy was 
smaller, at -0.013 logio copies/ml per week (95%CI -0.025, -0.0004). The largest 
difference in the parameter estimates from the model which included all women was that 
of the race effect; black women had estimated viral loads of 0.11 logio copies/ml (-0.39, 
0.60) above that of white women at delivery, but this was not significantly different from 
zero. Similar to the model presented in Table 3.4, the slope of change in viral load over 
pregnancy for black women was positive and significantly different to that for white 
women (0.030 logio copies/ml [95%CI 0.0010-0.055]), but the change in viral load over 
pregnancy for black women was not significantly different to zero (0.028 logio copies/ml 
[95%CI -0.45, 0.51]). The between- and within- women standard deviations were 
estimated to be 0.58 and 0.49, respectively. The within-woman correlation can be
calculated as o^tercept/ [ ^ tercept + cLduai]: therefore, the estimated correlation of logio
HIV RNA within a woman over the 24 weeks of pregnancy observed was 0.66 (95%CI 
0.50-0.79).
As mentioned in section 3.2.2, a nested mixed effects model was used to study HIV 
RNA changes in pregnancy, with midpoints imputed for measurements recorded at the 
assay lower limit of quantification. The LME model which takes into account the left- 
censoring using a conditional likelihood approach has been shown to be more accurate 
for analysing changes in left-censored HIV RNA measurements (Jacqmin-Gadda et al. 
2000) (see also Section 5.2.2). Therefore a sensitivity analysis was carried out using this
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method instead, with the sampling period included in the model as a covariate. Although 
the resulting estimate for mean HIV RNA at delivery was higher (4.32 logio copies/ml 
[95%CI 3.63-4.99]), the estimate for change in HIV RNA was similar (-0.022 logio 
copies/ml per week [95%CI -0.037, -0.007]). The conditional likelihood model resulted 
in a relatively more marked impact on the intercept estimate which is most likely due to 
the large number of undetectable measurements at delivery.
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3.4 Key points
• In this subgroup of untreated pregnant women, levels of HIV RNA viral load did 
not remain constant over pregnancy.
• HIV RNA viral load over pregnancy was estimated to decrease for white women 
and to remain generally stable for black women.
• Black women had significantly higher viral loads at delivery than white women
• Levels of HIV RNA in pregnancy were associated with baseline maternal CD4 
cell counts and on the type of blood sample used
• There was considerable variability between samples collected before and during 
the period of routine viral load testing, justifying the use of a nested random- 
effects model.
•  Accounting for left-censoring of HIV RNA levels with midpoints led to 
heteroscedasticity of the within-group errors. However, the addition of a variance 
function to model the within-group variability of undetectable values 
significantly improved the fit of the model.
•  In a model including women with only two measurements, HIV RNA viral load 
over pregnancy was also estimated to decrease for white women, but the 
magnitude of decrease was smaller.
•  The estimated correlation of logio HIV RNA within a woman over the second and 
third trimesters of pregnancy was estimated to be 0.66.
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Chapter 4 Time to undetectable HIV RNA viral load after initiation of 
HAART
4.1 Introduction
Plasma HIV RNA level is the pre-eminent risk factor for MTCT of HIV (Mofenson et 
al  1999;European Collaborative Study 2005b). HAART in resource-rich settings has 
substantially reduced MTCT rates through successful suppression of HIV RNA in 
pregnant HIV-infected women (European Collaborative Study 2005b;Cooper et al  
2002). While an increasing proportion of HIV-infected pregnant women in such settings 
are identified and treated before pregnancy, a substantial minority are diagnosed 
antenatally and start ARV drugs to delay disease progression and/or prevent MTCT for 
the first time in pregnancy (European Collaborative Study 2005b). In many Western 
European countries, these women are increasingly likely to have acquired HIV 
heterosexually and to be from countries with generalised epidemics, mostly sub-Saharan 
Africa (European Collaborative Study 2006). No clinical trials in resource-rich settings 
have addressed the question of which regimens are more effective for optimal viral 
response in ARV-naiVe pregnant women.
This analysis was carried out to determine whether choice of initial HAART regimen in 
HIV-infected pregnant women is associated with the time to achieving undetectable 
viral load by delivery.
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4.2 Methods specific to this analysis
4.2.1 Data
The analysis was restricted to the 240 women who were ART-nai've at conception, 153 
women identified for the first time in pregnancy and 87 before pregnancy. Of the 87 
women diagnosed before pregnancy, 46 were known not to have previously received 
any PMTCT prophylaxis (either because of no prior pregnancies or documented non­
receipt of ARVs in previous ECS pregnancies) and 41 were not on ARVs at conception 
with no documented prior ARV use. Viral load at the time of initiating HAART has 
been shown to be associated with the probability of reaching a viral load < 500 
copies/ml, with higher pre-HAART viral loads less likely to achieve this level 
(Powderly et al. 1999;Mocroft et al. 1998). Other studies examining the time to 
undetectable HIV RNA after initiation of different HAART regimens included patients 
with an HIV RNA measurement within 6 months before initiation (Phillips et al. 
2001;Ghani et al. 2001). However, in light of the findings in Chapter 3 of non-stable 
HIV RNA levels in pregnancy and given that this study was limited to pregnancy, the 
eligibility criterion was confined to women with a HIV RNA measurement within 6 
weeks before initiation and at least one subsequent measurement thereafter.
There were 759 HIV RNA measurements available on the 240 women included in the 
analysis. Classification of undetectable viral load (viral suppression) was based on the 
assay lower limit of quantification. Of the 759 measurements, 561 (74%) were 
measured using an ultrasensitive assay (with a quantification limit <50 copies/ml). 
HAART was defined as a regimen of three or more antiretroviral drugs consisting of a 
NRTI backbone and including NVP -  a NNRTI, or a PI.
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After adjusting for baseline viral load, race (non-black vs. black), HAART type (PI- 
containing vs. NVP-containing), baseline CD4 count (<200, 200-499 or >500 
cells/mm3), trimester at initiation (1st trimester, 2nd trimester or 3rd trimester), timing of 
HIV diagnosis (pre-pregnancy vs. antenatal), history of IDU (Y/N), year of delivery 
(1998-2000, 2001-2002 or 2003-2004) were considered in the Weibull model and 
propensity score model, respectively. These variables were deemed important potential 
confounders as they are known to or have the potential to be related to the time taken to 
achieve undetectable HIV RNA levels (Ghani et a l 2001;Mocroft et a l 
2006a;Matthews etal. 2002;Phillips et a l 2001).
4.2.2 Statistical methods
In observational studies, the timing of HIV RNA measurements after treatment 
initiation occurs at various times and with various frequencies. Thus, a common 
approach to compare different HAART regimens is to examine the times to events using 
survival analysis methods rather than comparing absolute changes in levels of 
virological and immunological markers. A frequently used measure of success of 
treatment is the time taken from initiation of treatment until HIV RNA reaches 
undetectable levels (Matthews et a l 2002;Ghani et a l 2001 ;Phillips et a l 2001). In this 
analysis, the association between initial HAART regimen and maternal baseline 
characteristics with viral suppression was examined by comparing the times taken from 
treatment initiation to the first undetectable HIV RNA measurement, through to the time 
of delivery.
The analysis of time to undetectable HIV RNA after initiation of HAART here results in 
a complicated censoring pattern. Figure 4.1 shows simulated HIV RNA data for patients
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after initiating HAART, where the time point 0 corresponds to the time of initiation. If a 
subject’s true endpoint is known only to occur in the interval [0, B), i.e. it has not 
occurred at the time of the last measurement, then the resulting survival time is right 
censored. Where a subject’s true endpoint, marked as x in figure 4.1, is known only to 
occur in the interval [B, C], the resulting survival time is interval-censored, that is x is 
known only to have occurred between B and C. Finally, the survival time is left- 
censored when x is known only to have occurred in the interval [0, C] and is an exact 
time when the endpoint is known to occur at x.
Figure 4.1 Figure to illustrate censoring pattern from analysing time to 
undetectable HIV RNA after initiation of HAART
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Therefore for women not achieving undetectable levels, the time was right-censored at 
the last measurement at or before delivery; for those reaching undetectable virus, the 
time was left-censored if the endpoint was known only to have occurred between 
initiation and the first measurement, and interval-censored if the endpoint occurred 
between any two measurements following initiation. There were no exact survival times 
as the true date of the first undetectable measurement was unknown for all women.
Standard time-to-event methods such as the Product limit estimator developed by 
Kaplan and Meier and the Cox proportional hazards models can only accommodate 
right-censoring; the use of these methods with interval-censored data, assuming that the 
true time x of the event occurs either at the time of the first undetectable measurement 
or halfway between the last detectable and the first undetectable measurement (between 
points B and C or between points 0 and C in Figure 4.1) has been shown to lead to 
invalid inferences and to underestimate the standard errors of the estimated parameters 
(Lindsey and Ryan 1998;Odell et al. 1992). Here, interval-censored survival methods, 
namely Turnbull’s generalisation of the Kaplan-Meier estimate and a parametric 
survival model based on the Weibull distribution, were used.
Turnbull’s generalisation o f  the Kaplan-Meier estimate
As usual in the analysis of right-censored survival data, here it is also of interest to 
estimate the survival function S  ) and to assess the importance of potential prognostic
factors upon interval survival times. The nonparametric procedure suggested by 
Turnbull (Turnbull 1976) will be used here as an initial descriptive tool.
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The modified Product-limit estimator suggested by Turnbull (Turnbull 1976) has no 
closed form and is based on the following iterative procedure (Klein and Moeschberger 
1997). Let Tt (/ = 1,2,...,«) be the time until event which is known only to occur
between an interval (Z,;> R,] where L, < T, < R,. Note that for right-censored observations 
Ri = oo and for left-censored observations Lt = 0. Let 0 = tQ < tx < t2 < ... < tm be a
partition which includes all the points Lt and Rj for /' = 1,...,«. For the rth observation, a
weight a t] is calculated, such that a t] =1 if the interval J is contained in the
interval (Lit /?/], and 0 otherwise. a tj is an indicator of whether the event which occurs 
in the interval (LitR,] could have occurred at t j . Turnbull’s algorithm is as follows:
Step 0: Produce an initial Kaplan-Meier estimator of the survival function at
each tj, by taking the end points of intervals Rt as the survival times.
Step 1: Compute the probability of an event occurring at time tj as
Step 4: Compute the updated Kaplan-Meier estimator based on the estimated number of
Step 2: Estimate the number of events occurring at // by
Step 3: Compute the estimated number of subjects at risk at time tj as
m
deaths and number at risk found in steps 2 and 3. If the updated estimate of is
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close to the old version for S  for all ffs then stop the iterative process, otherwise repeat 
steps 1-3 using the updated estimate of S.
At present, this algorithm is not available as a standard function in the R statistical 
software package, and an algorithm developed by Giolo was used to obtain stratified 
survival curves and associated survival probabilities (Giolo 2004). The R code for this is 
given in the Appendix D. 95% CIs for the survival probabilities were calculated using 
the adjusted bootstrap percentile method with 1000 replications (Davison and Hinkley 
1997).
Parametric regression models for survival data
The standard Cox proportional hazards model does not require any specific 
distributional assumptions about the shape of the survival function. In fact a parametric 
(linear) form is assumed only for the covariate effects, the baseline hazard is unspecified 
and is not actually estimated using the partial likelihood approach (Klein and 
Moeschberger 1997). Although this is one of the advantages of this type of model over 
parametric regression models, the resulting estimates are not as efficient as maximum 
likelihood estimates for correctly specified parametric survival models. Additionally, as 
a full likelihood is not specified, the standard Cox model can not allow for left or 
interval-censored data (Klein and Moeschberger 1997). It has also been shown 
elsewhere that when data are heavily censored, making assumptions about when events 
occurred (e.g. assuming midpoints) and using techniques such as Cox regression can 
lead to inaccurate conclusions (Lindsey and Ryan 1998). It has been suggested that 
parametric models are an appropriate alternative method, which can be highly 
satisfactory in their performance (Lindsey and Ryan 1998). Parametric regression
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models by definition assume a specific distribution for the shape of the survival function 
and are able to incorporate left-, right- and interval-censored data. Therefore, due to the 
nature and amount of censoring in this study (no women had exactly observed event 
times and a large majority had left- and interval-censored event times), a parametric 
regression model was preferred over the Cox model.
Parametric survival models can usually be represented as an accelerated-failure time 
(AFT) model or a linear model in log time. Let X  denote the time to event and Z  a 
vector of fixed-time covariates. The AFT model states that the survival function for an 
individual with covariate Z  at time x  can be is defined by
S ( x \ Z )  = S0 [exp (erz) x ] , for all jc, (4.1) 
where 0r = .,0p), where j  = 1 is a vector of regression coefficients and So is
the baseline survival function. The factor e x p ^ z )  is the acceleration factor and
describes how a change in the covariate value changes the time scale from the baseline 
time scale, i.e. whether the effect of changes in the covariates results in a shrinking or 
stretching of the time to event. An implication of this model is that the hazard rate for an 
individual with covariate Z  is related to the baseline by
h(x  | Z ) = exp (0 r Z )  Hq [exp (0 r Z j jc J , for all x.
The second representation is the log-linear form between log-time and the covariate 
values, such that
Y = \n X  = ^i + yTZ + (jW,
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where yr . , /p) is a vector of regression coefficients and W  is the random error
distribution. By taking So to be the survivor function of the random variable 
exp [ju + crW) , the linear log-time model is equivalent to the AFT model with 0 = - y .
Various parametric distributions can be used for the random term W  or So, including the 
log-logistic and the exponential distributions. Here a Weibull model is preferred as it is 
flexible, allowing for monotone increasing, decreasing or constant hazards and has been 
shown to be more appropriate than the Cox model in the analysis of data with a large 
proportion of left- and interval-censored observations (Lindsey and Ryan 1998). It is 
also the only parametric survival model which has both a proportional hazards and an 
AFT representation, facilitating the interpretation of the estimated model coefficients 
(Lindsey and Ryan 1998;Klein and Moeschberger 1997). Additionally the assumption 
of proportional hazards does not need to hold in a Weibull model and relative survival 
times can be obtained from the fitted model, additional to relative hazards (Cox et al. 
2007).
The baseline survival and hazard function for the Weibull distribution can be 
represented as
S0 (x) = exp (-/Lt“ )
Hq (x) = Xaxa~x,
respectively. Note that if cc=\, the Weibull distribution reduces to an exponential 
distribution.
The linear log-time representation of the Weibull model is then
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Y = \n X  = ju + yrZ + crW, 
where W has the standard extreme value distribution (the error distribution for the 
Weibull model). This model also leads to the proportional hazards model for X  with the 
baseline hazard function described above and can be expressed as
/? (jc | Z) = (cr/i.x:0'-1) exp (prZ ) .
This representation is linked to the coefficients in the linear log-time model as a  -  ,
>l = e x p | - ^ / j  and = The AFT representation of this model is the same as
in equation 4.1.
Likelihood construction for interval-censored data
Assuming a full-likelihood approach, the likelihood function for survival data can be 
constructed to account for right, left and interval-censoring through consideration of the 
information each observation provides (Klein and Moeschberger 1997).
For a specific individual under study, assume that X  denotes the time to event, Cr and C\ 
denote a right-censored and left-censored time, respectively, and the interval (L^R,]
denotes the left and right endpoint of an interval-censored time. Further, the X s  are 
assumed to be independent and identically distributed with probability density function 
/  (*) and survival function S  (*). An observation corresponding to an exact survival 
time then provides information on the probability that the event occurs at that time, 
which is approximately equal to f ( x ) ,  the density function of X  at this time. For a 
right-censored observation, it is only known that the event time is larger than this time, 
so the information is equivalent to S  (Cr) , the survival function evaluated at that study
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time. For a left-censored observation, it is known that the event has already occurred, so 
the contribution to the likelihood is the cumulative distribution function, 1-5 '(C /), 
evaluated at that study time. Finally, for interval-censored data it is known that the event 
occurred within an interval so the information is [S' ( / , , ) - £  (-K,)], the probability that 
the event time is in this interval.
The likelihood function for exact and right-, left- and interval-censored survival times 
can then be constructed by putting together the above components, such that
ian/wns(cr)nM(co)n[s(A)-s(;y}
ieE ie R  ieL ie l
where E is the set of event times, R is the set of right-censored observations, L is the set 
of left-censored observations and /  the set of interval-censored observations.
Propensity scores
Randomised controlled trials are recognised as the gold standard for making treatment 
comparisons, as randomisation of patients to each treatment group means that on 
average, each patient has a similar prognosis at the start of the study and treatment 
effects can be singled out. In observational studies however, there is no control over 
treatment assignment and therefore large differences on observed covariates in the two 
groups may exist at baseline, which could lead to biased treatment effects. Traditional 
methods of adjustment (matching, stratification, adjustment in regression models) 
remove some of this bias but can use only a limited number of covariates for 
adjustment. The propensity score can instead be used to reduce this bias without this 
limitation, as it provides a scalar summary score of all of the covariate information 
(D'Agostino, Jr. 1998).
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The propensity score for an individual is defined as the probability of being treated with 
one treatment over another (e.g. treatment vs. control, Pl-regimen vs. NNRTI regimen), 
conditional on the individual’s covariates at baseline. It can be used to reduce bias in 
treatment comparisons with observational data by balancing the covariates in the two 
groups.
Rosenbaum and Rubin (Rosenbaum and Rubin 1983), define the propensity score for 
subject / (/ = 1, ...., N) as the conditional probability of assignment to a particular 
treatment (Z* = 1) versus control (Z; = 0), given a vector of observed covariates,
e(x,) = pr ( Z l = \ \ X t =x, )  
where it is assumed that given the X s ,  the Z, are independent:
Pr (Z\ — zx,....,ZN = zN | X x = xx,....,XN = xN) = {l — e (*/)}
/= i
As a crude function of the covariates, the propensity score can be perceived as a 
balancing score, b(X), defined as “a function of the observed covariates X  such that the 
conditional distribution of X  given b(X) is the same for treated (Z=l) and control (Z=0) 
individuals (D'Agostino, Jr. 1998). Therefore, matching, stratification or regression 
adjustment on the propensity score will produce unbiased estimates of treatment effects, 
if the treatment assignment is ignorable, given the observed covariates. However, 
unmeasured variables can still be unbalanced between the two treatment groups even
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after incorporating the propensity score (Austin et al. 2005); in this study this includes 
among other unmeasured variables, data on adherence and time of seroconversion.
When complete data are available, the propensity score can be estimated using 
discriminant analysis or logistic regression. Although both techniques will lead to 
estimates of probabilities of treatment assignment given a set of observed covariates, 
discriminant analysis necessitates the added assumption of the covariates having a 
multivariate normal distribution (conditional on Z).
The propensity scores were used here for regression adjustment, i.e. using the 
probability (i.e. the propensity score) that any given patient is assigned one treatment 
over another, to adjust regression estimates of treatment effects. The estimation and use 
of the score in this analysis follows the recommendations from D’Agostino 
(D'Agostino, Jr. 1998) and is summarised below.
1) With a binary treatment outcome, estimate the propensity score using logistic 
regression, with covariates entered into the model and retained if significant at 
/K0.5 in a stepwise selection procedure.
2) Obtain estimated propensity scores from the fitted model.
3) Determine strata cut-offs using quintiles of the estimated propensity scores for 
the combined group.
4) Incorporate this 5-level factor into the model of interest, regardless of its 
significance, together with other confounders whose association with the 
treatment outcome is to estimated.
97
Covariance adjustment for all variables which appear in the propensity score model has 
been shown to result in a similar treatment effect (D'Agostino, Jr. 1998). However, an 
advantage of this approach over adjustment for all variables is that although a large set 
of background covariates can be used to estimate the propensity scores, only a subset of 
these covariates and the propensity score itself are needed in the regression adjustment. 
As the goal of the propensity score model is to obtain the most accurate probability of 
treatment assignment, covariates in this model can be included although they do not 
appear in the Weibull regression model. Although, by definition a variable will only be 
a confounder if it is associated with both treatment assignment and outcome, Austin and 
colleagues found that covariance adjustment for variables which were true confounders 
only resulted in biased estimation of the treatment effect hazard ratio, compared to 
models which adjusted for all variables or those which adjusted for variables associated 
with the event outcome only (Austin et al. 2007). Therefore, in order to reduce the 
possibility of a biased treatment effect estimate, to attempt to balance treatment 
assignment by observed covariates and to create a “quasi-randomised” trial setting, the 
final model was adjusted for both the propensity score and a subset of these covariates.
4.2.3 Model selection procedure
The model selection procedure follows that described in section 3.2 but was based on 
assessment of the deviance statistic for the logistic regression model and the LRT for 
the survival model. However, baseline viral load, stratified into tertiles, was included in 
the model a priori as the outcome of interest is expected to be linked to baseline viral 
load; therefore the model selection procedure involved the examination of 
improvements from the inclusion of additional covariates from a model including viral 
load only. Baseline CD4 cell counts were included in the final model regardless of the
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statistical significance of the improvement in model fit as is it also expected to be 
related to the outcome of interest and is an indicator of HIV disease status. The 
propensity of being treated with NVP-based HAART over Pi-based HAART, estimated 
through a logistic regression model was then included in the final adjusted models after 
stratification into quintiles (D'Agostino, Jr. 1998).
The Weibull regression model was carried out using the intcens function in Stata 
version 9.1 (StataCorp LP, College Station, Texas) and the survreg package in R 
version 2.2.0 (R Development Core Team 2006). The logistic regression model was 
fitted using R.
4.3 Results
Two hundred and forty pregnant HIV-infected women met the inclusion criteria, out of 
1,346 women on antenatal HAART delivering between 1997 and 2004. The 
characteristics of these women are given in Table 4.1. Most women (59%) were black, 
of whom 90% were bom in sub-Saharan Africa (Table 4.1).
Pi-based HAART was initiated in 156 (65%) women, with the remaining 84 (35%) 
receiving an NNRTI-based regimen (all NVP). Most women received a ZDV/3TC 
NRTI backbone (Table 4.1). Eighty percent (n =125) of Pi-based regimens included 
NFV, with the remaining containing lopinavir/ritonavir («=4), ritonavir («=13), 
indinavir (n=8) or saquinavir («=6). The proportion of women receiving NVP-based 
HAART increased from 25% (16/64) in 1997-2000 to 35% (37/105) and 44% (31/71) in 
2001-2002 and 2003-2004, respectively (p=0.02). Among the NVP group, 61 (73%) 
women had CD4 counts >250 cells/mm3 at initiation, of whom 57 (93%) delivered
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Table 4.1 Characteristics of the 240 treatment-naive study women at initiation of 
HAART and number of women reaching endpoint of undetectable HIV RNA viral
load by delivery
Characteristic Value
(Column %)
Number of women reaching 
undetectable viral load
(Row %)
Race
Non-black 96 (41) 63 (66)
Black 141 (59) 110(78)
Unknown 3 2
Region of birth*
Europe 75 (32) 46 (61)
The Americas 23 (10) 18(78)
Asia 8(3) 7(88)
Northern Africa 6(2) 5(83)
Eastern Africa 44(19) 33(75)
Southern Africa 2(1) 1(50)
Central Africa 40(17) 31 (78)
Western Africa 39(16) 32 (82)
Unknown 3 2
Age at delivery (years)
Median (IQR) 29 (25-33)
15-19 10(4) 6(60)
20-29 113(48) 86 (76)
30-39 107 (45) 74 (69)
>40 8(3) 7(88)
Unknown 2 2
%
- regions o f Africa were defined according to the United Nations groupings
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Table 4.1 contd.
Characteristic Value Number of women reaching
undetectable viral load
(Column %) (Row %)
History of IDU
Non-IDU
IDU
Unknown 
Timing of HIV diagnosis 
Antenatal 
Pre-pregnancy 
HIV RNA (logio copies/ml) 
Median (IQR)
>5
4-4.99
3-3.99
<3
CD4 count (cells/mm3)
Median (IQR)
<200 
200-499 
>500 
Unknown 
HAART category 
Pi-based 
NVP-based 
NRTI backbone 
zidovudine/lamivudine 
Other dual combination
215(91)
21(9)
4
153 (64)
87 (36)
4.16(3.62-4.58) 
20 (8)
125 (52)
74 (31) 
21(9)
328 (210-480) 
48 (22)
124 (56)
48 (22)
20
156 (65)
84 (35)
211 (88) 
29(12)
159 (74) 
12(57) 
4
113 (74) 
62 (71)
10(50) 
88 (70) 
58 (78) 
19(90)
29 (60) 
95 (77) 
38 (79) 
13
111 (71) 
64 (76)
160 (76) 
15(52)
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Table 4.1 contd.
Characteristic Value Number of women reaching
undetectable viral load
(Column %) (Row %)
Stage of pregnancy at initiation 
(weeks’ gestation)
Median (IQR) 23 (18-27)
First trimester 14(6) 12(86)
Second trimester 168(70) 129 (77)
Third trimester 58 (24) 34 (59)
Gestational age at delivery
Median (IQR) 38(37-39)
Delivery at term (>37 weeks) 187 (78) 148 (79)
Premature (<37 weeks) 53 (22) 27 (51)
before February 2004 (when NVP prescribing information changed (Public Health 
Service Taskforce 2006b)).
Characteristics by race
There were no differences between black and non-black women with respect to type of 
HAART (34% [48/141] vs. 35% [34/96] received NVP-based HAART respectively; 
p=0.94), the distribution of baseline median HIV RNA viral load (4.13 logio copies/ml 
[IQR 3.54-4.60] vs. 4.20 logio copies/ml [IQR 3.76-4.56];p=0.18) and baseline median 
CD4 cell counts (313 cells/mm3 [IQR 210-449] vs. 370 cells/mm3 [IQR 231-528]; 
/t=0.12). However, black women tended to start treatment later than non-black women 
(median 24 weeks’ gestation [IQR 20-28] vs. median 20.5 weeks [IQR 15-27]; 
p=0.007).
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Figure 4.2 shows the distribution of HIV RNA measurements at initiation by gestational 
weeks, together with baseline median viral loads and CD4 counts. Although numbers of 
women were too small to explore HIV RNA measurements by gestational week, time 
periods were categprised into periods of five weeks to better utilise the information 
without grouping measurements into trimesters of pregnancy. Twenty-four percent 
(39/165) of women starting HAART in the first or second trimester had CD4 counts 
below 200 cells/mm3 compared to 16% (9/55) of those starting in the third trimester 
(p=035).
Characteristics by HAART category
Table 4.2 shows the characteristics of women by HAART category. Overall, from 
initiation of treatment, the median number of virological measurements per woman was 
three (range 2-7), with a similar interval between successive tests for the two treatment 
groups (Table 4.2). Although timing of HAART initiation and baseline HIV RNA were 
similar between treatment groups, the Pl-based group had significantly lower baseline 
CD4 counts (Table 4.2). This suggests the possible presence of confounding by 
indication with women with lower baseline CD4 counts preferentially initiated on PI- 
based HAART rather than a NVP-based regimen; adjusting for baseline CD4 count 
category and for treatment assignment with the propensity score will reduce some of 
this bias. The proportion of women delivering prematurely was similar between the 
treatment groups, however women receiving NVP-based HAART delivered slightly 
earlier than women receiving Pi-based HAART (Table 4.2); this was chiefly due to the 
larger proportion of elective caesarean section deliveries being carried out at or before 
37 weeks’ gestation in women who received NVP-based HAART (74% [57/77] for 
NVP-based vs. 57% [84/148] for Pi-based HAART; x2=5.74,/?=0.02).
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Table 4.2 Characteristics by HAART category
Characteristic Pi-based HAART 
(« =156)
NVP-based HAART 
(/i =84)
p  value
NRTI backbone
zidovudine/lamivudine 139 (89%) 72 (86%)
Other dual combination 17(11%) 12(14%) 0.58
Median time of initiation 
(gestational weeks)
23 (IQR 18-27) 21.5 (IQR 16-28) 0.57
Median baseline HIV RNA viral 4.18 4.08 0.58
load (logio copies/ml) (IQR 3.60-4.58) (IQR 3.71-4.54)
Median baseline CD4 count 305 355 0.02
(cells/mm3) (IQR 190-452) (IQR 277-506)
Median number of measurements 3 (IQR 2-3) 3 (IQR 2-3) 0.77
Median interval between 
successive HIV RNA tests (weeks)
7.5 (IQR 4-10) 6 (IQR 4-10) 0.07
History of IDU
Non-IDU 140 (92%) 75 (90%)
IDU 13 (8%) 8(10%) 0.96
Timing of HIV diagnosis
Antenatal 103 (66%) 50 (60%)
Pre-pregnancy 53 (34%) 34 (40%) 0.37
Median gestational age at delivery 
(weeks)
Premature delivery (<37 weeks)
38 (range 25-42) 37 (range 23-41) 0.003
No 126 61
Yes 30 23 0.20
t  - p  values were calculated with the Chi-squared or Mann-Whitney test as appropriate
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Figure 4.2 Distribution of baseline viral load measurements and median baseline 
viral load and CD4 cell count at time of HAART initiation in pregnancy
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The median gestational age at delivery was 38 weeks (range 23-42) and 73% (175/240) 
of women had undetectable viral loads by this time; Table 4.1 shows the number 
reaching this outcome by maternal characteristics. The proportion of women achieving 
undetectable viral load did not differ significantly by treatment group (71% [111/156] 
for Pi-based and 76% [64/84] for NVP-based HAART; p=0.49). It should be noted here 
that as most women reached viral suppression, the relative hazards (RH) obtained from 
subsequent regression models will reflect the rapidity with (rate at) which this occurs,
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rather than solely the probability of the event occurring; larger RHs will therefore 
indicate more rapid attainment of viral suppression.
4.3.1 Exploring times to achieving undetectable HIV RNA
Figure 4.3 displays the proportions of women achieving undetectable viral load from 
time of initiation stratified by HAART category and by black race, as estimated with the 
Turnbull method (Klein and Moeschberger 1997;Giolo 2004), together with the 
numbers of women remaining in the risk set at each time point. Figure 4.3A reveals an 
overall similar survival curve between both treatment groups up to around 6 weeks after 
initiation, after which the curves diverge with the NVP-based group having a greater 
tendency to achieve undetectable levels; at 5 weeks 46% [95%CI 33-60] and 44% 
[95%CI 25-67] of the PI and NVP groups respectively reached undetectable levels, 
compared to 61% [95% 50-71] and 82% [95%CI 69-92] by 10 weeks. Figure 4.3B 
reveals similar proportions achieving undetectable levels in the first few weeks after 
initiation among non-black and black women, after which the black women were 
observed to have a greater tendency to achieve undetectable levels.
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Figure 4.3 Survival curves for the time from initiation of HAART to achieving
undetectable viral load by: (A) treatm ent category; (B) black race
o
n.risk n.events
Non-black
Black 141 110ooo
CD
d
o
d
20 250 5 10 15
o
n.risk n.events
156 111
NVPco
d
CDo
■M-o
CMo
oo
20 25
Weeks from HAART initiation Wfeeks from HAART initiation
n at risk (Fig 4.3A)
Weeks from initiation PI NVP
0 156 84
5 137 73
10 96 46
15 55 19
20 25 6
25 4 2
n at risk (Fig. 4.3B)
Non-black Black
96 141
81 126
58 81
32 40
15 13
4 2
107
Figure 4.4 reveals the survival curves for black and non-black women excluding IDUs; 
the survival curves were similar in the first few weeks after initiation, and although 
there was some evidence o f black women having a greater tendency to achieve 
undetectable levels than non-black women, the difference was attenuated slightly from 
that observed in Figure 4.3B, and there is some crossing of the two curves. This 
attenuation suggests that some of the difference seen in Figure 4.3B could be attributed 
to cases o f IDUs among non-black women and will be explored further in the 
parametric regression model.
Figure 4.4 Survival curves for the time from initiation of HAART to achieving 
undetectable viral load by black race, excluding IDUs
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Figure 4.5A shows the Turnbull estimates of the proportion achieving undetectable viral 
load according to baseline HIV RNA levels, and revealed marked differences in the 
rates of achieving undetectable viral load between these categories. Overall women with 
the highest baseline HIV RNA (>5 logio copies/ml) had a lesser tendency to achieve 
undetectable levels than those with lower baseline levels, although the curves for 
women in this group were similar to those with baseline HIV RNA 4-4.99 logio 
copies/ml for the first few weeks after initiation. Women with the lowest baseline HIV 
RNA (<4 logio copies/ml) had the fastest rate of achieving undetectable HIV RNA 
levels.
Figure 4.5B shows the Turnbull estimates of the proportion achieving undetectable viral 
load according to baseline CD4 cell counts. Women with low baseline CD4 counts 
(<200 cells/mm ) had a relatively slow rate of achieving undetectable HIV RNA 
compared to women with higher CD4 counts. Women with the highest CD4 counts 
(>500 cells/mm3) had a relatively faster rate up to about 10 weeks from initiation, after 
which there was little indication of differences in the proportions achieving undetectable 
levels for the women in the intermediate CD4 and highest CD4 categories.
Figure 4.5 A revealed baseline HIV RNA to be an important predictor of achieving an 
undetectable viral load, therefore Turnbull estimates of the proportion reaching 
undetectable viral loads by treatment group and race were calculated separately for 
women with baseline viral loads above or below the overall median viral load at 
baseline (« 4 logio copies/ml).
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Figure 4.5 Surv ival curves for the time from initiation of HAART to achieving
undetectable viral load by (A) baseline viral load; (B) baseline CD4 cell count
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Figure 4.6A revealed overall similar proportions achieving undetectable HIV RNA 
levels after the time of initiation by HAART regimen for women with baseline HIV 
RNA <4 logio copies/ml. Figure 4.6B revealed similar proportions by HAART regimen 
for women with baseline HIV RNA >4 logio copies/ml in the first few weeks after 
initiation, after which point women receiving NVP-based HAART had a greater 
tendency to achieve undetectable levels. For women with baseline HIV RNA >4 logio 
copies/ml, 35.2% (95%CI 20-51) and 53.0% (95%CI 20-94) of the PI and the NVP 
groups respectively reached undetectable levels by 5 weeks, 56.4% (95%CI 45-71) and 
76.4% (95%CI 56-94) by 10 weeks and 59.4% (95%CI 43-75) and 93.4% (95%CI 66- 
99) by 15 weeks, highlighting a potential differential response by treatment category.
Figure 4.7 displays the proportions of women achieving undetectable viral load from 
time of initiation stratified by race and baseline viral load. The proportion reaching 
undetectable virus for non-black and black women with baseline HIV RNA >4 logio 
copies/ml was 58.7% (95%CI 44-75) and 66.3% (95%CI 53-79) respectively at 10 
weeks and 64.1% (95%CI 38-85) and 79.3% (95%CI 65-93) at 15 weeks, suggesting the 
possibility of race as a prognostic indicator (Figure 4.7B). Figure 4.7B also revealed a 
crossing of the two survival curves, supporting the use of a Weibull survival model, 
which does not require the assumption of proportional hazards to hold (Cox et al. 2007).
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Figure 4.6 Survival curves for the time from initiation of HAART to achieving
undetectable viral load by initial treatm ent category: women with (A) baseline
viral load <4 logio copies/ml; (B) baseline viral load > logio copies/ml
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Figure 4.7 Survival curves for the time from initiation of HAART to achieving
undetectable viral load by race category: women with (A) baseline viral load <4
logio copies/ml; (B) baseline viral load > logio copies/ml
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As noted in Section 4.2.2, the survival curves and estimates produced by the Turnbull 
method are purely for use as an explanatory tool, they do not take account of any other 
variables and therefore only very limited inferences can be made on these findings. The 
appropriate way to further assess any potential differences in survival curves is through 
the use of a regression model.
4.3.2 Parametric survival model
As discussed in section 4.2, the Weibull model can provide more precise estimates for 
regression coefficients, provided the parametric distribution is chosen correctly. To 
ascertain the appropriateness of the Weibull distribution in examining the effect of 
treatment on times to undetectable HIV RNA, a graphical check of a function of the 
cumulative hazard rate by HAART regimen was used (Klein and Moeschberger 1997). A
plot of the function of the cumulative hazard rate ( In H )  should be linear in log time for 
the Weibull distribution to be considered a suitable distribution to model the hazards. 
Therefore a plot of In H  vs. In x by treatment group was used to assess the suitability of 
the Weibull distribution here, with the log cumulative hazard rates estimated from the 
survival rates obtained from the Turnbull method. The resulting curves for the two 
treatment categories shown in Figure 4.8 are roughly linear for each group, except for 
some variation in the tail for the NVP-based group. This suggests that the Weibull 
parametric model provides an adequate fit for these groups.
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Figure 4.8 Weibull hazard plot by HAART category.
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Twenty-three women with information missing on race (3/23) or CD4 counts (20/23)
were excluded; these women had similar characteristics with respect to baseline viral
load (median 4.35 [IQR 3.88-4.77] logio copies/ml for those with missing information
vs. 4.14 [IQR 3.61-4.56] for those with complete information; Wilcoxon test p=  0.19),
baseline CD4 counts (median 246 [IQR 204-470] vs. 330 [IQR 210-480]; Wilcoxon test
p=  0.85). There were no significant differences between, women with missing information
and those with complete information with respect to the numbers receiving Pi-based
HAART (15/23: 65% vs. 160/217: 74%; x2=0.84, p=0.84), the numbers reaching
undetectable viral load by delivery (15/23: 65% vs. 160/217: 74%; x2=0.39,/>=0.53) and
the numbers reaching undetectable levels by HAART regimen (60% [9/15] and 75%
115
[6/8]) by Pi-based and NNRTI-based HAART respectively for women with missing 
information vs. 72% [102/141] and 76% [58/76], respectively for those with complete 
information).
The inclusion of the main effects of type of HAART regimen, race and trimester of 
initiation were all associated with significant improvements in the log-likelihood of the 
model. These covariates were then considered together in one model, along with baseline 
CD4 cell counts (Table 4.3, Model 1). It should be noted here that although the inclusion 
of CD4 count to the model with baseline viral load alone did not lead to improvements in 
the log-likelihood, it was included due to its close relationship with HIV RNA viral load 
and disease status. The model could not be improved further with the addition of other 
main effects. Including two-way interaction terms between any of the variables in the 
final model did not significantly improve the fit (Table 4.3).
The resulting model included baseline viral load and CD4 cell counts, type of HAART 
regimen, race and trimester of initiation. The RH for black race after adjusting for 
baseline viral load only (RH 1.47; 95%CI 1.04-2.07) and all other covariates in the 
model (RH 1.49; 95%CI 1.04-2.13) confirmed the differences seen in the survival curves 
in Figure 4.3B and 4.7. It should be noted here that the inclusion of IDU to the model 
neither improved the model fit in terms of the LRT, nor resulted in a significant change 
in the estimate of the black race estimate or its standard error and was therefore not 
included in the final model. As the majority of black women in this cohort were
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Table 4.3 Likelihood ratio tests for model selection procedure
Model no. Model LRT d.f.a P
1 HAART regimen+ race+ VL+ 
CD4+ trimester of initiation
8
2 Model 1 + race*HAART 0.52 1 0.46
3 Model 1 + race*VL 4.27 2 0.12
4 Model 1 + race*CD4 5.49 2 0.06
5 Model 1 + race* trimester 0.92 2 0.63
6 Model 1 + VL*CD4 1.85 4 0.76
7 Model 1 + VL*HAART 0.19 2 0.91
8 Model 1 + CD4* HAART 2.13 2 0.34
9 Model 1 + VL*trimester 4.27 4 0.37
10 Model 1 + CD4*trimester 1.67 4 0.80
a - degrees of freedom
from different regions of Africa, these race-associated differences were explored in 
further models through the examination of region of birth, categorised as Non-African 
and Eastern, Central, Northern/Southern or Western Africa. Although constituting a 
small group of women, the Northern/Southern Africa group were included in a separate 
group as they could not feasibly be included in any of the other African regions and it 
was preferable to the alternative of removing them from the analysis completely; this 
however limits any inferences made on the resulting RH estimate. The presence of 
interaction terms in the model with region of birth instead of race was assessed; none 
were required. The univariable (adjusted for baseline viral load only) and multivariable 
RHs are shown in Table 4.4.
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Table 4.4 Factors associated with time to achieving undetectable HIV RNA viral 
load after initiation of HAART in pregnancy - model without propensity score
(n=217)
Univariable
analysis
Multivariable
analysis
if RH* (95% Cl) P RH (95% Cl) P
Region of birth
Non-African 96 1.00 1.00
Eastern Africa 42 1.15 (0.73-1.83) 0.55 1.42(0.86-2.32) 0.17
Central Africa 33 1.58(0.96-2.60) 0.07 1.43 (0.84-2.42) 0.19
Northern/Southern Africa 7 0.82 (0.31-2.13) 0.68 1.00(0.37-2.67) 0.99
Western Africa 39 1.58(1.0-2.50) 0.05 1.81 (1.11-2.96) 0.02
HAART regimen
Pi-based 141 1.00 1.00
NVP-based 76 1.62(1.14-2.31) <0.01 1.60(1.10-2.33) 0.02
Time of initiation of HAART
First trimester 12 1.00 1.00
Second trimester 150 1.05(0.55-2.04) 0.87 1.08 (0.54-2.17) 0.22
Third trimester 55 2.18(1.0-4.74) 0.05 2.16(0.95-4.88) 0.07
Baseline HIV RNA (copies/m l)b
>4.40 logio 72 1.00 1.00
3.81-4.39 logio 73 1.75 (1.15-2.66) <0.01 1.76(1.13-2.75) 0.01
< 3.81 logio 72 2.54(1.69-3.80) <0.001 2.46(1.57-3.83) <0.0
01
Baseline CD4 count (cells/mm3)
<200 47 1.00 1.00
200-499 123 1.39(0.89-2.15) 0.14 1.41 (0.90-2.21) 0.14
>500 47 1.42 (0.83-2.43) 0.20 1.52 (0.85-2.74) 0.16
— £
RH, Relative hazard. Baseline HIV RNA categorised according to their tertiles
NOTE: Univariable and multivariable estimates adjusted for baseline viral load; multivariable estimates 
adjusted for all covariates listed in table
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The probability (propensity score) of a woman being treated with NVP-based HAART 
was estimated using a logistic regression model with the following covariates; timing o f 
first HIV diagnosis during pregnancy, region o f birth, trimester o f initiation, year of 
delivery and baseline viral load and CD4 cell counts. The unadjusted and adjusted odds 
ratios (OR and AOR, respectively) for the propensity score are given in Table 4.5. The 
inclusion of the timing of first HIV diagnosis was regarded a priori as an important 
consideration for clinicians in assigning a treatment to ARV-naiVe pregnant women and 
was therefore included in the final model although it had a p>0.5. There was some 
evidence to suggest that women with baseline CD4 counts >200 cells/mm had a higher 
odds of being treated with NVP-based HAART than women with counts <200 
cells/mm3, as did women delivering in the period 2003-2004, compared to women 
delivering in the period 1998-2000. Additionally, there was some evidence that women 
initiating HAART in the second trimester of pregnancy were less likely to receive NVP 
than women initiating earlier in pregnancy (Table 4.5). The propensity scores from the 
adjusted model were then estimated and a histogram of the scores is shown in Figure 4.9. 
The majority of the values were clustered between 25 and 50%; Themeau et al. describe 
only small alterations in the RH estimates when regression models are adjusted by scores 
clustered around this range (Themeau and Grambsch 2000).
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Table 4.5 Unadjusted and adjusted logistic regression models for the probability of 
being treated with NVP-based over Pi-based HAART («=217)
Unadjusted Adjusted
OR* (95% Cl) p AOR*’b (95% Cl) p
Region of birth
Non-African
African
1.00
0.70 (0.40-1.22) 0.21
1.00
0.71 (0.39-1.32) 0.28
Timing of first HIV diagnosis
Before pregnancy 
During pregnancy
1.00
1.30(0.73-2.33) 0.37
1.00 
1.09 (0.58-2.06) 0.79
Time of initiation of HAART
First trimester 
Second trimester 
Third trimester
1.00
0.31 (0.09-1.02) 
0.55(0.16-1.96)
0.05
0.36
1.00
0.26 (0.07-0.95) 
0.46 (0.12-1.82)
0.04
0.27
Baseline HIV RNA 
(copies/ml)
>4.40 logio 
3.81-4.39 logio 
<3.81 log,0
1.00
1.44(0.91-19.68)
3.19(0.68-15.11)
0.07
0.14
1.00
4.04 (0.80-20.33) 
2.23 (0.42-11.86)
0.09
0.35
Baseline CD4 count 
(cells/mm3)
<200
200-499
>500
1.00
2.29(1.04-5.03) 
2.51 (1.01-6.23)
0.04
0.05
1.00
2.23 (1.01-5.36) 
2.36 (0.85-6.57)
0.05
0.10
Time period
1998-2000
2001-2002
2003-2004
1.00 
1.45 (0.68-3.09) 
2.01 (0.91-4.44)
0.34
0.09
1.00 
1.72 (0.76-3.90) 
2.43 (1.03-5.76)
0.19
0.04
a -  OR: Odds ratio; AOR: Adjusted Odds Ratio 
b - Model adjusted for all covariates listed in table
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Figure 4.9 Distribution of propensity score for treatment with NVP-based HAART
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The estimated propensity scores were included in the model specified in Table 4.4 after 
stratification into quintiles. Adding the propensity score to the model had only a small 
effect on the resulting adjusted RH estimates and their standard errors. There was a 
marginal attenuation of the RH estimate for NVP-based HAART to 1.54 (95%CI 1.05- 
2.26), which could be a result of the reduction in bias through inclusion of the propensity 
score. Additionally, the estimated RH women for Western African origin was 1.90 
(95%CI 1.16-3.12) compared to women of Non-African origin and baseline HIV RNA 
levels of 3.81-4.39 logio and <3.81 logio copies/ml had estimated RHs of 1.70 (95%CI
1.08-2.68) and 2.76 (95%CI 1.68-4.52), respectively. Although the resulting change in 
RH was only small, subsequent inferences were made and sensitivity analyses carried out 
on the adjusted survival model which included the propensity score
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4.3.3 Model assessment
The scale parameter for the Weibull model, a , was estimated to be 1.43 (95%CI 1.10- 
1.63); the confidence interval for this estimate is bounded away from 1 and suggests that 
the exponential model would not be a simpler parametric alternative (Klein and 
Moeschberger 1997).
A plot of the deviance residuals against index number (i.e. against the index number for 
subjects in the model, 1 , 2 in no particular order) has been suggested as a guide to 
detect outliers from a Weibull model (Klein and Moeschberger 1997). A plot of the 
deviance residuals against observation number (i.e. 1, 2,...., 217) from the final survival 
model, which included the propensity scores is given in Figure 4.10 and revealed no 
indication o f any major outliers.
4.3.4 Interpretation
The rate of women achieving undetectable viral load in the NVP group was estimated to 
be almost one and a half times of that in the PI group (ARH 1.54 [95%CI 1.05-2.26]). 
Women of Western African origin had an almost doubled rate of achieving undetectable 
viral load compared to women of Non-African origin (ARH 1.90 [95%CI 1.16-3.12]). 
Women with the lowest baseline viral loads (<3.81 logio copies/ml) had the fastest rate 
of achieving undetectable viral load compared to women with baseline levels >4.40 logio 
copies/ml (ARH 2.76 [95%CI 1.68-4.52]). There was no evidence of an association 
between baseline CD4 count and the rate of achieving undetectable vial load (RHs for 
baseline CD4 cell counts 200-499 and >500 cells/mm3 were 1.25 [95%CI 0.69-2.24] and 
1.40 [95%CI 0.71-2.76] compared to <200 cells/mm3).
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Figure 4.10 Deviance residuals from the adjusted Weibull model
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Using the acceleration format parameterisation of the Weibull model, the median time to 
undetectable viral load for a woman receiving Pi-containing HAART was estimated to 
be 1.38 (95% Cl 1.04-1.83) times that of a woman receiving NVP-containing HAART. 
The acceleration factor for the model without the propensity score was 1.42 (95%CI
1.08-1.88), similar to that which included the propensity score. The predicted median 
time to undetectable virus for non-African women with baseline CD4 counts 200-499 
cells/mm3 and viral load 3.81-4.39 logio copies/ml initiating treatment in the second 
trimester was 7.1 weeks (95% Cl 3.60-10.53) for the NVP group and 9.8 weeks (95% Cl 
5.38-14.16) for the PI group; for Western African women with similar characteristics, 
these times were 4.4 weeks (95% Cl 2.1-6.7) and 6 weeks (95% Cl 3.2-8.9), 
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4.3.5 Sensitivity analysis
The majority of women receiving Pi-based HAART received NFV, and therefore a 
sensitivity analysis to examine the time taken to achieve undetectable viral load between 
women receiving NFV-based HAART or NVP-based HAART was carried out. The 
resulting model revealed similar RHs for NVP-based HAART (RH 1.56, 95%CI 1.05- 
2.32). Similarly, a sensitivity analysis including only women initiating HAART in the 
first and second trimesters was carried out and resulted in an increase in the RH for 
NVP-based HAART (RH 1.82, 95%CI 1.18-2.84). The impact of including the baseline 
HIV RNA (logio copies/ml) as a continuous covariate was also evaluated and did not 
lead to a substantial change in the relative hazard for NVP-based HAART (RH 1.50 
95%CI 1.02-2.19).
Sub-analysis fo r women with CD4<250 cells/mm3
The time to achieving undetectable virus was also examined for the 70 women who 
would be eligible for NVP-based HAART according to current prescribing advice 
(Public Health Service Taskforce 2006b) (i.e. with baseline CD4 counts <250 
cells/mm3). The median baseline viral load for this group of women was 4.35 logio 
copies/ml (IQR 4.05-4.69) and the median time of initiation was 22 weeks gestation and 
16 (24%) actually received NVP.
Using the Turnbull method, the estimated proportion reaching undetectable viral load at
5 weeks was 34.8% (95%CI 20.4-46.7) for those on PI and 52.9% (95%CI 22.1-71.6) for
those receiving NVP, increasing to 50.4% (95%CI 34.0-62.8) and 82.4% (95%CI 50.7-
93.7) at 8.5 weeks (due to small numbers of women, the Turnbull estimates and
associated bootstrap confidence intervals were unstable after 8.5 weeks and were
therefore, not reported here). In a Weibull regression model adjusting for race, timing of
initiation in pregnancy (first/second trimester vs. third trimester), baseline viral load, and
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CD4 cell count (<200 cells/mm3 or between 200-250 cells/mm3), the estimated RH for 
NVP-based vs. Pi-based HAART was 1.89 (95%CI, 0.87-4.12). The RH was 
considerably larger than when women in all CD4 categories were included. However, 
although the power in this study may have been limited owing to the small sample size 
and this did not reach statistical significance, the set of values covered by the 95% Cl 
were not clustered closely to 1 suggesting that a larger effect of NVP-based HAART 
among women with CD4 counts <250 cells/mm3 should not be ruled out based on these 
data.
Women not achieving undetectable levels by the time o f  delivery 
The 65 (27%) women delivering with detectable viral load were not significantly 
different to those achieving undetectable levels, with respect to race (31/64: 48% non­
black vs. 110/173: 64% black; *2=3.84,/>=0.05) and type of HAART (20/65: 31% PI- 
based vs. 64/175: 37% NVP-based HAART; x2 =0.47, p=0.49). However, more were 
severely immunosuppressed (CD4<200 cells/mm3) (33% [19/58] vs. 18% [29/162], 
/?=0.03) and more had baseline viral loads >5 logio copies/ml (15% [10/65] vs. 6% 
[10/175], /?=0.03). The median viral load at delivery for the 65 women not achieving 
undetectable viral load was 2.48 logio copies/ml (IQR 2.26-3.11) and only 20 (31%) had 
viral load above 1000 copies/ml.
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4.4 Key points
• Most (73%) ARV-nai've women initiating HAART antenatally delivered with 
undetectable virus and the remainder delivered with detectable, but generally low 
levels.
• Adjusting for baseline prognostic factors, the RH of achieving undetectable viral 
load was greater for women on NVP-containing HAART than for women on PI- 
based HAART, with women in the PI group taking on average 1.4 times longer to 
achieve undetectable levels.
• Women with lower baseline viral load and o f Western African origin had a higher 
rate of achieving undetectable levels.
• There was no statistically significant differences in the time to attaining 
undetectable viral load by baseline CD4 status, although immunosuppressed 
women (CD4 count <200 cells/mm3) had a non-significantly lower rate.
• A sensitivity analysis comparing NFV-based PI regimens only with NVP-based 
regimens confirmed a higher rate of achieving undetectable viral load with NVP.
• The use of an interval-censored survival model to take into account the non- 
uniform intervals of HIV RNA measurement in pregnancy should improve the 
accuracy of the treatment effect estimates.
• Adjustment for the propensity score for treatment resulted in only negligible 
changes in the treatment effect HR.
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Chapter 5 Bivariate longitudinal model of HIV RNA and CD4 counts
in pregnant women on HAART
5.1 Introduction
The probability of further live births in HIV-infected pregnant women has increased 
substantially in Europe since 1995 especially among black women, and the time interval 
between births has shortened (European Collaborative Study 2005a). An increasing 
proportion of HIV-infected pregnant women in Europe can therefore be expected to be 
on treatment at or before the time of conception.
Viral load in women receiving HAART at the time of conception would be expected to 
be low or at undetectable levels for those responding successfully to treatment. Women 
receiving HAART at conception with detectable viral load at their first visit in 
pregnancy are a very different group with a comparatively higher risk o f transmitting 
their infection to their unborn child (European Collaborative Study 1999;Cooper et al.
2002) which may be an indication of a poorer response to treatment, non-compliance or 
resistance. Changes in viral load and CD4 count during pregnancy are of interest to 
evaluate the efficacy of treatment and the risk of MTCT for this group of women, and 
the factors which may affect these levels, including ethnicity and history o f IDU and the 
type of HAART regimen being taken at conception (Chapters 3 and 4).
Pregnancy data on viral load and CD4 count dynamics in women becoming pregnant on 
HAART are lacking at present. It has been shown in non-pregnant adults that the joint 
modelling of viral load and CD4 count is important due to the intrinsic correlation
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between them and results in improved parameter estimates for both markers (Thiebaut 
et al. 2002;Thiebaut et al. 2005). A bivariate random effects model is advantageous as it 
allows for direct interpretation of the relationship between the two markers without 
assuming the dependence of one marker in relation to the other (Thiebaut et al. 2002).
Using a bivariate linear mixed effects (BLME) model taking into account left-censoring 
due to the lower quantification limit of HIV RNA assays (Thiebaut et al. 2005;Thiebaut 
et al. 2003), levels of viral load and CD4 in HIV-infected HAART-treated women who 
become pregnant with detectable levels of viral load and the factors associated with 
these levels, were examined. Understanding how these levels change over pregnancy 
and identifying the factors which affect these will help to inform clinical decision­
making in this group of women. The correlation between the markers estimated from 
the bivariate model will be assessed as well as the fixed and random effects estimates 
compared to those estimated from the univariate models for CD4 counts and viral load 
to ascertain whether this is an appropriate method for analysis of HIV markers in treated 
pregnant women. Univariate models for viral load and CD4 as a function of the other 
marker will also be assessed.
The joint modelling of HIV RNA and CD4 for untreated women or women starting 
HAART for the first time is of interest but was not possible for this study due to the few 
measurements available on both markers for untreated women and the different 
initiation times for women starting HAART for the first time in pregnancy (Chapter 4).
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5.2 Methods specific to this analysis
5.2.1 Data
There were 597 HIV-infected pregnant women receiving HAART at conception. Two- 
hundred and fifty-five women with undetectable viral loads at their first visit in 
pregnancy were excluded as the use of a linear model is not appropriate to explain the 
complicated pattern of viral load markers in this group where rebounds may occur 
(Fitzgerald et a l 2002) and the inclusion of these women would not allow for a 
bivariate model to be fitted. An additional 180 women with neither viral load nor CD4 
counts available were also excluded. The exclusion of these women is unavoidable due 
to missing data and may introduce potential biases to the analysis; thus the results need 
to be interpreted under this condition (see Chapter 7)
The analysis was restricted to the remaining 162 women receiving HAART at 
conception with a detectable viral load at their first measurement in pregnancy, and at 
least one CD4 count available in pregnancy. The selection criteria were chosen so that a 
bivariate model of CD4 and HIV RNA could be fitted, but limit any inferences which 
can be made to women with detectable viral loads at first visit in pregnancy only (see 
Chapter 7).
Variables considered in the model included gestational age (expressed as weeks to the 
time of delivery), a variable combining race and history of IDU (non-IDU white, non- 
IDU black and white IDU; there were no black IDUs here), HAART type (Pi-containing 
vs. NNRTI-containing), time period (1998-1999, 2000-2001 and 2001-2006) and type 
of HIV RNA assay (Roche vs other). These variables were deemed important potential 
confounders as they are known to or have the potential to be related to levels of CD4
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counts or viral load (European Collaborative Study 1999;Anastos et a l 2000;Saul et al. 
2001;Touloumi et a l 2004) (Chapter 3 and 4). Due to the available number of 
observations, region of birth was not explored in this analysis as stratification by region 
of birth and IDU resulted in overly small groups of women, which did not facilitate 
model fitting and convergence for the left-censored HIV RNA model. To maximise the 
sample size of women in this analysis, timing of initiation was not considered in the 
initial models as only 109 women had information available on timing of treatment. A 
sensitivity analysis of women with information available on initiation of treatment 
(receipt o f HAART for > 6 months vs. < 6 months) was carried out on the final model to 
determine the impact o f the inclusion of this information on the parameter estimates.
A logio transformation of CD4 count was sufficient to satisfy the normality and 
homoscedasticity assumptions of linear mixed effect (LME) models (see Results 
section, Figure 5.9 and 5.13B). A logio transformation was also preferred to the often 
used square root transformation as it allows for direct interpretation of the parameter 
estimates.
5.2.2 Statistical methods
Random effects models are an appropriate method to deal with repeated measures data 
(Laird and Ware 1982;Pinheiro and Bates 2000). However, there are additional 
methodological issues to take into account in the analysis of longitudinal data on HIV 
markers such as HIV RNA viral load and CD4 counts.
The inherent natures of HIV RNA viral load, which represent the number of actively 
replicating HIV, and CD4 counts which are the target of HIV, mean that the both are
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intrinsically correlated. Univariate models to describe the levels of each marker, 
dependent on the other one is a possible approach but requires that measurements are 
available at the same time and with the same frequency. A bivariate random effects 
model allows the study of the relationship between these two HIV markers without this 
requirement (Goldstein 1989;Thiebaut et al. 2003). The bivariate model has also been 
shown result in a more appropriate estimation of the correlation between CD4 and viral 
load, providing a better fit to the data than two separate univariate models (Boscardin et 
al. 1998;Thiebaut et al. 2002;Thiebaut et al. 2005).
However, the study of levels of these two markers is further complicated by the 
sensitivity of assays used to detect HTV RNA viral load. Undetectable levels of HIV 
RNA viral load occur when the virus is below the lower quantification limit of these 
assays. Crude approaches to deal with these left-censored values such as imputation of 
half the value of the assay limit have been shown to lead to biased estimates of model 
parameters and their standard errors (Jacqmin-Gadda et al. 2000;Hughes 1999;Thiebaut 
and Jacqmin-Gadda 2004). An approach such as the conditional likelihood method 
proposed by Jacqmin-Gadda et al to estimate LME models with left-censored 
longitudinal data leads to comparatively smaller bias and mean squared errors of 
parameter estimates (Jacqmin-Gadda et al. 2000).
A similar approach based on conditional likelihoods and which can be implemented in 
SAS was used here (Thiebaut and Jacqmin-Gadda 2004). This approach has been shown 
to be comparable to the approach of Jaqmin-Gadda et al (Jacqmin-Gadda et al. 2000) 
and can be extended to the bivariate case.
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Bivariate linear mixed effects model
The extension of the usual univariate LME model (Laird and Ware 1982;Pinheiro and 
Bates 2000) can be extended to the BLME model as follows (Thiebaut et a l
2003;Goldstein 1989). Let Y( = y;
V2
be the response vector for the subject /=1, ...JV,
where Yk is the -vector of measurements for the HIV marker k (k= 1,2). Similar to the
LME model in Chapter 3, assuming that viral load measurements within each woman 
are representative of that woman’s viral load trajectory in pregnancy, there is no 
requirement that the same measurement times are sampled or that the same number of 
measurements is made on each subject (Goldstein 1989). As longitudinal measurements 
in pregnancy are expected to be few in number, the accuracy of parameter estimates can 
be increased with the inclusion of subjects with only one CD4 measurement or one viral 
load measurement. However, a single CD4 or viral measurement will contribute to the 
estimate of the intercept but will add little to the estimation of the slope.
The BLME model can be written as follows:
Y ^ X ^  + Z j '  + S'
with e. ~ V (0 ,Z , ) and y, ~ N (0 ,G ), and
P =
p X
P 2
X) 0
0  x f
Z\ 0
0  z 2
and s. =
For each marker k  (£=1,2), X k is a nt x p k design matrix of explanatory variables, p k is 
a p k -vector of fixed effects, Z* is a x qk design matrix and yk is a qk -vector of 
individual random effects with qk < p k. One of the assumptions made here is that the 
the residuals for each marker, s) and s f , are not correlated. The covariance matrix of
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measurement errors is therefore a diagonal matrix Z, containing the elements and 
a 1 , representing the measurement error for each marker.
The covariance matrix for the random effects can be represented as
This matrix can be divided into three parts: i) G1, the matrix of variances and
covariances of random effects for the first marker, ii) G2, the matrix o f variances and
10covariances o f random effects for the second marker, and iii) G the matrix of 
covariances between the random effects of each marker. The correlation between the 
two markers is taken into account through this sub-matrix of covariances (Thiebaut et 
a l 2005).
LME model with left-censoring o f  HIV RNA viral load
When one or more viral load measurements have left-censored values, the likelihood for 
estimating the LME model needs to be modified. The method proposed by Thiebaut et 
al using the NLMIXED procedure in SAS, takes into account left-censored values when 
estimating model parameters by maximising a full likelihood, distinguishing the 
contribution o f the observed measures and left-censored measures, and is given below 
(Thiebaut and Jacqmin-Gadda 2004).
For any of the Y ’s, assume that there exists an n° -vector o f observed responses Y° and 
a n f -vector of censored responses Ytc , where n °+n f = ni . The likelihood function for 
the parameter vector 6 is given by
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M *)= n J | n / ^  ( Y ° i r> =“) | x|  J I 1 r ‘ =“)}x/* i u ) du^ - du, (5.1),
where Yi}is the/th  measure at the time ttJ (/== 1 ,...,« /) for the subject i (/ =1,..., N), 
fy?\r, I') ls univar*ate normal conditional density of the observed measure j  in
subject i given the random effects and <f>vC (. | .) is the univariate normal distribution
function o f the censored measure j  in subject i given the random effects. The 
computation of this likelihood leads to the integration over the random effects, u = uj, 
U2, Ug, i.e. it requires computation of a multiple integral o f dimension q. In essence, 
rather than imputing midpoints for undetectable values of viral load, this method 
assumes instead that the left-censored values are part of a Gaussian distribution and 
estimates viral load values by completing this distribution using the likelihood method 
described above.
In practice, the calculation o f a ^-dimensional integral limits the number of random 
effects that can be feasibly included in the model; the method has been found to work 
well with up to four random effects (Thiebaut et al. 2003), but a larger number may lead 
to computational problems and needs to be considered here when fitting the bivariate 
LME model taking into account left-censoring.
Calculating standard errors fo r  the correlation coefficients
The covariance parameters and asymptotic covariance matrix for the random effects 
terms were used to calculate the standard error for the correlation coefficients using the 
Delta method (Lynch M. and Walsh B. 1998).
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p  =
where p  is the correlation coefficient, o f and o f are the variances of the two 
estimated random effects parameters a and b, respectively and crab is the covariance 
between them. The delta method yields the following expression for the variance of p :
and allows calculating 95% confidence intervals for p  using a Normal approximation.
5.2.3 Model selection
Mean plots of logio transformed viral load and natural scale CD4 count over pregnancy 
and supersmoothers were used to examine the changes in these markers over pregnancy.
The bivariate model takes into account the correlation between the two markers through 
the covariance of the random effects terms and there is no requirement for the univariate 
LME components for each marker to include the same covariates. The model selection 
process therefore began with univariate LME models for each marker. The modelling 
process is given in Figure 5.1, and shows the order in which the models were fitted and 
in which they will be presented in this chapter, the relationships between them and the 
names with which each model will be referred to throughout the chapter.
The first step was to determine the appropriate functional form of logio HIV RNA and 
logio CD4 changes over gestational age in separate univariate LME models with the use
2 cov ( o f , o f ) 2 cov (o f ,crab) 2 cov ( o f , crab) 
4tfftff 2<t2acrab 2cr2bcrab
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of Akaike’s Information Criterion (AIC) and likelihood ratio tests (LRT), with 
midpoints imputed for undetectable viral load measurements. After determining the 
appropriate functional form between these markers and gestational age, the inclusion of 
additional covariates and interaction terms were tested using LRTs resulting in a 
univariate LME model for viral load, with imputed midpoints for undetectable values 
(MODVL) and a univariate LME model for CD4 counts (MODCD4).
Using the parameter estimates from MODVL as starting parameters for the iterative 
procedure, the model was refitted using the conditional likelihood approach assuming 
the same form for viral load changes over pregnancy and with the same covariates and 
random effects parameters ( resulting in MODVL-CL).
The form and markers identified in univariate models (MODVL and MODCD4) were 
then included in a BLME model (MODBIV), dealing with the left-censoring using 
midpoints (Figure 5.1). The estimated correlation between the markers was assessed and 
the parameter estimates and their standard errors from this model were compared to 
those from the univariate LME models, MODVL and MODCD4.
Using the parameter estimates from MODBIV as starting parameters, the model was 
refitted using the conditional likelihood approach (MODBIV-CL). Finally, MODVL- 
CL was refitted with the inclusion of CD4 counts as a covariate (MODVL-CL2) and 
MODCD4 was refitted with the inclusion of HIV RNA viral load as a covariate 
(MODCD4-2).
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Figure 5.1 Process used in modelling HIV RNA viral load and CD4 cell counts in pregnancy
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An intention to treat approach was taken here; thus, interruptions and modifications in 
the treatment regimen were not taken into account in the analyses.
5.2.4 Model fitting and model selection
Model selection and estimation for MODVL, MODCD4 and MODCD4-2 were carried 
out using R version 2.4.1 (R Development Core Team 2006). The NLMIXED procedure 
in SAS was used to obtain MODVL-CL and MODVL-CL2. This procedure directly 
maximises the integrated likelihood in Equation 5.1 and the default method of the Quasi 
Newton-Raphson optimisation algorithm was used. Computation of the integral over the 
random effects was performed using an adaptive Gaussian quadrature method (SAS 
Institute Inc. 2004;Thiebaut and Jacqmin-Gadda 2004).
MODBIV was estimated with the SAS MIXED procedure and MODBIV-CL with the 
SAS NLMIXED procedure, with likelihood estimation and integral computations 
carried out using the above methods, unless otherwise stated (SAS Institute Inc. 2004).
An unstructured covariance matrix was assumed for random intercept and slope terms 
for all of the LME models estimated here. This allows estimating all the elements of this 
matrix without imposing any restrictions.
5.2.5 Model residuals
The residuals from MODCD4 and MODCD4-2 were examined using standard 
diagnostics for LME models (Pinheiro and Bates 2000). Assessing the residuals from 
MODVL-CL and MODVL-CL2 however, is complicated as the resulting residuals are 
right-censored. It has been suggested that a check of the model assumptions for such
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residuals can be carried out by computing the cumulative frequency distribution of the 
residuals with a Kaplan-Meier estimator (Jacqmin-Gadda et al. 2000). The Kaplan- 
Meier estimate was therefore computed by replacing the survival time by the value of 
the residual, with the censoring indicator specifying whether the original value 
corresponding to the residual was left-censored or observed. This curve was then 
compared to the cumulative distribution of a normally distributed variable with variance 
, i.e. the variance for the within-group residuals estimated from the viral load model.
One of the assumptions of the BLME model is that the (bivariate) residuals are not 
correlated, i.e. the within-group residuals for each response variable, s l and s 2are 
independently and identically distributed (Gallant 1987;Goldstein 1989;Thiebaut et a l 
2005). The Pearson correlation coefficient, and other scalar dependence measures, used 
to assess this relationship could be unreliable as the dependence will be averaged out 
over the range of the residuals. The local dependence map (LDM) (Jones and Koch
2003), an extension of the local dependence function (Holland and Wang 1987) was 
used to explore the dependence between bivariate residuals. The methodology for the 
estimation of the LDM is given in Appendix E.
5.3 Results
One hundred and sixty-two HIV-infected pregnant women were included in this 
analysis. The characteristics of these women are given in Table 5.1. Most women were 
white, although nearly a third were were black, 89% of whom were bom in sub-Saharan 
Africa. Of the 100 women on a Pi-based regimen at conception, 48 (48%) received 
nelfinavir, 17 (17%) indinavir, 14 (14%) lopinavir, ritonavir or saquinavir and the
139
Table 5.1 Characteristics of the 162 women receiving HAART at the time of
initiation
Characteristic Women No. of measurements
»(% ) CD4 Viral load
>?=450 «=482
Type of HAART regimen
Pi-containing 100 (62) 268 (60) 280 (58)
NNRTI-contain ing 62 (38) 182 (40) 202 (42)
Race
White 102 (67) 271 (63) 298 (64)
Black 44 (29) 136(32) 140 (30)
Other 7(4) 24(5) 26 (6)
Unknown 9 19 18
Age at delivery (years)
Median (IQR) 
18-25
33 (30-36) 
18(12) 42(10) 48(10)
26-34 79 (52) 231 (54) 256 (55)
>35 55 (36) 154 (36) 160 (35)
Unknown 10 23 18
History of injecting drug use 
(IDU)
Non-IDU 114(72) 329 (74) 353 (74)
IDU 45 (28) 115(26) 121 (26)
Unknown 3 6 8
Time period of delivery
1998-1999 24(15) 59(13) 58(12)
2000-2001 70 (43) 165 (37) 195 (40)
2001-2006 68 (42) 226 (50) 229 (48)
No. of previous live births
None 59 (38) 154 (35) 164(35)
1 59 (38) 179 (41) 195 (42)
2 27(17) 73(17) 76(16)
>3 11(7) 30(7) 34(7)
Unknown 6 14 13
Timing of HAART (months 
before pregnancy)
Median (IQR) 10.5 (4.8-21.8) - -
> 6 months 74 (68) - -
< 6 months 35 (32) - -
Unknown 54 - -
HIV RNA assay
Roche - - 375 (78)
Other - - 107 (22)
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remaining 21 (21%) received boosted-PIs. Of the 62 women receiving NNRTI-based 
HAART, 53 (85%) received nevirapine and the remainder received efavirenz.
The median number of measurements per woman was 3 [IQR 2-3] for viral load and 3 
[IQR 2-3] for CD4 counts; this limited any inferences on the shape of the patterns of 
HIV RNA and CD4 counts in pregnancy. Of the 482 viral load measures, 114 (24%) 
were undetectable (i.e. left-censored).
All women who had a history of IDU (28%) were white, of whom 6 (4%) actively used 
injecting drugs during pregnancy.
Table 5.2 shows the median CD4 counts and viral loads (with midpoints imputed for 
undetectable values) according to type of HAART regimen and by ethnicity and history 
of IDU, for the 143 women with complete information on ethnicity and IDU. This table 
includes all the CD4 and HIV RNA measurements available at these four time periods, 
ignoring the correlation between measurements on an individual and is used here as a 
crude exploratory tool for examining changes in the markers over pregnancy by the 
main covariates of interest.
There were 101 measurements (49 CD4 and 52 viral load measurements) on 19 women 
with missing information on ethnicity. The distribution of viral load for these 19 women 
was not significantly different to the 143 women with complete information (median
3.02 logio copies/ml [IQR 2-3.71] vs. median 2.69 [IQR 2-3.48] logio copies/ml; 
Wilcoxon test p=0.86). There were also no differences in the distribution of CD4 counts 
(median 408 cells/mm3 [IQR 313-609] for women with incomplete information, vs.
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Table 5.2 Median CD4 count and logio viral load over pregnancy stratified 
according to type of HAART regimen, ethnic group and history of IDU (n=143)
1st trimester 2nd trimester 3rd trimester Delivery
ALL
Number of women 
CD4 count 
Viral load
74
381 (257-490) 
3.52 (2.39-4.43)
114
376 (262-513) 
2.88 (2.30-3.55)
99
447 (310-604) 
2.13 (1.40-2.93)
61
407 (299-572) 
2.30(1.60-2.64)
Pi-based HAART
Number of women 
CD4 count 
Viral load
44
396 (280-502) 
3.60 (2.72-4.47)
69
390 (282-522) 
2.86 (2.46-3.50)
55
451 (329-601) 
2.30(1.40-2.89)
39
407 (297-514) 
2.40 (2.00-2.75)
NNRTI-based HAART
Number of women 
CD4 count 
Viral load
30
359 (252-460) 
3.30(2.59-4.27)
45
338(252-491) 
2.89 (2.00-3.63)
44
392 (301-619) 
2.00(1.40-3.02)
22
448 (309-669) 
2.00(1.40-2.30)
Non-IDU White
Number of women 
CD4 count 
Viral load
35
424 (323-615) 
3.69 (2.66-4.60)
42
365 (287-539) 
2.90 (2.30-3.64)
44
469 (360-658) 
2.31 (1.40-3.18)
22
451 (255-441) 
2.51 (2.00-2.87)
Non-IDU Black
Number of women 
CD4 count 
Viral load
22
313 (229-385) 
3.92 (2.79-4.43)
39
290 (209-410) 
2.90 (2.33-3.55)
27
309 (265-432) 
2.00(1.40-2.64)
25
290 (255-441) 
1.99(1.40-2.40)
IDU White
Number of women 
CD4 count 
Viral load
17
400 (285-473) 
3.11 (2.61-3.33)
33
476 (390-610) 
2.79 (2.08-3.43)
28
493 (420-632) 
2.00(1.60-3.18)
14
552 (403-870) 
2.13(2.00-2.46)
median 399 [IQR 281-545]; Wilcoxon test /t=0.40). The principal aim of this analysis 
was to assess factors affecting the levels of CD4 and viral load over pregnancy, and 
these 19 women were excluded from subsequent analyses.
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The median CD4 cell counts overall were similar in the first and second trimester but 
were comparatively higher in the third trimester and at the time of delivery (Table 5.2). 
Although there were no significant differences in the distribution of CD4 count between 
treatment group at the four time points shown (Wilcoxon test /?-value 0.39, 0.32, 0.63 
and 0.42 respectively; Table 5.2), counts were lower in the NNRTI group at all time 
periods except delivery. CD4 count values were lower in black women than in the other 
two groups and higher in white women with a history of IDU compared to other two 
groups for all four time points shown (Kruskal Wallis test for differences between the 
distributions for the three groups; /7-value 0.04 for the first trimester and <0.01 for all 
other time points).
Median viral load decreased over the four time points and was lowest in the third 
trimester and at delivery. The number of undetectable values increased over pregnancy; 
0% (0/81) in the first trimester, 18% (29/163) in the second trimester, 38% (47/125) in 
the third trimester and 46% (28/61) at the time of delivery. This is partly an artefact of 
the inclusion criteria of a detectable viral load at first visit in pregnancy. There were no 
differences in the distribution of viral load by type of HAART regimen in the first, 
second or third trimesters of pregnancy (Wilcoxon test /7-values 0.48, 0.55 and 0.55, 
respectively); the test could not be carried out at delivery due to the large number of ties 
in the data. Viral load in the first and second trimester tended to be lower in white IDUs 
compared to white non-IDUs and black women, but overall the groups were similar 
with respect to their distributions of viral load at the four time points (Kruskal-Wallis 
testp -values 0.17, 0.68, 0.39 and 0.08 respectively; Table 5.2).
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Figure 5.2 shows the weekly mean observed logio viral load and natural scale CD4 
counts over pregnancy with associated 95% confidence intervals for the 143 women.
Figure 5.2 Mean observ ed viral load and CD4 count during pregnancy for women 
becoming pregnant while receiving HAART (7V=143). Bars show 95% confidence 
intervals
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The narrowing of the confidence intervals over pregnancy reveals the larger number of 
measurements available in later pregnancy. This figure reveals some increases in viral 
load until around 30 weeks before delivery, at which point the mean viral load decreases 
up to the time of delivery. Mean CD4 counts can be seen to decrease up to around 28 
weeks before the time of delivery, at which point mean CD4 is seen to decrease until the
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time of delivery. This crude graphical approach describes the rough trend in the 
markers, and suggests that a change-point model may be suitable for both of them.
In order to smooth these changes over pregnancy to reveal the underlying structure of 
the logio transformed HIV RNA viral load and CD4 count, supersmoothers were used. 
Figure 5.3 shows a scatterplot of viral load and CD4 count over pregnancy, with a 
supersmoother to describe the changes in each marker. The figure reveals a two-slope 
evolution for both of the markers, confirming the pattern seen in Figure 5.2. There was a 
slight linear increase in logio viral load until around 27 weeks before the time of 
delivery, at which point viral load decreased linearly until the time of delivery. CD4 
counts decrease slightly for early pregnancy up to about 25 weeks before the time of 
delivery, after which point CD4 decreases up to the time of delivery although there are 
some fluctuations towards the time of delivery. These time points correspond roughly to 
the beginning of the second trimester and may be indicative of a physiological change 
occurring after completion of the first trimester (see Chapter 7).
The two-slope pattern of the markers revealed in Figure 5.3 suggests that a piece-wise 
linear model, or a change point model may be appropriate here (Thiebaut et al. 
2005;Naumova et a l 2001). The change-point model is similar to a cubic spline model, 
but the form of the model is constrained to be linear on either side of the point of 
change, or knot and is fitted as follows.
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Figure 5.3 Supersmoothers for loglO viral load and CD4 count over pregnancy
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Let d  represent the time of change-point for gestational weeks to delivery and gtj 
gestational weeks to delivery at they'th measurement for the fth subject. Let ti} = gij- d
be the time o f the /th  measurement for the /th subject before or after the change-point. 
Then using the indicator variable & = 1 for the time period before the change-point,
h  < 0 > and Sv = 0 for the time period after the change-point, ttj > 0. The change-point
model can then be written as
Y ,J =  f i o t  +  +  P l i h j  ( *  ~  S i j  )  +  £ i j »
where pQi, (3U and /?2j represent the intercept (at the point of change) and two slopes
before and after the change-point for the /th subject, respectively, ttj gestational weeks
relevant to the change point and stJ the measurement error at the /'th measurement for
the /th subject (Naumova et al. 2001). The change-point, d, can be determined as the 
point at which the AIC for the model is minimised.
Figure 5.4 shows changes in AIC as a function of d  for the LME models for logio viral 
load and logio CD4 counts. Figure 5.4A reveals that for the viral load model, AIC is 
minimised with the change-point at -30 weeks (black dashed line) and at -27 weeks for 
the CD4 model (black dashedline, Figure 5.4B). As the interest here was in assessing 
the correlation between the two markers in a bivariate model through the intercepts and 
slopes of the two markers, it was preferable that a common change-point is chosen for 
both markers (and thereby a common intercept). The red dotted lines in Figures 5.4A 
and 5.4B represent the optimum change-point for the CD4 and viral load models, 
respectively. Choosing a change-point between the red and black lines for the viral load
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Figure 5.4 Change in AIC from varying time of change-point for LME model for: A) viral load , B) CD4 count.
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model led to only very small increases in the AIC; this was true for the CD4 model only 
up to -28 weeks. Therefore a common change-point of -28 weeks was chosen for both 
models, which resulted in only marginal increases in AIC from that of the optimum 
change-point for each respective model. This time for the change-point also had the 
advantage that it corresponds approximately to the end of the first trimester/beginning 
of the second trimester for a woman delivering at term.
Natural cubic splines for modelling the form of logio viral load and logio CD4 counts 
over pregnancy were also considered. The number of knots of the spline at suitably 
chosen quantiles was determined by assessing the AIC of the resulting model. Figure
5.5 A and B show the changes in AIC resulting from increasing the number of knots in 
the LME model for viral load and CD4 count, respectively. The AIC was minimised by 
including a spline with 5 knots for the viral load model, and 2 knots for the CD4 model 
(indicated by dashed vertical lines).
Orthogonal polynomials for the markers were also considered up to and including a 
quartic term. The resulting AICs from the change-point, spline and polynomial LME 
models are shown in Table 5.3; all models included only a random intercept term.
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Figure 5.5 Changes in AIC from additional knots of the spline for: A) viral load, B) 
CD4 count model.
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Table 5.3 AIC from models comparing functional forms for logio viral load and 
logio CD4 count
AIC from LME model
Model logio Viral load logio CD4 count
Change-point 1141.40 -381.52
Linear 1148.24 -373.40
Quadratic 1149.06 -376.18
Cubic 1139.46 -376.60
Quartic 1141.35 -374.62
Cubic spline 1140.32 -375.74
The change-point model resulted in the smallest AIC for modelling logio CD4 counts 
over pregnancy, while the cubic model resulted in the smallest AIC for logio viral load
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(Table 5.3). However, little was gained in terms of the reduction in AIC (and therefore 
model goodness-of-fit) with the cubic over the change-point model for viral load. 
Additionally, the parameter estimates from an orthogonal polynomial model are 
difficult to interpret directly and therefore the change-point model was used for both 
markers, with a common change-point fixed at -28 weeks.
The inclusion of an additional random effect term for the first slope did not result in an 
improved log-likelihood for either the viral load model (Xd/ = 2  =3.12; p= 0.21) or the
CD4 model ( ; i£ ,2 = 2.66; /t=0.26). However, inclusion of a random effect for the 
second slope resulted in a considerable improvement in the model for CD4 count 
{Xd/ = 2 =7.09 ; /t=0.03), and a relatively smaller improvement for the viral load model
(Zd/ = 2 =4.51; /?=0.10). The random effect for the second slope was however retained
for both models, so that the correlation between the two slopes (through their estimated 
covariance) could be investigated in the bivariate model, in addition to the correlation 
between the intercepts.
5.3.1 Model selection for univariate LME models (MODVL and MODCD4)
The main covariates of interest were considered in the change-point model for both 
markers separately and the resulting changes in log-likelihood and associated /7-value 
from the LRTs are given in Table 5.4.
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Table 5.4 Likelihood ratio tests for including main covariates
Covariates
Viral load model CD4 count model
l r t  x2m P LRT x2 (df) P
Race by IDU 5.06 (2) 0.078 15.70(2) <0.001
Type of HAART regimen 0.16 0.075 (i) 0.78
Time period 6.02 (2) 0.049 2.100 (2) 0.35
Type of assay 3.14(1) 0.076 - -
Model 1 for viral load: - -
Race/IDU, year and assay
Model 1- race/IDU 5.30 (2) 0.06 - -
Model 1 -  type of assay 2.51 (1) 0.11 - -
Model 1 -  time period 5.70 (2) 0.06 - -
Model 2 for CD4 count: - -
Race by IDU only
Model 2 + time period - - 0.260 (2) 0.87
Model 2 + type HAART - - 0.003 (i) 0.95
regimen
CD4 model
Only the inclusion o f the race by IDU history covariate resulted in an improvement in 
the CD4 change-point model (Table 5.4). The inclusion of an interaction term between 
the race/IDU covariate and either of the slopes did not result in an improvement in the 
fit of the model.
Viral load model
The inclusion of the main effects of race/IDU, time period or type of assay to the 
change-point model resulted in an improvement in the log-likelihood, and these were 
considered together in one model (Model 1, Table 5.4). Removal of the covariate for
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Table 5.4 Likelihood ratio tests for including main covariates
Covariates
Viral load model CD4 count model
LRT j 2(d0 P LRT j 2(df) P
Race by IDU 5.06 (2) 0.078 15.70(2) <0.001
Type of HAART regimen 1.93 (1) 0.16 o © 0.78
Time period 6.02 (2) 0.049 2.100 (2) 0.35
Type of assay 3-14(1) 0.076 - -
Model 1 for viral load: - -
Race/IDU, year and assay
Model 1- race/IDU 5.30(2) 0.06 - -
Model 1 -  type of assay 2.51 (,) 0.11 - -
Model 1 -  time period 5.70(2) 0.06 - -
Model 2 for CD4 count: - -
Race by IDU only
Model 2 + time period - - 0.260 (2) 0.87
Model 2 + type HAART - - 0.003 (i) 0.95
regimen
CD4 model
Only the inclusion of the race by IDU history covariate resulted in an improvement in 
the CD4 change-point model (Table 5.4). The inclusion of an interaction term between 
the race/IDU covariate and either of the slopes did not result in an improvement in the 
fit of the model.
Viral load model
The inclusion of the main effects of race/IDU, time period or type of assay to the 
change-point model resulted in an improvement in the log-likelihood, and these were 
considered together in one model (Model 1, Table 5.4). Removal of the covariate for
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type of assay did not result in a significant worsening of the model, whereas the removal 
of either the covariates for race/IDU, or time period did. Therefore, the final model for 
viral load included the main effects of race/IDU and time period (MODVL). The 
inclusion of any interaction terms between the main effects of race/IDU and time period 
or between these covariates and either of the two slopes did not result in an 
improvement in the model.
The viral load model was fitted again with the same covariates and random effect terms, 
but using the conditional likelihood method which allows for left-censoring. The 
estimates from MODVL were used as starting parameters for the iterative procedure. 
However, the adaptive Gaussian quadrature method failed to compute the integral over 
the random effects. Changing the number of quadrature points manually and changing 
the integral method did not result in successful computation of the integral. 
Parameterisation of gestational weeks to the time of delivery as years instead of weeks 
was considered instead; this parameterisation increased the magnitude of the estimated 
slope and the magnitude of the associated random effects term for the slope. Fitting the 
model again using the adaptive Gaussian quadrature method with this parameterisation 
resulted in the successful computation of the integral and the model converged. This 
highlights the complex nature of this model and the importance of choosing both 
appropriate time-scales and starting parameters for successful estimation. The adjusted 
coefficients estimated from the two methods are given in Table 5.5, with the time of 
measurement reparameterised as weeks from delivery.
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Table 5.5 Adjusted coefficients from MODVL and MODVL-CL (/i=143)
MODVL MODVL-CL
logio viral load logio viral load
Coefficient (95%CI) P Coefficient p
(95%CI)
Mean at 28 weeks before 
delivery
4.12(3.70, 4.53) <0.001 4.12(3.63-4.61) <0.001
Initial slope (<-28 weeks) 
Slope to delivery (>-28 weeks)
0.039 (-0.03, 0.10) 
-0.055 (-0.06, -0.045)
0.240
<0.001
0.060 (-0.012, 0.13) 
-0.069 (-0.082, - 
0.056)
0.100
<0.001
Race by IDU
White non-IDU 
Black non-IDU 
White IDU
0.00
-0.21 (-0.49, 0.063) 
-0.31 (-0.59, -0.032)
0.240
0.030
0.00
-0.15 (-0.49, 0.19) 
-0.37 (-0.70, -0.024)
0.370
0.036
Time period
1998-1999
2000-2001
2002-2006
0.00
-0.24 (-0.64, 0.16) 
-0.44 (-0.82, -0.059)
0.250
0.025
0.00
-0.10 (-0.59, 0.39) 
-0.37 (-0.84, 0.092)
0.690
0.120
Random effects parameters
Intercept 
Slope to delivery 
Correlation between intercept 
and slope
0.69 (0.50, 0.93) 
0.02(0.013,0.042) 
-0.70 (-0.88, -0.36)
0.62 (0.27, 0.84) 
0.036 (0.013,0.049) 
-0.39 (-0.82, 0.05)
Within-group residual 
deviation
0.74 (0.67, 0.82) 0.81 (0.71,0.90)
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There was little change in the estimates of the mean viral load at the time of the change- 
point and their standard errors between the two models (as evidenced by the similar 
95% CIs). There was some change in the estimated coefficients for the race covariates, 
with white women with a history of IDU estimated to have a slightly lower viral load 
when left-censoring was taken into account. Additionally, the estimated viral load for 
women delivering after 2001 was no longer significantly different from that of women 
delivering between 1998 and 1999, partly due to the larger estimated standard error 
from the conditional likelihood method. However, the parameter estimates suggested 
lower HIV RNA levels in later time periods, which could be representative of a general 
improvement in adherence and health of pregnant women over the years (the number of 
undetectable measurements increased over the three time periods, from 14% [5/36} in 
1998-1999, to 17% [25/145] in 2000-2001 to 27% [55/206] in 2002-2006; zL*d = 5-59 i 
/?=0.018).
The main difference between the models however was in the estimation of the slopes. 
The estimate for the initial slope from MODVL-CL was greater than that from 
MODVL, although the 95% Cl remained bounded by zero. The estimate of the second 
slope to delivery was also greater in MODVL-CL and was estimated to be almost 25% 
lower than that estimated with the simpler approach. Figure 5.6 shows the estimated 
slopes, highlighting the differences in the estimated slopes resulting from the two 
methods.
The estimated random intercept terms were similar between the two models; however 
those for the slopes were not. MODVL-CL estimated the random deviation around the 
slopes to be almost twice as large as that from the simpler model. Subsequently, the
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correlation between the two intercepts was estimated to be almost half as small in 
MODVL-CL as in MODVL, and was not significantly different from zero.
MODVL-CL which accounts for the left-censored viral load using the more complex 
method is the preferred model, especially where interest lies in estimating the intensity 
of the slope of viral load.
Figure 5.6 Estimated mean change in logio viral load accounting for undetectable 
values using the two approaches
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5.3.2 Interpretation of univariate viral load with conditional likelihood approach 
(MODVL-CL)
Allowing for a change in slope of viral load at 28 weeks before delivery (roughly 
corresponding to the start of the second trimester), viral load was estimated to increase 
by 0.060 logio copies/ml per week (95%CI -0.012, 0.13) in the period up to 28 weeks 
from delivery; this increase was not however significantly different from zero, i.e. the 
slope was stable (Table 5.5). Viral load thereafter was estimated to decrease by 0.069 
logio copies/ml per week (95%CI -0.082, -0.056) until the time of delivery; this 
corresponds to a 15% weekly decrease in copies/ml (95%CI -12%, -17%) until the time 
of delivery. Figure 5.6 shows the estimated slope over pregnancy (red line). 
Additionally, white women with a history of IDU had an estimated 0.37 logio or 57% 
lower viral load than white women with no history of IDU, while black women were 
estimated to have similar levels of viral load as white women with no history of IDU. 
Women delivering after 1999 were estimated to have mean viral loads lower than 
women delivering between 1998 and 1999, but these differences were not statistically 
significant.
The estimated random effects standard deviations for the intercept and slope were both 
bounded away from zero. The magnitude of these parameters reveals the considerable 
deviation from the estimated mean intercept and second slope between women. The 
correlation between the two terms was not significant, but suggests a negative 
relationship between the intercept and the slope; i.e. the higher the viral load at the 
change point (28 weeks before delivery), the greater the decrease in viral load up to the 
time of delivery ( p  = -0.39).
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5.3.3 Univariate CD4 model and interpretation (MODCD4)
The table below shows the estimated coefficients from the adjusted univariate CD4 
model.
Table 5.6 Adjusted coefficients from MODCD4 («=143)
logio CD4 count 
Coefficient (95%CI) P
Mean at -28 weeks 2.56(2.51,2.61) <0.001
Initial slope (<-28 weeks) -0.013 (-0.02, -0.003) 0.008
Slope to delivery (>-28 weeks) 0.0037 (0.002, 0.005) <0.001
Race by IDU
White non-IDU 0.00
Black non-IDU -0.12 (-0.19, -0.05) 0.001
White IDU 0.028 (-0.05,0.10) 0.46
Random effects parameters
Intercept 0.18(0.15, 0.22)
Slope to delivery 0.004 (0.0025, 0.0062)
Correlation between intercept and slope -0.37 (-0.62, -0.051)
Within-group residual deviation 0.09(0.081,0.10)
Allowing for a change in slope of CD4 count 28 weeks before delivery, CD4 count was 
estimated to decrease by 0.013 logio cells/mm3 per week in the period up to 28 weeks 
before delivery and thereafter to increase by 0.0037 logio cells/mm3 per week up to the 
time of delivery (Table 5.6). This equates to a 3.0% decrease in cells/mm3 per week
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(95%CI -0.69%, -4.5%) for the first period of pregnancy up to 28 weeks before 
delivery, followed by a 0.86% increase in cells/mm3 per week (95%CI 0.46%, 1.16%) 
up to the time of delivery. Although the estimated change in CD4 count over pregnancy 
was small, both slopes were highly statistically significant (Table 5.6). Figure 5.7 shows 
the estimated slopes over pregnancy from MODCD4.
Black women had estimated CD4 counts 0.12 logio lower than white women without a 
history of IDU, which equates to a 24% lower CD4 count (95%CI -11%, -55%), while 
levels were similar among white women irrespective of their history of IDU.
The significant correlation between the random effects for the slope and intercept was 
large and revealed that the higher the CD4 count at the change point (28 weeks before 
delivery), the smaller the increase in CD4 counts up to the time of delivery {p  = -0.37 ). 
The estimated standard deviation for the random effects for the slope and intercept were 
both bounded away from zero and the deviation for the slope was relatively small; this 
may lead to computational problems in the estimation procedure and in the computation 
of the integral for the bivariate random effects model fitted with the conditional 
likelihood approach (MODBIV-CL), especially with respect to the estimation of the 
covariance (correlation) between the random effects terms (Goldstein 1989).
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Figure 5.7 Estimated mean change in loglO CD4 count
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5.3.4 Model residuals from MODVL-CL and MODCD4
Both of the univariate LME models, MODCD4 and MODVL-CL, assume that the 
within-group residual errors are normally distributed with mean zero and constant 
variance (Pinheiro and Bates 2000;Jacqmin-Gadda et al. 2000). Figure 5.8 shows the 
Kaplan-Meier estimate of the cumulative frequency distribution of the computed right- 
censored residuals from MODVL-CL and the cumulative distribution of a normal 
variable with mean zero, and variance 0.66, i.e. the estimated within-group residual 
variance. The distribution of the residual error terms was similar to that of the assumed 
Gaussian distribution, but there were some visible departures in the tails of the two
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distributions, where the curve of the assumed Gaussian distribution can be seen to fall 
just outside of the 95% Cl for the within-group residuals.
Figure 5.8 Plot of the cumulative frequency distribution of the within-group 
residuals from MODVL-CL (with 95% CIs; dashed lines) and cumulative 
Gaussian distribution with mean zero and residual error variance of the estimated 
model
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Figure 5.9 shows plots o f the standardised within-group residuals from MODCD4
Figure 5.9 A) Normal probability plot of standardised residuals, B) Plot of 
standardised residuals against fitted values,MODCD4
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The assumption of normality for the within-group errors was first assessed with a 
normal probability plot of the residuals, as shown in Figure 5.9A, where the assumed 
cumulative Gaussian distribution for these residuals is represented by the straight line. 
The distribution of the residuals follows the line fairly well, although there is evidence 
of some departure from normality in the tails. Figure 5.9B shows a plot of the within-
group errors against the fitted values; the residuals are mostly centred on zero with 
constant variance. However, the residuals for the tails appear to be centred slightly 
above or below zero, again suggesting a departure from normality caused by very few 
points in the tails of the distribution as seen in Figure 5.9A.
Overall, the assumption of a Gaussian distribution for the within-group residuals for the 
two univariate models appears plausible, which supports the accuracy of the estimated 
parameters and standard errors from the model and any inferences made.
5.3.5 Bivariate model for CD4 and viral load using midpoints for undetectable 
values (MODBIV)
MODBIV was fitted using the same covariates included in the two univariate models, 
MODVL and MODCD4. The estimated coefficients from the joint model, together with 
those from the univariate models are given in Table 5.7.
There were no substantial changes in the estimates from the bivariate model and their 
standard errors for the fixed effects, compared to those from the univariate model. The 
estimated parameters for the random effects were also unchanged, although there were 
some modest changes in the standard errors. This suggests that the information provided 
by the CD4 and viral load data contributes little to the estimation of the fixed effects 
estimates for either of the other markers in the joint model.
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Table 5.7 Estimated coefficients from bivariate model and univariate models
Bivariate model Univariate model
Coefficient (95%CI) P Coefficient (95%C1) p
logio viral load (MODBIV) log io viral load (MODVL)
Mean at -28 weeks 4.12(3.71,4.53) <0.001 4.12(3.70,4.53) <0.001
Short term slope (<-28 weeks) 
Long term slope (>-28 weeks)
0.043 (-0.02, 0.11) 
-0.055 (-0.06, -0.045)
0.190
<0.001
0.039 (-0.03,0.10) 
-0.055 (-0.06, -0.045)
0.240
<0.001
Race by IDU
White non-IDU 
Black non-IDU 
White IDU
0.00
-0.20 (-0.47, 0.076) 
-0.32 (-0.60, -0.04)
0.160
0.020
0.00
-0.21 (-0.49, 0.06) 
-0.31 (-0.59, -0.03)
0.240
0.030
Time period
1998-1999
2000-2001
2001-2006
0.00
-0.24 (-0.63, 0.15) 
-0.44 (-0.81,-0.07)
0.240
0.020
0.00
-0.24 (-0.64, 0.16) 
-0.44 (-0.82, -0.06)
0.250
0.025
Random effects -  viral load
Intercept 
Second slope
Covariance between intercept 
and slope
0.68 (0.52, 0.99) 
0.024 (0.015,0.054) 
-0.70 (-0.96, -0.44)
0.69 (0.50, 0.93) 
0.024 (0.013,0.042) 
-0.70 (-0.88, -0.36)
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Table 5.7 contd.
Bivariate model Univariate model
Coefficient (95%CI) p Coefficient (95%CI) p
log, 0  CD4 (MODBIV) logI0 CD4 (MODCD4)
Mean at -28 weeks 2.56(2.51,2.61) <0.001 2.56(2.51,2.61) <0.001
Short term slope (<-28 weeks) 
Long term slope (>-28 weeks)
-0.012 (-0.02,-0.003) 
0.0038 (0.002, 0.005)
0.01
<0.001
-0.013 (-0.02,-0.003) 
0.0037 (0.002, 0.005)
0.008
<0.001
Race by IDU
White non-IDU 
Black non-IDU 
White IDU
0.00
-0.12 (-0.19, -0.05) 
0.025 (-0.05, 0.09)
0.001
0.510
0.00
-0.12 (-0.19, -0.05) 
0.028 (-0.05,0.10)
0.001
0.460
Random effects -  CD4 counts
Intercept 
Second slope
Covariance between intercept and 
slope
0.18(0.16, 0.22) 
0.004 (0.003, 0.007) 
-0.37 (-0.66, -0.09)
0.18(0.15, 0.22) 
0.004 (0.003, 0.006) 
-0.37 (-0.62, -0.05)
Table 5.8 shows the correlation matrix and 95% confidence intervals estimated from the 
bivariate model for CD4 count and viral load, using the Delta method (Lynch M. and 
Walsh B. 1998).
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Table 5.8 Estimated correlations between viral load and CD4 (95% Cl) from 
MODBIV
Viral load 
intercept
CD4 count 
Intercept
Slope of 
viral load
Slope o f 
CD4 count
Viral load intercept 1
CD4 count intercept -0.36 (-0.66, -0.07) 1
Slope o f viral load -0.70 (-0.96, -0.44) 0.25 (-0.21,0.71) 1
Slope o f CD4 count 0.27 (-0.21,0.75) -0.37 (-0.66, -0.09) -0.29 (-0.99, 0.53) 1
There was evidence of correlation between the random intercept terms for the two 
markers, but not between any of the slopes (Table 5.8). The subject-specific intercepts 
for viral load and CD4 were negatively and significantly correlated 
{PcDAmtvLitA = -0-36), i.e. the higher a woman’s CD4 count at the time of change-point,
the lower her mean viral load. The correlations between the other random effect terms 
were weak i.e. not statistically significant, and had wide confidence intervals. However, 
the estimates suggest the following possible correlations: a) the higher a woman’s CD4 
count 28 weeks before delivery, the more gradual the decrease in viral load to the time 
of delivery (/?KLs/t)/*,CD4im = 0.25), b) the higher a woman’s viral load 28 weeks before 
delivery, the steeper their increase in CD4 count to the time of delivery 
(PcD^siopeVLmi =0.27), and c) the steeper the decrease in the slope of viral load to the 
time of delivery, the steeper the increase in CD4 counts over the same period
( PcDAslopeVLslope =  ~ '0 . 2 9 )  .
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5.3.6 Bivariate residuals
Figure 5.10 shows a scatter plot of the bivariate residuals; the residuals were mostly 
scattered around zero, although there was some indication of a pattern in the lower right 
quadrant of the plot.
Figure 5.10 Scatter plot of the residuals from the bivariate model for CD4 and 
viral load
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The corresponding Pearson correlation coefficient between the residuals was -0.13 
(95%CI -0.23, -0.03). However, the Pearson correlation summarises the dependence 
between the residuals with a single scalar measure only and may be an unreliable 
summary measure over the whole range of residuals from the CD4 and viral load model.
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The local dependence map (LDM) of the residuals was used to test for ‘local’ 
dependence between the residuals and is shown in Figure 5.11.
Figure 5.11 Local dependence map of the residuals from MODBIV
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The LDM carries out localised Pearson correlation tests and provides an associated 
significance test for the local dependence between residuals, with the colours given in 
the figure legend indicating the presence of positive, negative or no dependence. 
Overall, the LDM revealed a very weak indication of local dependence between the 
residuals for viral load and CD4 counts, confirming the assumption of independence 
between the residuals from MODBIV.
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As mentioned in section 5.2, the BLME model (MODBIV) accounts for the correlation 
between the two markers through the covariance of their random effects terms; 
however, the estimated correlation between the random effects terms for the slopes, or 
between the slopes and intercepts was not significant here. Although the correlation 
between the intercept terms was significant, the estimates for the fixed effects for the 
two markers remained unchanged from their respective univariate models suggesting 
that little is gained from the bivariate model for these data other than estimation of the 
correlation between the random intercepts. This could be due partly to the relatively 
crude manner in which undetectable viral load measurements were dealt with in this 
bivariate model.
5.3.7 Bivariate model for CD4 and viral load accounting for left-censoring 
(MODBIV-CL)
The estimates for the fixed and random effects from MODBIV presented in Table 5.7 
were used as starting parameters with gestational weeks to delivery parameterised in 
years. The full model converged after 160 iterations but the estimates for the covariance 
elements of the random effect terms (corresponding to the correlation coefficients) were 
very close to the starting parameters and none of their standard errors had been 
meaningfully estimated.
The Quasi-Newton optimisation procedure used for this model is a gradient method, 
where the final estimated parameters are such that they maximise the partial-derivatives 
of the likelihood function with respect to each parameters, i.e. corresponding to the 
point where the gradient of the likelihood function is zero (Everitt 1987). However,
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although the SAS procedure converged successfully, the final model resulted in 
elements of this final gradient to be >|0.001| for 12 of the 24 estimated parameters with 
some gradients ranging from as high as 0.05 to 0.20. This indicated that the estimated 
parameters were not those that optimise the likelihood suitably, and may be far from the 
true optimal values (SAS Institute Inc. 2004). Additionally, the final estimated Hessian 
matrix was not positive definite; this occurs when the likelihood is maximised by setting 
one or more of the variance components to zero (SAS Institute Inc. 2004). As a 
consequence, the inverse of the Hessian matrix, i.e. the estimated variance-covariance 
matrix, may be unreliable for some or all of the fixed and random parameter estimates.
The estimates of the correlations between the slope and intercept terms for the two 
markers were small and not significant in MODBIV (Table 5.8). Goldstein suggests 
omitting these poorly estimated parameters to stabilise the estimates for the remaining 
parameters, particularly for estimation of the random parameters when the sample size 
is relatively small (Goldstein 1989). Therefore, MODBIV-CL was refitted with the 
same covariates, but with only the random intercepts for the two markers and the 
covariance between them. This model converged, but still resulted in gradients >|0.001| 
for some of the parameters and a Hessian matrix which was not positive-definite. 
Attempts to fit the model with gestational age only or with random effects for the slopes 
only also resulted in unstable estimates.
One of the principal reasons for using the bivariate model here was to improve the 
estimates for the fixed effects for both viral load and CD4 through estimation of the 
correlation between them, while also accounting for the presence of left-censoring. An
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alternative approach, modelling viral load and CD4 count in univariate LME models as 
a function of the other marker, was considered.
5.3.8 Univariate viral load model accounting for left-censoring as a function of 
CD4 count (MODVL-CL2)
This analysis included the 143 women from the previous models. There were 367 
measurements available on viral load and CD4 count taken at the same time in 
pregnancy, with an additional 20 measurements where a CD4 count was taken within 4 
weeks of the viral load measurement; 43 viral load measurements without a close CD4 
measurement were excluded. The median number of measurements per woman was 3 
(IQR2-3).
MODVL-CL (Table 5.5) was fitted again with the same random effects (for the 
intercept and slope) and the fixed effects, with the addition of logio CD4 count and an 
interaction between logio CD4 and both slopes. The removal of the interaction term 
between the second slope and CD4 did not result in a significant increase in the log- 
likelihood (LRT: z i - i  = 0-5; p  = 0.48), hence it was excluded. Although the Wald tests
for the covariate for time period was not significant at the 5% level, their removal led to 
a significant worsening of the fit of the model and were therefore retained
(LRT: =7.6; p  = 0.02). The fixed and random effects estimates from the final
model are given in Table 5.9.
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Table 5.9 Adjusted coefficients from MODVL-CL2 (/i=143)
logio viral load 
Coefficient (95%CI) P
Initial slope (<-28 weeks) -1.00 (-1.73,-0.27) <0.001
Slope to delivery (>-28 weeks) -0.063 (-0.075, -0.05) <0.001
logio increase in CD4 -1.11 (-1.77, -0.45) 0.001
logio increase in CD4*initial slope 0.41 (0.13, 0.69) 0.005
Race by IDU
White non-IDU 0.00
Black non-IDU -0.34 (-0.68, 0.009) 0.06
White IDU -0.38 (-0.72, -0.04) 0.03
Time period
1998-1999 0.00
2000-2001 0.043 (-0.44, 0.53) 0.86
2002-2006 -0.36 (-0.82,0.11) 0.13
Random effects parameters
Intercept 0.65 (0.33, 0.86)
Slope to delivery 0.033 (0.003, 0.046)
Correlation between intercept and slope -0.41 (-0.85, 0.03)
Within-group residual deviation 0.75 (0.64, 0.84)
The overall level of viral load was dependent on CD4 count in the adjusted model (an 
estimated mean HIV RNA level 1.11 logio copies/ml lower for each unit increase in 
logio CD4 cells/mm3). The change in viral load over the period up to 28 weeks before 
delivery was also dependent on CD4 count (Table 5.9), and thereafter was estimated to
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decrease by 0.063 logio copies/ml per week (95%CI -0.075, -0.05) until the time of 
delivery independent of CD4 count. The change in viral load after 28 weeks to the time 
of delivery corresponds to a 14% weekly decrease in copies/ml (95%CI -11%, -16%) 
until the time of delivery. Due to its dependence on CD4 count, the change in the initial 
slope in pregnancy is more easily interpreted graphically. Figure 5.12 shows the 
estimated slopes over pregnancy by CD4 count at 28 weeks before delivery; the blue 
line represents women with CD4 counts of 281 cells/mm3 (lower quartile), the black 
line represents women with CD4 counts of 391 cells/mm3 (median) and the red line, 
women with CD4 counts of 544 cells/mm3 (upper quartile). This figure depicts the 
relationship between the initial slope of viral load in pregnancy and CD4 count; women 
with the highest CD4 count were estimated to have the steepest increase in the initial 
period, with women with the lowest CD4 count experiencing little change in viral load 
over the same period. It should be noted here that although the 95% CIs for the initial 
slope and the interactions between CD4 and this slope did not contain zero, they were 
relatively large, reflecting the relatively small number of measurements contributing to 
the estimation of the initial slope.
White women with a history of IDU were estimated to have a 0.38 logio lower viral load 
than white women with no history of IDU (Table 5.9); this equates to a 58% lower viral 
load (95%CI -8.8% -81%). Black women were also estimated to have a similar 
magnitude of viral load below that of white women with no history of IDU, but this was 
only borderline significant.
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Figure 5.12 Estimated mean change in logio viral load by CD4 count from 
MODVL-CL2
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There estimated random effects terms reveal the considerable variation among the 
intercept and slopes between women; the estimated correlation between the two random 
terms was moderate, but the associated confidence interval was bounded by zero. This 
suggests that the estimated slope of viral load to delivery is relatively invariant to 
deviations from the estimated mean; i.e. women with mean viral loads above or below 
the estimated intercept will experience similar changes in viral load over the 28 weeks 
to the time of delivery.
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It is not appropriate to make direct comparisons of the estimates with the univariate 
model which did not adjust for CD4 counts (Table 5.5) as the two models are based on 
slightly different datasets, but it is interesting to see that the estimates for the random 
effects terms, time period, race/IDU and those for the second slope remain unchanged. 
The main difference between the models however was the estimate of the first slope and 
of the mean viral load at the time of change-point, the respective slope and magnitude of 
which are now dependent on CD4 count.
5.3.9 Univariate CD4 count as a function of HIV RNA viral load (MODCD4-2)
Due to the left-censoring of undetectable viral load measurements, viral load was 
included in the CD4 regression model as a factor, with the cut-off for the levels based 
on the tertiles of logio HIV RNA viral load. This three-level factor together with the 
same random effects and fixed effects included in MODCD4 (Table 5.6) were included 
in the model, with additional interaction terms between viral load and both slopes. 
Neither the removal of the interaction term between the second slope and viral load, nor 
that of the interaction with the first slope resulted in a significant increase in the log- 
likelihood (LRTs: ^j/=2 = 2.44; p  = 0.29, and x]f=i = 0-42; p  = 0.81), hence both terms
were excluded. The fixed and random effects estimates from the final model are given 
in Table 5.10
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Table 5.10 Adjusted coefficients from MODCD4-2 («=143)
logio CD4 count 
Coefficient (95%CI) P
Mean at 28 weeks before delivery 2.64 (2.58, 2.70) <0.001
Initial slope (<-28 weeks) 
Slope to delivery (>-28 weeks)
-0.007 (-0.015, 0.0017) 
0.0014 (-0.0001, 0.0029)
0.120
0.077
Tertiles of HIV RNA
< 2.30 logI0 copies/ml 
2.30-3.25 logio copies/ml 
>3.25 logio copies/ml
0.00
-0.026 (-0.056, 0.0043) 
-0.072 (-0.11,-0.035)
0.100
<0.001
Race by IDU
White non-IDU 
Black non-IDU 
White IDU
0.00
-0.13 (-0.21,-0.062) 
0.021 (-0.053,0.094)
<0.001
0.580
Random effects parameters
Intercept 
Slope to delivery
Correlation between intercept and slope
0.19(0.17, 0.22) 
0.0046 (0.0034, 0.0063) 
-0.45 (-0.65, -0.20)
Within-group residual deviation 0.079 (0.070, 0.089)
Allowing for viral load and a change in slope of CD4 count 28 weeks before delivery, 
CD4 count was estimated to be relatively stable up to 28 weeks before delivery (Table
5.10). CD4 counts were estimated to increase by 0.0014 logio cells/mm3 per week in the 
subsequent period; this equates to a 0.32% weekly increase in cells/mm3 (95%CI - 
0.023%, 0.67%) up to the time of delivery, but was of borderline significance. Although
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there was no evidence of any dependence between the slope of CD4 over pregnancy and 
viral load, the mean level of CD4 count was 0.072 logio lower with viral loads above 
3.25 logio copies/ml, which equates to a mean CD4 count 15% lower (95%CI -7.7%, - 
22%). That is, women with the highest viral load had consistently lower CD4 counts 
than women with viral loads below 2.30 logio copies/ml, over the period of pregnancy.
The association between lower CD4 counts and black race was also significant, with 
this group of women estimated to have CD4 counts which were 0.13 logio or 26% lower 
than white women without a history of IDU (95%CI -13%, -38%), while levels were 
similar among white women irrespective of their history of IDU.
Adjusting for viral load in MODCD4-2 resulted in CD4 slopes which were no longer 
significant, compared to those in MODCD4 (Tables 5.6 and 5.10). There were only 
small changes in the estimates for the remaining fixed effects terms and random effects 
terms. However, the estimated correlation between the two random effects terms 
remained negative and statistically significant but was considerably stronger here than 
in MODCD4. The correlation suggests that the higher the CD4 count for a woman at the 
intercept, the more gradual the subsequent increase in CD4 over pregnancy (Table
5.10).
The Kaplan-Meier estimate of the cumulative frequency distribution of the computed 
right-censored residuals from the adjusted viral load model are shown in Figure 5.13A.
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Figure 5.13 Residuals from univariate models for: A) Viral load adjusted for CD4 count and accounting for left-censoring, B) CD4 
count adjusted for viral load level
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The within-group residuals here appear to satisfy the assumption of normality better 
than MODVL-CL, with the Gaussian curve sitting closer inside the 95% CIs in the tails 
of the distribution. Figure 5.13B shows a plot of the within-group errors against the 
fitted values for the adjusted CD4 model; the two plots reveal no major violations in the 
assumption of a Gaussian distribution for the within-group residuals.
Sensitivity analysis
A sensitivity analysis including the 109 women with available information on timing of 
initiation of HAART was carried out. The univariate LME models for CD4 count and 
HIV RNA (shown in Table 5.9 and 5.10) were refitted with the same covariates and 
random effect terms together with a binary variable for the timing of initiation (receipt 
of HAART for > 6 months vs. < 6 months).
HIV RNA model (MODVL-CL2) with timing o f  initiation
Women who had received HAART for less than 6 months before pregnancy had an 
estimated mean HIV RNA 0.16 logio copies/ml lower (95%CI -0.49, 0.17) than women 
who were receiving HAART for more than 6 months, although this was not statistically 
significant. The parameter estimates and standard errors for the slopes in pregnancy 
were similar although marginally smaller in magnitude; they all remained statistically 
significant. The biggest change in estimates was for the race by IDU effect, which had 
larger parameter estimates and smaller standard errors. As a result the estimate for black 
women was now statistically significant with black women with no history of IDU 
estimated to have viral loads 0.39 logio lower (-0.76, -0.023) than white women with no 
history of IDU, while white women with a history of IDU had a viral load which was 
0.52 logio lower (95%CI-0.89, -0.15).
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CD4 model ( MODCD4-2) with timing of initiation
Women who had received HAART for less than 6 months before pregnancy had an 
estimated mean CD4 0.040 logio cells/mm3 higher (95%CI -0.029, 0.11) than women 
who were receiving HAART for more than 6 months, although this was not statistically 
significant. The parameter estimates and standard errors for the initial slope in 
pregnancy, race and viral load categories were similar. However, the slope from -28 
weeks up to the time of delivery was now marginally larger and the associated standard 
error was smaller (0.0017 logio cells/mm3 per week increase, 95%CI 0.0006, 0.0034).
In conclusion, the bivariate model (MODBIV) was able to estimate the relationship 
between the two markers over the whole period of pregnancy, without assuming any 
dependence of one marker in relation to the other. However, it had little impact on the 
fixed effects estimates. This suggests that accounting for the relationship between the 
two markers through their random effects covariance may not be sufficient to explain 
important variation in the markers resulting from their joint distribution. A bivariate 
model with left-censoring could not be estimated and therefore adjustment for the two 
markers within a univariate model for CD4 count and HIV RNA viral load accounting 
for left-censoring (MODCD4-2 and MODVL-CL2) was used instead which resulted in 
marked differences in the estimates of the fixed-effects. For this data therefore, 
MODCD4-2 and MODVL-CL2 were the preferred models.
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5.4 Key points
• Mean plots of CD4 and HIV viral load suggested a two-slope evolution of the 
markers over pregnancy.
• The change in slope for both markers was estimated to occur around the end of 
the first trimester of delivery, around 28 weeks before the time of deliveiy.
Univariate HIV RNA viral load model independent o f CD4 counts (MODVL-
CL)
• The slope of viral load over pregnancy was underestimated in the model which 
did not account for left-censoring appropriately.
• When CD4 was not adjusted for, viral load was estimated to be relatively stable 
over the beginning of pregnancy, thereafter decreasing by a weekly 15% until the 
time of delivery.
• White women with a history of IDU were estimated to have lower viral loads 
than white women with no history of IDU.
• The estimated correlation between the random terms suggested that the estimated 
slope of viral load to the time of delivery was relatively invariant to deviations 
from the estimated mean.
Univariate HIV RNA viral load model as a function o f CD4 counts (MODVL-
CL2)
• The initial slope of viral load in pregnancy was found to be dependent on a 
woman’s CD4 count; women with low CD4 count had relatively stable changes 
in viral load over this period while women with high CD4 counts experienced a 
steeper increase in this period.
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• The level o f CD4 count was associated with the mean viral load resulting in 
shifts in the slope o f viral load, but was found to be independent o f the second 
slope itself.
• There were little changes in the estimates o f viral load for the second slope and 
for race between the two models.
Univariate CD4 model independent o f  H IV RNA viral load (MODCD4)
•  CD4 count was estimated to decrease in the first period o f pregnancy up to 28 
weeks before the time o f delivery, and thereby to increase by 0.9% each week 
until the time of delivery.
• Black women were estimated to have CD4 counts which were 24% lower than 
white women.
Univariate CD4 model as a function o f  H IV RNA viral load (MODCD4-2)
• Adjusting for viral load, CD4 count was estimated to be stable up to 28 weeks 
before delivery, and to then increase by 0.32% each week up to the time of 
delivery, although this change was only borderline significant.
• Large viral loads (greater than 3.25 logio copies/ml) were associated with 
significant decreases in the mean CD4 count but there was no association 
between viral load and either o f the slopes during pregnancy.
• The estimated correlation between the random terms was strong and suggested 
that higher the CD4 count for woman 28 weeks before delivery, the more 
gradual their subsequent increase in CD4 over pregnancy.
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Bivariate model for HIV RNA viral load and CD4 count (MODBIV)
•  The bivariate model assuming midpoints for undetectable viral load
measurements resulted in negligible changes in the estimates and standard errors 
o f the fixed and random effects terms from those from the univariate models.
•  There was evidence o f substantial negative correlation between the intercepts for
the two markers, such that the higher a woman’s CD4 count at the time o f
change-point, the lower their mean viral load.
• The correlations between the two slopes, or between the slopes and intercepts
were weak and not significantly different from zero.
•  Attempts to fit a bivariate model accounting for left-censoring were
unsuccessful, resulting in unstable estimates of the model parameters and 
associated standard errors.
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Chapter 6 ART use during pregnancy and adverse neonatal outcomes
6.1 ART use during pregnancy and risk of congenital abnormalities
6.1.1 Introduction
The use of HAART during pregnancy, particularly in the early stages when 
organogenesis is taking place, has raised concerns relating to the safety for the exposed 
fetus (Public Health Service Taskforce 2006b). However, few data are available to 
ascertain whether the risk of congenital abnormalities is increased by first trimester 
exposure to antiretrovirals and/or by certain combinations of treatment, including 
HAART.
The aim of this analysis was to assess the possible teratogenic risks related to in utero 
exposure to any antenatal ART, by investigating the prevalence of congenital 
abnormalities among infants bom to HIV-infected women by earliest exposure to and 
by type of treatment regimen among infants.
6.1.2 Methods specific to this analysis 
Data
This analysis included data on 3740 mother-child pairs enrolled in the ECS by 
December 2003.
To assess the outcome of pregnancies by type of treatment regimen, ART exposures 
were grouped into four categories, NRTI only, combinations of NRTI and PI, NRTI and 
NNRTI or a combination of NRTI, NNRTI and PI. As organogenesis occurs in the first 
trimester, rates of congenital abnormalities among infants with second/third trimester
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exposures to ART were grouped together and compared with those with first trimester 
exposures. The first trimester of pregnancy was defined as up to and including 12 
gestational weeks.
Infants were assessed for the presence of congenital abnormalities at birth by a senior 
obstetrician and/or a senior paediatrician; additional perinatal assessments were made 
by experienced paediatricians, who were also responsible for reports on further 
paediatric follow up visits.
The association between type of antenatal ART and the presence of congenital 
abnormalities was assessed with a logistic regression model, after adjusting for 
information available on IDU in pregnancy (Y/N) and maternal age at delivery (<25, 
25-34 and >35 years).
The analysis was carried out using R version 1.9.0 (R Development Core Team 2006).
6.1.3 Results
Of the 3740 infants enrolled at the time of this analysis, 1973 (53%) were exposed to 
ART in utero, including 602 to HAART. Of these 1973 infants, 789 (40%) were 
conceived while their mother was taking ART and exposed in the first trimester, and the 
remainder exposed from the second and third trimester («=702 and n=482, 
respectively). Median maternal age at delivery was 28 years (range: 10-45 years). Most 
mothers were white (72%, 2700/3740), 21% (781/3740) were black (mainly from sub- 
Saharan Africa) and 7% (256/3740) were from other ethnic groups. Thirteen percent 
(493/3740) of infants were exposed to illicit drugs during pregnancy. CD4 counts were
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available for 2042 (55%) mothers; median CD4 count at delivery was 420 cells/mm3 
(range: 280-600 cells/mm3). Median gestational age at delivery was 38 weeks (range 
22- 43 weeks) and median birth weight was 2940g (range 500 -  5190g).
Congenital abnormalities
Congenital abnormalities were recorded in 1.5% (55/3740) of children, 31 (56%) of 
whom had been exposed to ART in utero, including 14 in the first trimester of 
pregnancy. Table 6.1 gives a summary of the congenital abnormalities by exposure 
group. Among the 31 exposed children, abnormalities included ear malformations (2), 
cleft palate (2), ventricular septal defect (6), atrial septal defect (2), blood-clotting 
disorder (1), hydrocele in both testes (1), polydactyly (3), Down’s syndrome (3), 
polycystic kidney (3), hydronephrosis (2), oesophageal atresia (2), ileostoma and 
enteritis (1), gastric perforation (1), hydrocephalus (1 died four days after birth), 
cataract (1) and situs inversus, transposition of arteries (1). Congenital abnormalities in 
the 24 unexposed children included cleft palate (1), ventricular septal defect (4), cardiac 
rhabdomyoma (1), tetralogy of fallot (1), polydactyly (2), syndactyly(l), polycystic 
kidney (2), hydronephrosis (2), oesophageal atresia (3), microcephalus (1), 
hydrocephalus (1), hip dysplasia (2), cataract (1), situs inversus, transposition of arteries 
(1), and diaphragmatic hernia (1).
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Table 6.1 Summary of congenital abnormalities by exposure to ART
Earliest Antiretroviral Therapy (ART) Exposure in First Trimester
Earliest
ART
No 
Antenatal 
exposure 
To ART
NRTI(s)
Only
PI(s)
+
NRTI(s)
NRTI(s)
+
NNRTI (s)
PI(s)
+
NRTI(s)
+
NNRTI(s)
Overall
First
Trimester
Exposure
Exposure
2nd
and/or
3rd
Trimester
Mother-child pairs (n) 1767 280 273 195 41 789 1,184
Children with congenital abnormalities (n) 24 1 7 6 0 14 17
Number o f abnormalities: 
EAR, FACE AND NECK 0 0 0 0 0 0 2
CLEFT PALATE 1 0 0 0 0 0 2
VENTRICULAR SEPTAL DEFECT 4 1 1 1 0 3 3
OTHER HEART DEFECTS 2 0 1 I t 0 2 0
OTHER CIRCULATORY SYSTEM 0 0 1 0 0 1 0
MALE GENITALIA 0 0 0 I f 0 1 0
LIMB REDUCTION/ADDITION 3 0 0 0 0 0 3
DOWN’S SYNDROME 0 0 0 0 0 0 3
RENAL AND KIDNEY 4 0 1 2 0 3 2
GASTROINTESTINAL 3 0 2 2 0 4 0
NEUROLOGICAL 2 0 0 0 0 0 1
HIP DYSPLASIA 2 0 0 0 0 0 0
CATARACT 1 0 0 0 0 0 1
OTHER 2 0 1 0 0 1 0
t  - one child with two defects; hydrocele in both testes and atrial septal defect
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Type and timing o f ART during pregnancy
There was no apparent increase in any particular abnormality with the use of ART or 
HAART during pregnancy. Among the 3740 infants, 1.4% of those not exposed to 
antenatal ART (24/1767) had a congenital abnormality versus 1.6% of those exposed 
(31/1973; x2==0-16, p=0.69). There was also no discernible pattern of congenital 
abnormalities between the type and timing of ART during pregnancy (Table 6.1).
The prevalence of congenital abnormalities in children exposed to any antenatal ART in 
the first trimester of pregnancy (14/789 [1.8%, 95%CI 0.97-3.0]) was similar to those 
exposed in the second or third trimester (17/1184 [1.4%, 95% Cl 0.84 -  2.3]) (x2==0.17, 
p=0.6S); the relative risk for first trimester exposures compared to later exposures was
1.3 (95%CI 0.6-2.5). Among the 789 infants with first trimester exposure, there was no 
difference in the prevalence of congenital abnormalities among infants exposed to 
HAART (11/546, 2.0% [95%CI 1.0-3.6]) compared with those exposed to mono/dual 
therapy only (3/243, 1.2% [95%CI 0.26-3.6]) (Fisher’s exact testp=0.57).
In multivariable logistic regression analysis involving 3471 mother-child pairs with 
information on all variables, the presence of congenital abnormalities was not associated 
with the use of mono/dual therapy or HAART during pregnancy, after adjusting for 
maternal age at delivery and IDU during pregnancy (adjusted odds ratio (AOR) 1.05, 
[95%CI 0.49, 2.2, />=0.91] and 1.22, [95%CI 0.57, 2.6,/?=0.61] for mono/dual therapy 
and HAART respectively with ‘no antenatal ART’ as the reference category).
In a sub-analysis among 1810 mother-child pairs with antenatal ART use, after adjusting 
for maternal age at delivery, there was no increased risk of congenital abnormalities 
associated with first trimester exposure to ART compared with later exposures (AOR
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1.33, [95%CI 0.64, 2.8, /?=0.44]). None of the mothers of children with congenital 
abnormalities used injecting drugs during pregnancy, precluding adjustment for this 
variable here.
Nineteen women in this cohort received efavirenz-containing HAART regimens at the 
time they became pregnant and continued taking the drug for a median of 40 days into 
their pregnancy (range 24-106 days). No congenital abnormalities (0%, 95% Cl 0, 17.6) 
were reported in this group, but with the small numbers in this exposure group an 
increased risk cannot be excluded.
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6.2 ART use during pregnancy and the risk of premature delivery
6.2.1 Introduction
European studies have confirmed the association between antenatal HAART use and 
premature delivery (ECS and Swiss Cohort and European Collaborative Study and the 
Swiss HIV Pregnancy Cohort 2000;European Collaborative Study 2004;Townsend et al. 
2006). Data from a prospective study in America also reported an increased risk of 
premature delivery with the use of Pi-based HAART, compared with HAART without 
(Cotter et al. 2006). Recent studies from Brazil and the US have also examined the 
impact of Pi-based HAART on increased risk of prematurity, but with respect to none or 
mono/dual therapy only (Szyld et a l 2006;Schulte et al. 2007). However, data are 
lacking on whether the use of Pi-based HAART increases the risk of prematurity over 
and above that associated with NNRTI-based HAART.
The aim of this analysis was to assess whether the use of antenatal Pi-based HAART 
regimens is associated with an increased risk of premature delivery compared to NNRTI- 
based HAART in a European population of HIV-infected women.
6.2.2 Methods specific to this analysis 
Data
This analysis was restricted to women who were receiving HAART at conception or who 
received HAART during pregnancy and who delivered a live bom singleton infant with 
known gestational age. HAART was defined as a regimen of >3 ARV drugs, consisting 
of at least 2 NRTIs and at least one PI or NNRTI; women receiving both NNRTIs and 
Pis in pregnancy were excluded.
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By June 2006, 1493 mother-child pairs enrolled in the ECS met these criteria. Ten were 
stillborn, 26 were missing gestational age at delivery and an additional 42 women 
received HAART with both NNRTI and PI and were excluded from the analysis. A 
further 121 were of a multiple birth and were excluded due to the higher preterm birth 
rate among multiple pregnancies (Slattery and Morrison 2002). A total of 199 mother- 
child pairs were therefore removed from the analysis and the study population for this 
analysis consisted of 1294 pairs.
Mode of delivery was categorised as vaginal or caesarean section (CS) delivery, with CS 
before labour and rupture of membranes (ROM) defined as elective CS and after 
labour/ROM as emergency CS.
Type of HAART regimen (NNRTI-containing or Pi-containing) was considered in the 
regression model along with the following variables, which have elsewhere been shown 
to be important predictors for preterm delivery (ECS and Swiss Cohort and European 
Collaborative Study and the Swiss HIV Pregnancy Cohort 2000;European Collaborative 
Study 2004;Cotter et al. 2006;Patel et a l 2004;Slattery and Morrison 2002); timing of 
HAART initiation (before pregnancy, first, second or third trimester), race (white, black 
or other), CD4 cell count closest to the time of delivery (<200, 200-499, >500 
cells/mm3), maternal age (<25, 26-34, >35 years), IDU during pregnancy (Y/N) and 
parity (0, 1, 2, >3 previous live births).
Statistical methods
European guidelines for management of pregnant HIV-infected women recommend 
elective CS deliveries, to be scheduled at 38 weeks, for PMTCT and the rate of elective 
CS in the ECS has therefore been high in recent years (65.4% in the period 2000-2004)
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(European Collaborative Study 2004). However, some centres in the ECS had a policy of 
scheduling elective CS at 36 weeks (Newell et al. 2002;Brockmeyer 1999). This large 
number of elective CS deliveries, some carried out before 37 weeks, complicates the 
investigation of the association between antenatal HAART use and premature delivery. 
The use of %2 tests and logistic regression models to assess differences between treatment 
groups with respect to premature delivery could lead to spurious results, as these tests 
would not distinguish between significant differences due to prematurity or early elective 
CS. Removing the elective CS deliveries would allow for comparisons of prematurity 
between treatment groups for “natural deliveries” only (i.e. those excluding elective CS), 
but would exclude a large number of mother-child pairs from the analysis and could bias 
any inferences made from the model. Deliveries which start with the onset of labour 
and/or rupture of membranes can therefore be considered as spontaneous deliveries, 
regardless of whether the delivery was vaginal or emergency CS, while an elective CS 
delivery can be considered as an ‘unspontaneous’ delivery (whether scheduled before or 
after 37 weeks) as in principle the infant could have had a longer gestation than that 
observed.
A different approach is to examine the association of HAART exposure and prematurity 
by comparing gestational ages at delivery between groups, while accounting for the 
right-censoring of elective CS deliveries. This is more appropriate than the approach 
outlined above as it makes use of all available information. Therefore a survival analysis 
approach was taken to assess the association between type of antenatal HAART 
exposure and the hazard of delivery at different gestational ages, with deliveries by 
vaginal and by emergency CS taken to be observed events and those by elective CS as 
censored events. This is based on the risk sets of women who are still being followed up
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at each gestational age at which a woman delivers and therefore accounts for the 
censored deliveries as opposed to simply removing them.
Survival curves obtained with the Kaplan-Meier method (Kaplan and Meier 1958) were 
used to explore the proportion of women delivering at different gestations, stratified by 
HAART group. Differences between survival curves were tested with a log-rank test 
(Themeau and Grambsch 2000). A Cox proportional-hazards model was used to estimate 
unadjusted and adjusted relative hazards (RH and ARH, respectively) of delivery by 
HAART group, after adjusting for the potential confounders mentioned above (Cox DR 
and Oakes D 1984;Themeau and Grambsch 2000). The assumption of proportional 
hazards both by the individual covariates, and for the model as a whole, was formally 
assessed with tests based on the examination of scaled Schoenfeld residuals over time 
(Themeau and Grambsch 2000;Grambsch and Themeau 1994).
The analysis was carried out using R version 2.3.1 (R Development Core Team 2006).
6.2.3 Results
The majority of the 1294 women (760/1294; 59%) received a Pi-based HAART regimen, 
of whom 479 (65%) received nelfmavir (NFV). Of the 534 women receiving a NNRTI- 
based HAART regimen, 94% received nevirapine (NVP) as their NNRTI component. 
The characteristics of the mother-child pairs by type of HAART exposure are given in 
Table 6.2. There were no statistically significant differences between treatment groups 
with respect to most characteristics. However, the proportion of women delivering before 
2001 was higher for the PI group and there were some differences in the proportion of 
women beginning treatment in the second and third trimester between treatment groups.
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Prematurity
The overall median gestational age was 38 weeks (range 23-42), the prevalence of 
premature and severlye premature deliveries was 21.9% (284/1294, 95%CI 20-24%) and 
5.6% (72/1294, 95%CI 4-7%) respectively and was similar between the two HAART 
groups when tested with a test (Table 6.2).
Figure 6.1 shows a cumulative plot of the estimated proportion of women delivering at 
different gestational ages by Kaplan Meier analysis according to type of HAART 
exposure. Overall, the plot revealed little evidence of differences in the proportion of 
women delivering by exposure group, especially for gestations <37 weeks.
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Table 6.2 Characteristics by HAART category
Characteristic NNRTI-based 
HAART+ 
(/!= 534)
PL-based HAARTt 
(n = 760)
p  value1
M aternal age
Median (IQR) 31 (27-35) 31 (27-35) 0.38
< 25 years 99(19) 123(17)
2 6 -3 4  years 286 (54) 391 (54)
>35 years 141(23) 214(29) 0.50
Unknown 8 32
Race
White 274 (52) 368 (50)
Black 236 (45) 323 (43)
Other 19(4) 49(7) 0.06
Unknown 5 20
CD4 cell count at delivery 
(cells/mm3)
Median (IQR) 418(310-597) 413 (286-582) 0.33
<200 37(9) 76(12)
200-499 230 (54) 345 (53)
>500 156 (37) 225 (35) 0.28
Unknown 111 114
HIV RNA at delivery 
(logio copies/ml)
Median (IQR) 1.69(1.69-5.56) 1.69(1.69-2.60) 0.18
Unknown 136 145
Parity (previous live births)
None 239 (45) 338(46)
1 188 (36) 230 (31)
2 71 (13) 108(15)
>3 31(6) 56 (8) 0.33
Unknown 5 28
Injecting drug use during 
pregnancy
No 511 (97) 728 (97)
Yes 16(3) 23 (3) 0.89
Unknown 7 9
T n (%) unless otherwise stated
* p  values were calculated with the Chi-squared or Mann-Whitney test as appropriate
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Table 6.2 contd.
Characteristic NNRTI-based 
HAART 
(«= 534)
Pi-based HAART 
(n= 760)
p  valueT
Initiation of ART
Pre-pregnancy 156 (31) 217(31)
First trimester 57(12) 68(10)
Second trimester 168 (34) 315(45)
Third trimester 115(23) 98 (14) <0.001
Unknown 38 62
Year of delivery
1995-1997 0 4(0.5) -
1998-2000 79(15) 232 (30.5)
2001-2003 313(59) 335 (44)
2004-2006 142 (27) 189 (25) <0.001
Mode of delivery
Vaginal 107 (20) 171(23)
Emergency CS 38(7) 76(10)
Elective CS 388(73) 512(67) 0.08
Unknown 1 1
Median gestational age at delivery
(range) 38 (26-42) 38 (23-42) 0.11
>37 weeks 405(76) 605 (80)
34-36 weeks 100(19) 112(15)
<34 weeks 29(5) 43 (6) 0.16
* n (%) unless otherwise stated
* p  values were calculated with the Chi-squared or Mann-Whitney test as appropriate
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Figure 6.1 Cumulative survival plot of the estimated proportion of women 
delivering by gestational age stratified by HAART regimen
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An estimated 3.6 % (95%CI 2.3-5.7) and 4.5% (3.3-6.3) of women receiving NNRTI-
and Pi-based HAART, respectively had delivered by 34 weeks, and 11.9% (95%CI 9.3-
15.2) and 11.5% (95%CI 9.4-14.1), respectively, by 37 weeks. A log-rank test comparing
the two HAART groups revealed no evidence for significant differences over gestational
ages (x2=1.1,/?=0.29). Log rank tests revealed no differences between the estimated time
to delivery by maternal CD4 count (x2df=2=3.2; p=0.21), time of starting HAART
(X2dT=3=3.1; /?=0.38), maternal age (x2df=2=2; p=0.38) and race (x2dr=2=L4; p=0.49).
However the log rank test revealed significant differences between women who used
injecting drugs in pregnancy and those who did not (x2df=i=4.9; p=0.03). A plot of the
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associated survival curves shown in Figure 6.2 and reveal a higher proportion of 
deliveries for IDU.
Figure 6.2 Cumulative survival plot of the estimated proportion of women 
delivering by gestational age stratified by IDU in pregnancy
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An estimated 4.0 % (95%CI 3.0-5.4) and 11% (95%CI 9.6-13.3) of women who did not 
use injecting drugs during pregnancy had delivered by 34 and 37 weeks respectively, 
compared to an estimated 2.7% (95%CI 0.4-18) and 22% (95%CI 11.0- 41 .l)o f women 
who did.
A Cox proportional-hazards model was used to investigate the association between
antenatal HAART regimen and risk of premature delivery further while adjusting for
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confounders. There were 364 women with information missing on the variables 
considered for inclusion in the model, with the majority of these cases missing 
information on maternal CD4 cell count or timing of treatment (Table 6.2). The 
proportion of women missing information on timing was similar between treatment 
groups (7% vs 8% for NNRTI-containing and Pi-containing HAART; (x2df=i=0.34, 
p= 0.34) but not for information missing on CD4 cell counts (21% vs 15% for NNRTI 
and PI; x2df=i—6.91, /K0.01). Simply removing the substantial number of mother-child 
pairs missing CD4 cases from the Cox regression could lead to a reduction in efficiency 
and bias any inferences made from the regression model (Themeau and Grambsch 
2000;Pugh et al. 1992), given that the proportion of missing values differed between the 
two HAART groups. A propensity score correction was therefore used to weight 
observations based on their likelihood of having incomplete CD4 cell count information. 
This approach is similar to those outlined in Chapter 4, but here a logistic regression was 
used to estimate each woman’s probability of complete data on timing of HAART and 
CD4 cell count instead. The logistic regression model was adjusted for HAART type and 
timing, maternal age, IDU during pregnancy, race, year of delivery, gestational age at 
delivery, and whether the woman delivered by elective CS or not. The inverse of each 
woman’s probability of having complete information on CD4 and timing of HAART was 
then included as case weights in the Cox regression model. Conservative 95% 
confidence intervals for ARHs were derived using robust standard errors, an appropriate 
variance estimate for weighted Cox regression models (Themeau and Grambsch 2000).
The RHs and ARHs from the Cox regression model with no adjustment for missing 
information and WARHs from the weighted Cox regression model are given in Table 
6.3.
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There was no evidence of a violation of the proportional hazards assumption for the 
model as a whole (global test, p=0.57), or with any individual covariates in the model 
(all /?>0.06).
In unadjusted analyses, the RH for delivery was similar between the two HAART 
groups. The only significant univariable predictors of the rate of deliveiy was the use of 
injecting drugs during pregnancy and having a parity of >3 live births (compared to no 
previous live births; Table 6.3).
Although the estimated ARHs and WARHs were roughly similar between the two Cox 
regression models, the standard errors were not and the associated p-values and 95% CIs 
in the weighted model were more conservative. The main difference was in the estimate 
for IDU in pregnancy. Both models estimated an approximate doubling in the rate of 
delivering for women using injecting drugs during pregnancy, but the effect was slightly 
higher and statistically significant in the model without the probability weights. By 
including information from the missing variables which were found to depend on 
treatment group, the weighted Cox regression model appeared to result in more 
conservative confidence intervals; as a result, the WARH estimate for IDU in pregnancy 
was slightly lower than the ARH but was not significant.
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Table 6.3 Relative risks for delivery from weighted Cox regression model (/i=930)
Model without probability weights Weighted model
RH
(95% Cl)
P ARH+
(95% Cl)
P WARH1 
(95% Cl)
P
Antenatal 
HAART regimen
NNRTI-based
Pi-based
1.00
1.10(0.86-1.40) 0.46
1.00
1.10(0.85-1.41) 0.47
1.00
1.12(0.89-1.43) 0.33
Time of starting 
HAART
Third trimester 
Second trimester 
First trimester 
Pre-pregnancy
1.00 
1.14(0.83-1.57) 
1.03 (0.64-1.68) 
1.12(0.79-1.61)
0.42
0.90
0.52
1.00
1.25(0.90-1.75) 
1.16(0.71-1.92) 
1.22 (0.83-1.78)
0.18
0.55
0.31
1.00 
1.21 (0.88-1.67) 
1.11 (0.68-1.81) 
1.20 (0.83-1.75)
0.25
0.68
0.34
Race
White
Black
Other
1.00
0.97 (0.76-1.24) 
0.80 (0.47-1.37)
0.81
0.42
1.00
0.94 (0.72-1.21) 
0.77 (0.44-1.34)
0.62
0.36
1.00 
0.96 (0.74-1.24) 
0.78 (0.46-1.30)
0.73
0.33
Maternal age
<25
26-34
>35
1.00
0.99 (0.75-1.33) 
0.92 (0.66-1.29)
0.99
0.62
1.00 
0.89 (0.66-1.22) 
0.76 (0.53-1.10)
0.48
0.15
1.00
0.91 (0.68-1.23) 
0.76 (0.52-1.09)
0.54
0.13
Use of IDU
None/ex-user 
Used during 
pregnancy
1.00
2.06(1.06-4.01) 0.03
1.00
2.17(1.09-4.33) 0.03
1.00 
1.99 (0.87-4.57) 0.10
CD4 cell counts at 
delivery
>=500
200-499
<200
1.00
1.07 (0.84-1.37) 
1.18 (0.75-1.83)
0.59
0.48
1.00 
1.09(0.84-1.41) 
1.23 (0.78-1.94)
0.50
0.38
1.00 
1.09 (0.85-1.40) 
1.19(0.74-1.92)
0.48
0.48
Parity
No previous 
livebirths
1 livebirths
2 livebirths 
>3 livebirths
1.00
1.23 (0.94-1.61) 
1.29 (0.91-1.85) 
1.84(1.23-2.74)
0.13
0.16
<0.01
1.00
1.30(0.98-1.72) 
1.45 (0.99-2.12) 
2.18(1.42-3.35)
0.07
0.06
<0.001
1.00
1.30(0.99-1.73) 
1.46 (0.98-2.16) 
2.20(1.50-3.23)
0.06
0.06
<0.001
model adjusted for all other variables in the table
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In the weighted Cox regression model, the estimated rate of women delivering was 
marginally higher for women receiving Pi-based HAART than NNRTI-based HAART in 
pregnancy, but this was not statistically significant (WARH 1.12 [95%CI 0.89-1.43]). 
Additionally, there was no significant association between the rate of women delivering 
and the timing of HAART initiation, CD4 cell counts at delivery, maternal age, race or 
IDU (WARHs, Table 6.3). The WARH estimate for IDU in pregnancy suggested a 
doubling of the rate of delivering and although the 95%CI contained one, it suggested 
that IDU could be associated with as much as a four-fold increase in the rate however 
this study had only limited power to detect an effect owing to the small number of 
women IDUs. The rate of delivery for women with three or more previous live births 
however was estimated to be twice that of nulliparous women, and was the only 
significant predictor in the model.
Of clinical relevance are proportion of deliveries at 34 and 37 weeks of gestation; as 
proportional hazards are assumed in a Cox model (an assumption which was shown to 
hold for this model), the above interpretation of a similar rate of women delivering 
between HAART regimens, and an increased rate among women who have three or more 
previous live births also apply to the rate at 34 or 37 weeks of gestation.
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6.3 Key points
• There was a similar pattern and prevalence of congenital abnormalities among 
infants exposed to antenatal ART and those who were not and this was also true 
for exposure to HAART.
• There was no evidence to suggest that exposure to first trimester ART increases 
the risk of congenital abnormalities.
• The proportion of women delivering by 37 weeks of gestation was around 11% 
for women receiving PI- or NNRTI-based HAART.
• The use of Pi-based HAART was not associated with an increased rate of women 
delivering in adjusted analyses compared to NNRTI-based HAART.
• Women who have delivered three or more previous live births had a significantly 
higher rate of delivery than nulliparous women.
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Chapter 7 Conclusions on the analysis of data on HIV infection in 
pregnancy
7.1 Introduction
HAART in resource-rich settings has substantially reduced MTCT rates through 
successful suppression of maternal HIV RNA (Mofenson et al. 1999;European 
Collaborative Study 2005b). An increasing proportion of HIV-infected pregnant women 
in these settings are identified and treated before pregnancy with a substantial minority 
diagnosed antenatally who start HAART for the first time in pregnancy (European 
Collaborative Study 2005b). In many Western European countries, these women are 
increasingly likely to have acquired HIV heterosexually and to be from countries with 
generalised epidemics, mostly sub-Saharan Africa. Data available on whether 
pregnancy may impact on HIV RNA and CD4 levels and the response of HAART, and 
whether any effect varies by the characteristics of these women, are limited.
This thesis explores the changes in CD4 counts and HIV RNA viral load during 
pregnancy in HIV-infected women treated with HAART from conception as well as 
changes in viral load in pregnancy in untreated women with the aim of informing 
understanding of the effect of pregnancy, race and IDU and the impact of ART on these 
markers. Viral response to initial HAART regimens in pregnancy was determined in 
treatment-naive women and the association between antenatal ART and adverse 
pregnancy outcomes (birth defects and premature delivery) was assessed.
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These findings using data collected within the ECS contribute to the evidence-base for 
management and understanding of HIV infection in pregnancy. Analyses were based on 
pregnancy data collected since 1987 from centres across Europe, which in recent years 
have been shown to be highly representative of the clinic population from which they 
were drawn.
7.2 Virological and immunological changes over pregnancy
The untreated and treated women in these analyses were all relatively healthy at the 
beginning of pregnancy with a median of 437 and 381 cells/mm3, respectively. A 
healthy pregnant woman effect has been described elsewhere among HIV-infected 
women in resource-rich settings (Bessinger et a l 1998) and uninfected women in 
developing countries (Ronsmans et a l 2001). An American study of HIV infected 
women reported significantly higher CD4 cell counts among the 192 pregnant women in 
the study, compared to those that were not pregnant (median 519 vs. 333 cells/mm3) 
(Bessinger et a l 1998). Possible explanations for this difference is that the pregnancy 
confers benefits to the women through the associated physiological changes or, more 
likely, that this simply represents a selection bias, where healthier women are more 
likely to become pregnant than those who are not (Ronsmans et a l 2001).
The few studies that have addressed HIV RNA dynamics in pregnancy in untreated 
HIV-infected women, have reported levels to be relatively stable over pregnancy (Bums 
et a l 1998;Mayaux et a l 1997a;0'Shea et a l 1998), or described only small and non­
significant decreases in viral load (Cao et a l 1997;Watts et a l 2003;Melvin et al 1997). 
However, only two of these five studies used appropriate statistical methods for 
correlated longitudinal data (Bums et a l 1998;Watts et a l 2003), and most did not
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report adjustment for maternal immune status (Cao et al. 1997;0'Shea et al. 1998;Watts 
et al. 2003;Mayaux et al. 1997a;Melvin et al. 1997), which together with HIV RNA 
levels is an important prognostic indicator (Mellors et al. 1997). Here, HIV RNA viral 
load during pregnancy was assessed for untreated women in the ECS using a linear 
mixed effects model, which was able to account for variability in viral load 
measurements within and between women and also allowed for women with only one 
measurement to contribute to estimation of the model (Chapter 3). This analysis 
included 324 women with viral load measurements available from the start of the 
second trimester of pregnancy, a relatively larger number of exclusively untreated 
women than included in previous studies. After adjusting for CD4 count status and race, 
HIV RNA levels did not remain stable during pregnancy: white women were estimated 
to have a 4.3% weekly decrease in viral load from the start of the second trimester up to 
the time of delivery. For black women, mostly bom in sub-Saharan Africa, the change 
in RNA viral load was estimated to be positive and significantly different to the change 
in viral load for white women. However, the increase in viral load over pregnancy in 
black women was not significantly different to zero, i.e. the slope for viral load in 
pregnancy was relatively stable for black women and decreasing for white women.
These results stand in contrast to published studies of untreated women in pregnancy 
that report no significant association between gestation and viral load in untreated HIV- 
infected pregnant women, or those receiving mono or dual therapy (Cao et al. 
1997;0'Shea et al. 1998;Watts et al. 2003;Mayaux et al. 1997a;Melvin et al. 1997). A 
study of 204 women in the Ariel project reported that viral load did not vary 
significantly during pregnancy (estimated decrease of 2 copies/m 1/day) for 29 untreated 
women or those receiving ZDV monotherapy in unadjusted linear regression, but rose
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significantly in the postpartum period (Cao et al. 1997). An analysis using pairwise 
comparisons (with a two-sample Wilcoxon test) of viral load values involving 254 
pregnant women in the SEROGEST cohort without adjustment for CD4 count, revealed 
no significant variations during pregnancy among, although postpartum values were 
significantly lower (Mayaux et al. 1997a). Women enrolled in this French study had a 
median viral load in the second trimester of pregnancy of 3.5 logio copies/ml and an 
overall mean CD4 count of 529 cells/mm3 (Mayaux et al. 1997a), similar to the median 
viral load and CD4 count in untreated women in the ECS of 3.51 logio copies/ml and 
437 cells/mm3 (Chapter 3). None of these studies used an appropriate statistical method 
for correlated longitudinal data, which could explain the discordance in results seen 
between these studies and in untreated women in the ECS. Using data on 160 women 
enrolled in the US Mother and Infants Cohort Study mostly from the third trimester of 
pregnancy, an LME model adjusting for blood sample type did not reveal any decreases 
in viral load in pregnancy, and revealed only increases in the second year postpartum; 
IDU and use of ZDV during pregnancy was not associated with a significant change in 
viral load and was therefore not included in the final model (Bums et al. 1998). In a 
sub-analysis of the 48 women with at least two HIV RNA measurements from before 
the third trimester and during the third trimester (mostly close to delivery), there was no 
overall change in viral load levels in pregnancy (Bums et al. 1998). However, although 
this US study was able to account for correlated measurements, it included only 48 
women with limited measurements available from before the third trimester of 
pregnancy and the limited duration of follow-up in pregnancy may explain why 
relatively stable levels of viral load were seen in pregnancy in this study but not in the 
analysis carried out in this thesis (Bums et al. 1998). In contrast to the first two studies 
mentioned above, the analysis in Chapter 3 used an LME model to account for repeated
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measures and unlike the analysis in the Mother and Infants Cohort Study, was also able 
to adjust for immune status in pregnancy, which was strongly associated with levels of 
viral load; women with CD4 counts <200 cells/mm3 were estimated here to have a 6- 
fold higher viral load than women with CD4 counts >500 cells/mm3, highlighting the 
importance for adjustment for this variable.
There were 367 measurements on 246 untreated women available in the ECS analysis of 
viral load in pregnancy, larger than the numbers included in the studies above with the 
exception of the SEROGEST cohort, which included data on 526 measurements on 254 
untreated women in pregnancy (Mayaux et a l 1997a); the analyses in both studies 
included women with one measurement only. The majority of untreated women in the 
ECS with only one measurement, had this taken at the time of delivery (Chapter 3) and 
although this contributed to estimation of the intercept, it will have added only limited 
information to the estimate of the slope, which may be confounded by factors 
influencing when in pregnancy this measurement was made. However, a sensitivity 
analysis including only the 80 women with at least two measurements («=215) also 
revealed a decrease in HIV RNA viral load over pregnancy albeit of smaller magnitude, 
which suggests that the influence of women with single measurements on the estimate 
of the slope in pregnancy was not large. The influence of these measurements on the 
intercept estimate however was greater, which was estimated to be -0 .4  logio copies/ml 
larger when excluded, reflecting the fact that they were taken around the time of 
delivery/intercept and with generally lower levels of HIV RNA (Chapter 3). In addition, 
the analysis in the SEROGEST study included only paired comparisons of values 
between two time points, whereas through the use of an LME model the analysis in this 
thesis was able to include all measurements across the second and third trimester of
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pregnancy while adjusting for factors associated with the level of viral load; the 
differences in statistical methods may help explain why a significant decrease in 
pregnancy was seen in the untreated women in the ECS, but not in this French study.
No studies to date have examined levels and patterns of viral load during pregnancy 
among women receiving HAART, with most focusing on viral load at the time of 
delivery and the associated risk of MTCT (Cooper et al. 2002;Dorenbaum et al. 
2002;Mofenson et al. 1999). In the analyses presented in this thesis, among the group of 
women on HAART at conception and with detectable viral load at this time, estimated 
changes in HIV RNA viral load in the first trimester of pregnancy were dependent on 
CD4 count and thereafter decreased by 14% per week up to the time of delivery, 
independent of race and history of IDU, CD4 count and type of HAART regimen 
(Chapter 5). This group of treated women had similar viral loads at the beginning of 
pregnancy to untreated women in the ECS (median in first trimester of 3.50 logio 
copies/ml and 3.52 logio copies/ml for untreated and treated women, respectively). The 
decrease in HIV RNA viral load from the second trimester of pregnancy to delivery was 
almost four times as rapid among these treated women as observed in untreated women 
over the same period in pregnancy, reaffirming the effectiveness of HAART in reducing 
viral load in pregnancy. Recent data on viral load changes in previously untreated adults 
have shown a very rapid decrease in the first six weeks of treatment, with HIV RNA 
levels decreasing by 97% per month during this period, with a considerably more 
gradual decline, of 14% each year thereafter (Thiebaut et al. 2006). This group of 
treated women in the ECS had all been on HAART for longer than 1.5 months by the 
start of the second trimester and although a very different group, the magnitude of the
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decreases seen here in pregnancy may be greater than would be expected from treatment 
alone.
The finding of a decrease in HIV RNA viral levels over pregnancy in untreated white 
women (Chapter 3) and a relatively large decrease in treated women (Chapter 5) suggest 
a possible mechanism related to physiologic changes during pregnancy. Haemodilution 
occurring in pregnancy results in increases in plasma volume of up to 50%, with most of 
the increase in volume occurring after the first trimester (Hytten 1985). The likelihood- 
based time of change-point for the viral load and CD4 models was determined to be 
around the beginning of the second trimester and the two slope change-point models 
shown in Chapter 5 may therefore reflect this physiological change (Hytten 1985). In 
the study of untreated ECS women, viral load was estimated to decrease by 0.019 logio 
copies/ml per week, roughly equal to a decrease of 0.46 logio copies/ml in the 24 weeks 
of follow up over the second and third trimesters of pregnancy; this equates to a 
decrease of 65% and therefore may not be completely explained by changes in plasma 
volume alone. Plasma HIV RNA levels have been reported to be relatively stable on a 
week-to-week or month-to-month basis in clinically stable non-pregnant patients, as 
long as antiretroviral therapy is not initiated or changed (Saag et a l 1996). Intra-assay 
sample variability of HIV RNA is between 0.1 and 0.2 logio copies/ml and the natural 
biologic variation of HIV RNA in plasma is around 0.3 logio copies/ml (Saag et al. 
1996). In practice, therefore a change in viral load of > 0.5 logio is generally considered 
to reflect a biologically relevant change in the level of viral replication. Although the 
mean decrease of 0.46 logio copies/ml is small enough to be consistent with biological 
and intra-assay variability, the confidence interval for the change over pregnancy was 
between -0.17 and -0.72 logio copies/ml indicating that the data may also be consistent
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with a decrease large enough to indicate a possible pregnancy effect. Immunological 
changes occurring in pregnancy including the depression of cell-mediated immunity and 
a shift to a type 2 (humoral immunity) cytokine environment, have been shown to be 
important in modifying HIV replication and may impact on levels of CD4 counts (see 
below also), as well as those of HIV RNA viral load (Weinberg 1984;Kidd 
2003;Johnstone et al. 1994). More specifically, pregnancy is associated with increased 
levels of particular cytokines, such as interleukin-10, which have been reported to down 
regulate HIV-replication and may explain the decreasing levels of HIV RNA in 
pregnancy seen here, over and above that associated with biologic and assay variability 
alone (Montaner et al. 1994).
In a sub-analysis of untreated women who had at least two HIV RNA measurements in 
pregnancy, the correlation of logio HIV RNA within women was obtained from the 
LME model and was estimated to be 0.66. This estimate was similar to the correlation 
estimate of 0.69 for 198 men in the MACS, who contributed 1139 HIV RNA 
measurements during the period of minimal antiretroviral use (Yamashita et al. 2003). 
Although based on comparatively small numbers per individual, this result suggests that 
gestation over the second and third trimester of pregnancy does not have a large effect 
on the within-woman correlation of viral RNA measurements, when compared to that 
observed in HIV-infected men.
The analysis of CD4 counts in treated pregnant women in the ECS revealed levels to 
decrease in early pregnancy and to increase thereafter (Chapter 5). However, after 
adjusting for viral load category, CD4 counts were estimated to be stable in early 
pregnancy and to increase by 0.32% per week thereafter, although this increase did not
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reach statistical significance. In both HIV-infected and uninfected women, findings 
regarding pregnancy-related changes in immunological markers conflict, with reports of 
declining, stable and increasing CD4 cell counts over pregnancy (Johnstone et al. 
1994;Brettle et al. 1995;Castilla et al. 1989;van Benthem et al. 2005). A study from the 
Mother and Infants Cohort Study comparing changes in CD4 levels during pregnancy 
and postpartum in 340 HIV untreated seropositive and seronegative women estimated 
CD4 counts to decline by 0.68% per month during pregnancy (Bums et al. 1996). The 
non-significant increase in CD4 counts observed in this analysis of treated women from 
the ECS therefore may represent a tempering of treatment-related increases in CD4 
counts due to a naturally occurring decline in pregnancy. A recent study of 198 HIV- 
infected pregnant women in Ireland found that women receiving treatment prior to 
conception had a significantly reduced decline in CD4 counts between pre-conception 
and the first trimester (mean 485 to 410 cells/mm3), compared to women who did not 
receive treatment during pregnancy (mean 575 to 421 cells/mm3) and may be due to a 
similar mechanism in pregnancy (Mucahy et al. 2006). A pregnancy-related decline has 
also been supported by findings of an increase in CD4 counts postpartum in untreated 
and treated women (Mucahy et al. 2006;Ekouevi et al. 2006;ECS and Swiss Cohort and 
European Collaborative Study and the Swiss HIV Pregnancy Cohort 1997). The 
influence of pregnancy on immunologic changes is poorly understood, and these 
pregnancy-related changes in CD4 could be due to a variety of factors, such as 
haemodilution in pregnancy (Johnstone et al. 1994;Brettle et al. 1995;Ekouevi et al. 
2006). It has also been suggested that the decline in CD4 in early pregnancy may be 
partially responsible for the survival of the fetal allograft (Johnstone et al. 1994). An 
alternative explanation is that the immunological changes observed could be due to 
recompartmentalisation of CD4 cells in response to hormonal changes in pregnancy
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(Johnstone et al. 1994). This is the first study to examine changes in CD4 counts over 
pregnancy in HAART-treated women and revealed some increases in CD4 count over 
the last two-thirds of pregnancy. Adjusting for viral load category at the time of the 
CD4 measurement improved the reliability of the estimates and only the highest viral 
load category (>3.25 logio copies/ml) was a significant predictor of mean CD4 count, 
with CD4 counts estimated to be 15% lower in this group than those in women with 
viral loads <2.30 logio copies/ml. The modified estimates of the two markers after 
adjustment for CD4 and viral load (Chapter 5) confirm the well established relationship 
between the two markers (Mellors et al. 1997;Boscardin et al. 1998;Thiebaut et al. 
2002) in pregnancy. Unlike other studies which found a significant correlation between 
the slopes and intercepts of viral load and CD4 from bivariate models in patients 
initiating HAART (Thiebaut et al. 2005;Thiebaut et al. 2006;Thiebaut et al. 2003), there 
was only evidence of a negative correlation between the intercepts for the two markers.
The time period of delivery variable (1998-1999, 2000-2001 and 2002-2006) was 
included in the analysis of viral load among women receiving HAART at the time of 
conception to account for changes in HIV management, although its parameter 
estimates were not statistically significant (Chapter 5). However, this may have been 
due to limited statistical power and the parameter estimates and 95% CIs suggest that a 
trend of lower HIV RNA levels over the time periods cannot be ruled out. This trend 
could be representative of general improvements in HIV care including better adherence 
and health of the pregnant women and was evidenced also by an increase in the number 
of undetectable measurements over these time periods. However, although a 
conditional-likelihood method was used to take account of left-censoring, HIV RNA 
assay specific cut-offs were not adjusted for as this data was not routinely collected in
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the ECS, and improvements in the assay detection limits over the time periods may also 
partially explain this finding.
7.3 Choice of initial HAART regimen in pregnancy and time to achieving an 
undetectable HIV RNA viral load by delivery
Suppressing plasma HIV RNA viral load below detectable limits is one of the goals for 
effective management of HIV-infected women in pregnancy and for PMTCT (British 
HIV Association 2005;Public Health Service Taskforce 2006a). Among the analysis of 
previously ARV-naive women in the ECS initiating HAART during pregnancy, most 
(73%) delivered with undetectable viral load and the remainder delivered with 
detectable, but generally veiy low levels (Chapter 4). Less than a quarter of women had 
immunological indications for treatment (British HIV Association 2005;Public Health 
Service Taskforce 2006a), with the remaining women started on HAART primarily for 
PMTCT.
Most women were prescribed Pl-containing HAART, with a highly homogenous 
approach, with 76% of these women on NFV+ZDV+3TC. A third of women received 
NVP-containing HAART, with increasing use over time (i.e. between the periods 1997- 
2000 and 2003-2004). Updated NVP prescribing advice, which recommends that NVP 
be avoided in women with CD4 cell count above 250 cells/mm3 because of the potential 
increased risk of hepatotoxicity (Public Health Service Taskforce 2006b), suggests that 
this trend is unlikely to continue: only 12 women in the ECS initiated NVP with CD4 
counts above the recommended threshold in 2005 (unpublished data). The 
predominance of ZDV+3TC-containing regimens here reflects current 
recommendations for this NRTI combination as the backbone for pregnant women
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(DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents 2006;Public 
Health Service Taskforce 2006a) and is consistent with prescribing patterns in Europe in 
non-pregnant individuals (Mocroft et al. 2006b).
Adjusting for baseline prognostic factors, the hazard of achieving undetectable viral 
load in this cohort was greater for women initiating HAART with NVP, with women 
initiating with Pi-based HAART taking on average 1.4 times longer to achieve viral 
suppression. To my knowledge, this analysis is the first to suggest that choice of initial 
HAART regimen has implications for timely achievement of undetectable viral load in 
pregnancy. Accumulating evidence from adult cohorts suggest that types of initial 
HAART may have a differential impact on the time to short term immunological and 
virological response and delaying disease progression, particularly the long-term 
sustainability of viral suppression and immune reconstitution (Matthews et al. 
2002;Mocroft et al. 2006b;Mocroft et al. 2006a;The Antiretroviral Therapy Cohort 
Collaboration 2006). A study of 789 patients from EuroSIDA found that those receiving 
HAART with a single PI (mostly NFV) were significantly less likely to achieve 
undetectable viral load <500 copies/ml (RH 0.74) than women receiving NNRTI-based 
HAART (mostly efavirenz) (Mocroft et al. 2006a). A London study of 888 patients also 
reported a differential response between regimens, with the rate of achieving 
undetectable viral load significantly higher for patients on efavirenz than those on a 
single PI or NVP (Matthews et al. 2002). However, a Canadian population-based 
analysis of 439 ART-nai've HIV-infected patients, most of whom were women, found 
that the use of NNRTI-containing HAART (94% NVP) was associated with a more 
rapid HIV-RNA suppression compared to both patients receiving double PI or single PI-
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containing HAART in adjusted analyses, which is in line with the findings presented in 
this thesis (Wood et a l 2003).
Findings from randomised controlled trials in non-pregnant adults conflict on the 
relative effectiveness of Pl-(non-boosted) versus NNRTI-containing HAART. A recent 
direct meta-analysis of “head-to-head” randomised trials suggested NNRTI-based 
HAART (predominated by efavirenz) was 60% more effective for virological 
suppression than Pi-based HAART (50% boosted Pis), although no difference in 
clinical outcomes was reported (Chou et al. 2006). However, an indirect meta-analysis 
yielded contradictory results, i.e. NNRTI-based HAART was worse than Pi-based 
HAART for virological suppression (Chou et a l 2006); these discordant results may be 
due to differences in population, study design or type of NRTI backbone, highlighting 
the difficulties in translating trial findings into clinical recommendations and the 
importance of direct comparisons (Chou et a l 2006). The comparison of NVP-based 
HAART and Pi-based HAART in the analysis here was facilitated by the overall similar 
NRTI backbone used in conjunction with these components.
Therapeutic decision-making in pregnancy is complicated by unique factors including 
the need to consider PMTCT, safety/toxicity and physiological changes, which may 
affect pharmacokinetics (Public Health Service Taskforce 2006b;Mirochnick and 
Capparelli 2004). Accumulating data on NFV pharmacokinetics suggest that drug levels 
in the third trimester may frequently be sub-therapeutic (Villani et a l 2006;Nellen et a l 
2004;van Heeswijk et a l 2004). This may explain the finding of a superior virological 
response to women receiving NVP-based HAART, in contrast to the Combine Study, 
where an equivalent response was reported among ARV-naive non-pregnant individuals
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randomised to a ZDV+3TC backbone with NVP or NFV (Podzamczer et a l 2002). A 
sensitivity analysis examining the time taken to achieve undetectable viral load between 
NFV-based and NVP-based HAART also revealed similar results of a superior virologic 
response with NVP-containing HAART, reinforcing the possibility of underlying 
differences in pharmacokinetics explaining the differing responses among the two 
treatment groups.
There were no significant differences in time to attaining undetectable viral load 
between severely immunosuppressed women (CD4 count <200 cells/mm3) and those 
with greater immunocompetence. This is consistent with other studies which have found 
a significant association between baseline viral load and subsequent virological 
response after HAART initiation, but not with baseline CD4 counts (Phillips et a l 
2001;Matthews et a l 2002). Few studies have examined this association in ARV-naive 
pregnant women and these findings suggest that the relationship between baseline CD4 
count and viral load and subsequent treatment effect in this group of women may not 
differ from non-pregnant adults.
7.4 Adverse pregnancy outcomes
7.4.1 Prematurity
The association between HAART and prematurity has been consistently reported in 
Europe since 1998 (ECS and Swiss Cohort and European Collaborative Study and the 
Swiss HIV Pregnancy Cohort 2000;European Collaborative Study 2004;Townsend et 
al 2007b). The reference groups in these studies assessing the risk of prematurity were 
mostly either untreated women, or those receiving mono or dual therapy. However, the 
relevance of this comparison group is questionable given that most women in resource-
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rich settings are now expected to receive HAART, with either an NNRTI or PI 
component. These combinations have predominated in the ECS in recent years and 
other pregnancy cohorts have reported similar uses of these combinations in pregnancy 
(Townsend et al. 2007b).
In a comparison of Pi-based or NNRTI-based HAART with an appropriate statistical 
analysis to account for the high number of elective CS deliveries, there were no 
differences between the two HAART groups with respect to the rate of women 
delivering by 34 or by 37 weeks gestation (Chapter 6). Adjustment for maternal IDU, 
race and maternal CD4 cell count, established risk factors for prematurity (Patel et al. 
2004;Slattery and Morrison 2002;The European Collaborative Study 1996) increased 
the reliability of the estimated relative hazards. The only significant predictors of the 
rate of delivering in the final weighted and adjusted Cox model was the categoiy of 
women with at least 3 previous live births, however IDU was significantly associated 
with a doubling of the rate of delivering in the adjusted model which did not include the 
probability weights. Although IDU was not statistically significant in the weighted 
model, the RH for IDU was similar and had a 95% Cl which contained zero but was not 
clustered closely around zero; given the width of the 95% Cl and the confirmed 
association between IDU in pregnancy and prematurity (Slattery and Morrison 2002), a 
finding of a non-significant result here suggests that this study was limited by statistical 
power to examine the effect of IDU.
A recent study of 4445 mother-child pairs exposed to ART and enrolled in the UK 
National Study of HIV in Pregnancy and Childhood (NSHPC) also found an equivalent 
risk of prematurity between those receiving HAART with PI compared to HAART
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without a PI (including some women who received triple NRTI HAART) (Townsend et 
al. 2007b). A recent study of 681 women from Latin America and the Caribbean 
reported similar results (Szyld et a l 2006). However, these findings were in contrast to 
Cotter et al, who reported a 1.8 increased odds of premature delivery with Pi-based 
HAART (single and boosted) compared to both monotherapy and HAART without a PI 
(exact details of the PI and NNRTI components were not given), in a US study of 999 
women (Cotter et al. 2006). There are several possible explanations for the discrepancy 
in results between this ECS analysis and those from the Cotter study. Despite 
adjustment for several known confounders, data on other risk factors for prematurity 
such as prior preterm births, smoking and alcohol use in pregnancy, clinical disease 
stage and presence of sexually transmitted diseases were not routinely collected in the 
ECS and therefore could not be adjusted for (Slattery and Morrison 2002). Cotter et al. 
were able to adjust for these factors which could improve the reliability of their 
estimates, but most of these factors were reported not to have been significant factors of 
preterm delivery (odds ratios for these factors were not reported) (Cotter et al. 2006). 
However, the association between a history of a prior preterm was high and an adjusted 
odds ratio of 3.4 (95% Cl 2.3-5.0) was reported. The inability to control for prior 
preterm deliveries in this ECS analysis may have resulted in a potential bias, especially 
if there was an imbalance in the number of women with a history of preterm births 
between the two treatment groups.
In the ECS analysis, there were no significant differences in the distributions of CD4 
cell counts between treatment groups (Chapter 6). Cotter et al. described prescribing 
patterns in their cohort such that Pi-based regimens were reserved for women who were 
immunocompromised and/or who had more advanced HIV disease (Cotter et al. 2006).
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It could be possible therefore that the finding of an association between Pi-based 
HAART and prematurity in this US study was confounded by indication for therapy of 
maternal disease. Furthermore, another principal difference between the studies is that 
the study by Cotter et al. used data from only one clinical site where the ECS analysis 
was based on data from up to 23 centres, where centre-associated differences were not 
accounted for directly. Standardised management protocols were used in both studies 
but the possibility of unmeasured centre-based differences is expected to be greater in 
the ECS and offers a further explanation for the discordance in these results. Although it 
is not possible to make any firm conclusions based on the ECS data given here, based 
on these data there was little evidence to suggest that the use of Pi-based HAART 
regimens were associated with an increased risk of prematurity compared to the use of 
NNRTI-based HAART.
Finally, the overall crude severe prematurity rate was 5.6%, but there were no 
differences observed between women receiving Pi-based or NNRTI-based HAART. 
Severely premature infants are likely to pose a substantial demand on health care 
services, both in the immediate and longer-term (European Collaborative Study 
2004;Slattery and Morrison 2002).
7.4.2 Congenital abnormalities
In the ECS, 1.5% of children exposed to ART in utero were bom with a congenital 
abnormality (Chapter 6). There was a similar pattern and prevalence of congenital 
abnormalities among infants exposed to antenatal ART and those who were not and this 
was also true for exposure to HAART. Furthermore, based on these data there was no 
evidence to suggest that exposure to first trimester ART increases the risk of congenital
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abnormalities. As such, these findings are consistent with those of the Antiretroviral 
Pregnancy Registry (Covington et al. 2004;Antiretroviral Pregnancy Registry Steering 
Committee 2004). However, as a long-running birth-cohort study, the ECS benefits 
from a large number of mother-child pairs (both exposed and non-exposed), and are not 
subject to the potential for ascertainment and reporting bias which limit interpretation of 
registry data (Antiretroviral Pregnancy Registry Steering Committee 2004), and these 
findings are consistent with other observational studies from Europe (Townsend et al. 
2006) (I. Grosch-Womer, Personal communication).
7.5 Race and injecting drug use
Significant and substantial differences between black and white women were observed 
in the analysis of HIV RNA viral load and CD4 counts over pregnancy (Chapter 3 and 
5) and in that investigating time to undetectable viral load in ARV-naive pregnant 
women (Chapter 4). In black untreated women who were mostly bom in Africa, the 
estimated change in viral load over pregnancy was significantly different to that of 
white women (mostly bom in Western Europe), but this slope was not significantly 
different to zero. The estimated mean viral load at delivery for black women was 3.86 
logio copies/ml, and was significantly higher than white women who had a mean of 3.41 
logio copies/ml. This significant difference between HIV RNA levels conflicts with 
other European studies of pregnant and non-pregnant adults which have found black 
ethnicity to be associated with lower viral loads (Mayaux et al. 1997a;Saul et al. 2001). 
A longer duration of infection in these African women is a possible explanation for this 
difference, which has been associated with higher HIV RNA levels (Sabin et al. 
2000;Lyles et al. 1999); another is the presence of co-infections. A recent ECS sub­
study analysis of 1,050 women found that women bom in Africa were at a significantly
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increased risk of having a viral sexually transmitted infection (STI) in pregnancy 
(Landes et al. 2006). Concurrent co-infection with viral STIs, particularly the herpes 
virus, have been shown to increase the rate of viral replication, purportedly through 
increased levels of certain cytokines or through modulation of immune responses that 
control HIV viraemia (Anzala et al. 2000). The effect of haemodilution seen among 
white women therefore may have been attenuated by an increase in HIV RNA levels 
over pregnancy among black women and may explain the relatively stable slope of viral 
load in pregnancy, with significant differences seen at delivery only.
In the analysis of treated pregnant women (Chapter 5), white women with a history of 
IDU were estimated to have an almost 60% significantly lower HIV RNA viral load 
than white women with no history, but a similar slope of viral load decrease over 
pregnancy. A recent analysis by the CASCADE Collaboration based on 943 patients, 
most of whom were male (82%), found that the short term virological response was 
poorer in men infected by IDU than for men who have sex with men, but reported no 
differences in the long-term response (Thiebaut et al. 2006). Other studies have reported 
a negative effect of current IDU on virological and immunological responses to 
HAART (Lucas et al. 2001;Palepu et al. 2003). It has been suggested that the poorer 
response seen in IDUs is due to incomplete adherence (Spire et al. 2002), which does 
not appear be the case in this group of pregnant women who had a similar response to 
treatment regardless of IDU status but with lower initial levels of virus in those with 
IDU history. Of note, most of the women with a history of IDU were ex- rather than 
current users and thus would not be experiencing the chaotic lifestyle of an active IDU 
that is held to be the reason for poor adherence.
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Among women treated with HAART from conception, there was no evidence of 
significant differences between white and black women with respect to viral load, 
although the estimated mean level was lower in black women (Chapter 5). Black 
women experienced similar changes in CD4 counts over pregnancy to white women, 
but were estimated to have 25% lower CD4 counts throughout pregnancy. This is 
consistent with a previous ECS analysis, which reported untreated black women to have 
45% lower CD4 count compared to white women (Thome et al. 1995). Possible 
explanations for the lower CD4 counts in black women, most of who were bom in 
Africa, may include a longer duration of infection, or a higher prevalence of bacterial, 
protozoan and helminthic infections, which have been associated with lower CD4 cell 
counts (Lepage et al. 1993;Anzala et al. 2000;Chirenda 1999). Lower initial levels of 
CD4 cell count (i.e., pre-seroconversion) are another explanation, which may also be 
caused by a higher prevalence of bacterial infections in early life (Bunders et al. 2006). 
A study of HIV-uninfected children with or without in utero HIV exposure in Europe 
and Uganda found CD4 counts to be lower in Ugandan-born children than in children 
living in Europe with Ugandan mothers (Bunders et al. 2006). It has been suggested that 
differences in diet, environment and exposure to micro-organisms may be responsible 
for these differences and may also explain the differences seen in viral load and CD4 
counts between black and white women in the ECS (Bunders et al. 2006;0zkan et al. 
1993).
In the analysis of time to undetectable viral load, black women responded to HAART 
more favourably than non-black women in unadjusted analysis; further investigation, 
stratifying by region of birth, revealed that this effect was limited to women of West 
African origin. African and non-African pregnant women had similar baseline immune
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and virological status in this analysis; this is in contrast to previous findings based on 
the whole cohort (European Collaborative Study 2006) and those presented here in 
treated women (Chapter 5), in which black African women had lower CD4 counts at 
baseline. This probably reflects eligibility criteria for this analysis, i.e. all women were 
ARV-nai’ve and facilitated the comparison of treatment effect between these women. 
The median baseline CD4 count among black women here was marginally lower than 
those reported from African PMTCT trials, which were in the range of 335-363 
cells/mm3 in ARV-nai've pregnant women (Taha et a l 2006;Shapiro et al. 2006). 
Limited information is available regarding response to HAART in African populations, 
and even less in pregnant African women. In the DREAM pilot study in Mozambique, 
65% of 40 pregnant women starting on HAART with median baseline HIV RNA 4.2 
logio copies/ml achieved viral suppression to <400 copies/ml by delivery, after an 
average of 12 weeks (Giuliano et a l 2006), consistent with the results of this ECS 
analysis (Chapter 4). An impact of race on disease progression or response to HAART 
has been suggested by several studies in pregnant and non-pregnant individuals, 
generally showing poorer virological responses in black and/or African groups, which 
have been suggested to be due to coinfections and/or adherence (Frater et a l 
2002;Cunningham et a l 2004;Anastos et al 2000). Data on adherence was not 
available in the ECS, but it seems unlikely that differing adherence levels could explain 
these findings, as the better virological response to HAART was limited to the West 
African group only. ARV drugs are usually developed using subtype B, the predominant 
subtype in resource-rich settings, as a reference virus, and little is known about the 
susceptibility of the different non-B HIV-1 subtypes to ARV drugs (Bocket et a l 
2005;Geretti 2006). A study of 416 ARV-nai've patients infected with B and non-B 
HIV-1 subtypes found no differences between these groups with regards to the time to
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achieving undetectable viral load in adjusted analyses (Bocket et a l 2005). A recent 
paper reviewing studies examining the association between HIV-1 subtype and the risk 
of disease progression and treatment response found that most studies were 
characterised by small numbers and short follow-up, and did not account for potential 
confounding such as the clustering of subtypes within risk and ethnic groups (Geretti 
2006). The authors concluded that based on the limited clinical evidence, responses to 
HAART did not appear to differ significantly among subtypes, but further research will 
be necessary to confirm this (Geretti 2006). Immunogenetic and other human genetic 
variations have been known to impact on the natural history of HIV disease progression 
where individuals are untreated, but it is unclear whether these differences are relevant 
in the context of individuals receiving HAART (Brumme and Harrigan 2006). 
Differences in underlying maternal biological and genetic differences between Western 
African and European women may however explain the findings in this cohort (Chapter 
4) (Brumme and Harrigan 2006). Another explanation is that West African women had 
better rates of adherence than Non-African women which would result in a faster 
response to treatment (Conway 2007;Moore et a l 2005), however adherence data were 
not collected in the ECS and therefore the results may be biased. Further work on 
treatment responses in African women needs to be carried out with adherence data 
collected to clarify these findings.
7.6 Management of HIV-infected pregnant women -  implications of the research 
findings for clinical practice
In Western Europe, the combination of high antenatal coverage, universal HIV testing 
in most countries and access to a range of PMTCT interventions has resulted in very 
low MTCT rates of <1-2% (Townsend et a l 2007a;European Collaborative Study
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2006). Maternal HIV RNA viral load is the most important predictor and modifiable 
risk factor for MTCT (European Collaborative Study 1999;Cooper et al. 2002;Ioannidis 
et al. 2001;Mofenson et al. 1999). Viral load is also a strong predictor of progression to 
AIDS and death (Mellors et al. 1997;Sabin et al. 2000). Therapeutic decision-making 
and management in pregnancy must consider the risk of transmission to infants by 
maintaining viral suppression to the time of delivery, but also the longer-term 
sustainability of treatment started or maintained in pregnancy. These decisions are 
further complicated by unique factors in pregnant women including the need to consider 
maternal and fetal safety, potential adverse pregnancy outcomes and physiological 
changes during pregnancy, which may affect pharmacokinetics (Public Health Service 
Taskforce 2006b;Mirochnick and Capparelli 2004).
With the widespread use of HAART in developed settings and increasing number of 
women having subsequent pregnancies, a large number of infected pregnant women can 
be expected to be receiving HAART before pregnancy ( European Collaborative Study 
2005b;Boer et al. 2007). Sequential measurements of viral load and CD4 cell counts are 
crucial for monitoring treatment response in HIV-infected individuals and help inform 
clinical decision-making, particularly regarding switching regimens. The findings here 
facilitate the interpretation of changes in these markers among HIV-infected pregnant 
women receiving HAART at conception, and may be useful for examining treatment 
response in pregnancy. However, it should be noted that these women were a select 
group in that they all had detectable viral loads at their first visit in pregnancy. These 
results may therefore not be generalisable to women who begin pregnancy on HAART 
with undetectable viral loads and should be interpreted with this in mind.
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In resource-rich settings where HAART is commonplace, the added benefit of elective 
CS for PMTCT has been questioned for women with undetectable HIV RNA viral loads 
(Boer et al. 2007;British HIV Association 2005). In particular, the risk of vertical 
transmission without elective CS has been reported to be as low as 0-2% and there are 
concerns that the benefits of this intervention may be outweighed by the costs, such as 
increased risk of post-partum complications and greater burden on health care services 
associated with elective CS (Boer et al. 2007;Marcollet et al. 2002;Read et al. 2001b). 
As more evidence becomes available, the use of vaginal deliveries over elective CS may 
increase and indeed, guidelines are already changing with the offer of a vaginal delivery 
deemed acceptable in cases where women have low/undetectable viral load on stable 
HAART (Iribarren et al. 2001;The American College of Obstetricians and 
Gynecologists 2000; British HIV Association 2005). Decisions on the appropriate mode 
of delivery in infected pregnant women will be based on sequential measurements of 
viral load and a better understanding of changes of this marker in pregnancy may help 
facilitate these choices.
Prompt identification of undiagnosed HIV-infected women in pregnancy is crucial to 
the success of PMTCT. The few annual cases of vertically-acquired HIV infections in 
Western Europe largely due to late or non-identification of infection in the mother in 
pregnancy (Mayaux et al. 2003;European Collaborative Study 2005b). Although, for 
many reasons, the earlier an HIV-infected pregnant woman can be diagnosed the better, 
the finding of a faster time to viral suppression in ARV-naive women initiating with 
NVP-based HAART highlights the importance of the choice of initial HAART regimen 
in women identified late in pregnancy.
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Although guidelines state that pregnancy should not preclude use of optimal ARV 
regimens (DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents 2006), 
in reality there are limited options. NFV has the most extensive pregnancy data on 
pharmacokinetics and safety of all Pis and is currently preferred within antenatal 
HAART, especially where there are no maternal indications for treatment (DHHS Panel 
on Antiretroviral Guidelines for Adults and Adolescents 2006). NFV was the 
overwhelming choice to accompany ZDV+3TC in ARV-naiVe women to date here, but 
was less effective regarding virological suppression than NVP-containing HAART. In 
non-pregnant adults, NNRTI-containing HAART is recommended as a first-line 
regimen, preserving Pi-containing HAART for later, with efavirenz as the preferred 
agent. As efavirenz is contraindicated in the first trimester of pregnancy, NVP- 
containing HAART has been increasingly used for ARV-naive pregnant women in 
Europe, but this is now no longer recommended for women with relatively good 
immune functioning. The potential option of initiating efavirenz-based HAART in the 
second or third trimester, if contraception can be assured after delivery, has been 
suggested in current WHO recommendations for resource-limited countries (World 
Health Organisation 2006), but this approach is unlikely to be taken in Europe: among 
women in the ECS who initiated HAART during pregnancy in 2005, none did so with 
an efavirenz-based HAART regimen (unpublished data).
In the absence of clinical trials of HAART in pregnant women, these findings add to the 
evidence-base to assist therapeutic decision-making for ARV-naive pregnant women. If 
clinicians comply with prescribing advice, one would expect the future group of ARV- 
naive women starting on NVP-containing HAART to have lower CD4 counts than 
women here. These results strongly suggest that an ARV-naive pregnant woman with
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CD4 count <250 cells/mm3 should be started on NVP-containing rather than NFV- 
containing HAART and highlight the urgent need for further research in 
pharmacokinetics, efficacy and safety of antiretroviral drugs in pregnancy. Additionally, 
once HAART becomes more readily available in low and middle-income countries, 
such data will also be important as a basis for comparisons with treatment responses in 
resource-poor settings where women are likely to be receiving HAART for the first time 
in pregnancy.
The use of HAART during pregnancy, particularly in the early stages when 
organogenesis is taking place, has raised concerns relating to the safety for the exposed 
fetus (Public Health Service Taskforce 2006b). The focus of safety issues in this thesis 
was neonatal outcomes only (i.e. prematurity and birth defects). Longer-term adverse 
effects of exposure to ARV in utero and/or neonatally have been documented by several 
groups including the ECS and include mitochondrial and haematological abnormalities 
(Blanche et al. 1999;Le Chenadec et al. 2003;Bunders et al. 2005).
Although further data are needed to confirm the findings here, based on these data there 
was no evidence of an association between HAART use and birth defects and an 
equivalent risk of prematurity between PI- and NNRTI-based HAART regimens was 
observed. Although both analyses included reasonably large sample sizes (3471 and 
931, respectively), an increased risk of birth defects associated with treatment use in 
pregnancy cannot be ruled out, given that the study may not have had sufficient power 
to detect significant differences.
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7.7 Data from the European Collaborative Study and their analysis: strengths and
challenges
7.7.1 Data
The ECS clinical centres are the principal referral centres for HIV-1 infected pregnant 
women in their regions. Antenatal testing for HIV is routine in all centres and women 
enrolled in the ECS are likely to be representative of the HIV-infected pregnant clinic 
population in Europe who visited these centres for antenatal care. This is evidenced by 
the survey results from Section 2.3.1, which showed an enrolment rate of over 95% of 
HIV-infected pregnant women, with geographical relocation explaining most of the 
non-enrolments. As these data have been collected from a number of centres, 
characteristics of the centre-specific populations of infected pregnant women may vary 
and could have influenced these results. The ECS centres followed a standard protocol 
and the use of standardised data collection forms to collect important socio­
demographic, obstetric and paediatric variables, details on treatment use, illicit drug use 
and immunological and virological markers of HIV disease, allowed for adjustment for 
these variables where appropriate in statistical analyses. However, most analyses did not 
explicitly adjust for centre-differences owing to the large numbers of centres within the 
ECS and differences in unmeasured confounders between centres could therefore not be 
accounted for which may have introduced some bias. For instance, clinician- and clinic- 
based preferences/policies for the timing and frequency of HIV RNA and CD4 count 
measurements or initial ART regimens may be confounded by unmeasured variables, 
which in turn could have an impact on all the results presented in this thesis. For 
example if some centres were more likely to take regular virological and immunological 
measurements than other centres, then this could lead to a bias in the results. A centre- 
based random effects term could be used to account for some of the unmeasured
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confounders in LME models but was not feasible in the sub-group of women starting 
pregnancy on HAART (Chapter 5) as nested random effects cannot be incorporated into 
left-censored models at present (Thiebaut et al. 2005), and a nested random effects term 
for the sampling period was already included to account for differences in the storage 
time of samples in untreated women (Chapter 3). However, in an LME model with a 
random effect term for untreated women nested within centres, instead of the sampling 
period, the slope estimate for viral load in pregnancy was similar (estimate -0.016 logio 
copies/ml per week; 95%CI -0.004, -0.029) as was the centre-associated random effect 
terms, suggesting that centre-associated variability in HIV RNA although significant, 
did not explain more variability than that associated with the sampling period.
The number of undetectable HIV RNA measurements (152; 31%) among the untreated 
group of women in the ECS was high (Chapter 3) and the extent to which the women in 
this study are representative of other untreated women with HIV infection during the 
same period is unknown. The prevalence of undetectable measurements reported in 
studies of untreated pregnant and non-pregnant adults varies. In a longitudinal study of 
1256 non-pregnant adult women enrolled in the Women’s Interagency HIV Study in the 
US, 48% and 18% of measurements taken prior to the initiation of ART were estimated 
to be <1466 and <80 copies/ml, respectively (Anastos et al. 2000). The proportion of 
undetectable HIV RNA measurements reported among 254 untreated pregnant women 
enrolled in the SEROGEST cohort (with a quantification limit of 400 copies/ml) was 
lower and varied from 16% in the second trimester of pregnancy to 15% at the time of 
delivery (Mayaux et al. 1997a). Eighty-percent of the viral load measurements included 
in the analysis of HIV RNA during pregnancy in Chapter 3 was from women enrolled 
before 1998, when viral load was not routinely collected within the study protocol. The
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proportion of undetectable measurements among samples taken before 1998, where 
some had been stored for a longer duration, was considerably higher than among those 
from the later period (135/392; 34% vs. 17/98; 17%: x2=5.54, p= 0.02). Accurate 
retrieval of HIV RNA has been reported from serum and plasma stored at -70°C for 
around 9 months (Coombs et al. 1993). In this study, early HIV RNA measurements 
were obtained from serum and plasma samples stored at -70°C for anything up to 
several years and the extent of the effect of a possible longer duration of storage on the 
accuracy of quantification of test results is not known (Coombs et al. 1993;Sabin et al. 
2000). Although the analyses here did not directly control for heterogeneity of 
laboratory methods and storage times, all labs were university hospitals or tertiary 
referral centres with high levels of quality control. The analyses were therefore adjusted 
for HIV RNA sample and assay type where appropriate and a nested random effects 
structure used to account for unobserved differences between measurements taken in the 
two time periods, which should reduce some of the bias in the estimates from these 
models. Nevertheless, the finding of a large number of undetectable measurements in 
this study could feasibly represent the degradation of samples from several years’ 
storage and this should be taken into account when interpreting the results from the 
analysis of untreated women. Additionally, there was no record of any ART use during 
pregnancy or in previous pregnancies among the 15 women in this analysis who had 
their second child in the ECS, and thorough data checks were carried out (see Section 
2.3.1). However, it could be possible that the ART start dates for these women or any 
treatment received pre-pregnancy were not accurately recorded and that some of the 
decreases observed in pregnancy may be treatment-related. Even with these possible 
limitations of the data, the proven success of ART means that it is unlikely that 
additional information on untreated pregnant women will become available and
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measurements on this group of women offered a unique opportunity to study the natural 
dynamics of HIV RNA in pregnancy and add to the limited knowledge on viral load 
patterns in pregnancy.
In the analysis of HIV RNA and CD4 counts among women becoming pregnant on 
HAART (Chapter 5), information on the duration of HAART pre-pregnancy was not 
available for all women and therefore the resulting parameter estimates may be 
confounded by time on treatment. A sub-analysis of 109 women with available 
information on timing of treatment revealed mostly negligible changes in the parameter 
estimates for the intercept and slopes of viral load and CD4 count over pregnancy. The 
only exception was the estimate of the second slope of CD4 count in pregnancy which 
was of similar magnitude but had a 95% Cl which was no longer bounded by zero; this 
suggests that any confounding effect of treatment duration on the results here was 
negligible in the viral load model, but may have resulted in a slope estimate biased 
towards the null for the CD4 model.
The gold standard for comparison of the effectiveness of different treatments is a 
randomised controlled trial (RCT) and the comparison of HAART regimens in 
pregnancy on the time taken to achieve undetectable viral load by delivery is limited by 
the observational nature of the data (Phillips et al. 1999). RCTs, in which randomisation 
can be expected to remove all confounding factors, is the only design that can guarantee 
unbiased, reliable estimates of treatment effects (Chalmers et al. 1983). However, there 
are also a number of well-documented problems associated with RCTs (Sabin and 
Phillips 2001). The relevance of findings from an RCT in a group of patients who have 
consented to participate and who have been selected based on restricted immunological
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and virological criteria may not reflect clinical practice, and their relevance to the 
general patient population is debatable (Sabin and Phillips 2001;Sabin 2004;Munoz et 
a l 2000;Phillips et a l 1999). In the absence of data from RCTs and other observational 
studies, the findings in this thesis on the effects of choice of initial HAART regimen on 
achieving a timely undetectable viral load in pregnancy are important. The use of 
analytical methods which allowed for interval-censoring (Lindsey and Ryan 1998), 
adjusted for timing of initiation in pregnancy and minimised confounding by including 
treatment-naive women should improve the estimated treatment effects. A disadvantage 
of these data is their limited contemporary relevance where therapeutic practices have 
changed over time. A case-in-point is the NVP prescribing changes following the 
association with hepatotoxicity in women with moderate to high CD4 counts (Public 
Health Service Taskforce 2006b). Although specific data were not available on 
ALT/AST levels and drug-related toxicities, all ARV-naive women who started NVP- 
based HAART in this analysis continued with this treatment to at least delivery, 
suggesting that any toxicities arising were minor and/or not necessitating treatment 
modification.
The results in the time to undetectable viral load analysis depend on the assumption that 
women receiving NVP or Pi-based HAART with the same values of measured 
prognostic factors were similar. Additionally, the results from the analysis of viral load 
and CD4 counts among women becoming pregnant on HAART assume that all 
confounders were adjusted for so that any changes seen in pregnancy can be attributed 
to measured covariates. However, factors potentially influencing response to HAART 
could not be accounted for such as adherence, biological differences in drug activity 
arising from variations in body weight and pharmacokinetics between groups, HIV sub­
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types and other genetic factors (Stebbing and Bower 2006;Lowe et al. 2004;Mirochnick 
and Capparelli 2004). Residual confounding by these or other factors is unlikely to be 
entirely eliminated from observational studies and the results must be interpreted in this 
light.
In a recent review paper, the most common reason given for failure to achieve or sustain 
expected treatment benefits was non-adherence (Conway 2007). Therapeutic success, 
including virological and immunologic responses, has been demonstrated across PI- 
and NVP-containing HAART regimens for patients who maintain good levels of 
adherence (generally >95%) (Conway 2007;Moore et al. 2005;Wood et al. 2004). This 
has been corroborated in studies of directly observed therapy and directly administered 
therapy where levels of adherence are near 100% (Lucas et al. 2006;Conway 2007). 
Pregnancy is associated with significant physiologic changes, and nausea and vomiting 
are common. This in itself could lead to decreased drug levels in the first trimester of 
pregnancy and any nausea and vomiting may also increase the patient’s reluctance to 
maintain a pill regimen which is associated with a perceived additional side-effect 
(Hammer et al. 2006;Conway 2007). There is also the possibility that pregnant women 
may be less likely to adhere in pregnancy due to concerns over the effect these 
treatment regimens may have on their unborn child. However, a recent study of 
adherence from Brazil based on 72 pregnant women and 79 non-pregnant women found 
that pregnant women had a more than three times odds of adhering than non-pregnant 
women (Vaz et al. 2007). Given these results, it is feasible that the women who were 
receiving HAART at conception (Chapter 5) may have increased their adherence in the 
first trimester of pregnancy once they were aware of their pregnancy, and may help 
explain why a two-slope pattern was necessary to describe viral load and CD4 count
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changes in pregnancy. However, results from studies examining adherence for women 
who were on ART before pregnancy are limited and conflicting. The Brazilian study 
mentioned above found a similar rate of adherence among women who were on ART 
before pregnancy compared with those who began ART during pregnancy (Vaz et al.
2007), while a New York cohort of 2714 HIV-infected women found that women on 
ART before pregnancy were more likely to adhere (Laine et a l 2000). Whether 
adherence was a confounder in this study could not be determined, but this uncertainty 
should be taken into account when making inferences based on these results.
Unobserved differences in the rate of adherence, pill burden, and associated side-effects 
in the receipt of PI- and NVP-based HAART may also bias the results from the time to 
undetectable viral load analysis (Chapter 4). However a meta-analysis of virologic 
outcomes in relation to pill burden in studies of triple-drug HAART in treatment-naive 
HIV-infected persons found that pill count was not a consistent predictor of virologic 
suppression (Bartlett et al. 2006), suggesting that any differences in pill burden may 
have only had a limited influence on the observed results here. Nevertheless, without 
information on pharmacokinetics of drugs in pregnancy in the ECS, it was not possible 
to confirm findings from studies suggesting that NFV drug levels in the third trimester 
are sub-therapeutic (Villani et al. 2006;Nellen et al. 2004;van Heeswijk et al. 2004), 
and it is possible that differences in the rate of adherence between treatment regimen 
groups were a confounding factor. Additionally, data on seroconversion was not 
available, and the data of first HIV diagnosis is unlikely to be a good proxy for this. 
Studies of viral load trends in mostly male seroconverters found that viral load 
decreased in the first few years from seroconversion, after which they gradually 
increased (Lyles et al. 1999;Sabin et al. 2000). It is not possible to verify whether West
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African women in the time to undetectable viral load analysis had seroconverted earlier 
than other women, but may offer an additional explanation to why this group of women 
were seen to respond faster to treatment than Non-African women (Chapter 4).
7.7.2 Statistical methods
The analysis of HIV data in pregnancy was complicated by several factors, which 
required the use of complex, non-standard statistical methods.
The monitoring of HIV markers in pregnant women in the ECS resulted in repeated 
measurements of immunological and virological markers and were analysed using LME 
models which took into account the correlation between measurements on each woman 
(Chapter 3 and 5). In the analysis of viral load measurements in untreated pregnant 
women, the use of a nested random effects model was justified by the considerable and 
significant variation between the two periods of HIV RNA data collection, but 
precluded the use of complex methods to take into account the left-censoring resulting 
from undetectable measurements (Chapter 3). In an attempt to remove the 
heteroscedasticity in residuals resulting from use of the simple method of imputing 
midpoints, a power function was incorporated into the model to account for this 
variance structure, which led to an improvement in the fit of the model. The lack of 
homoscedasticity among residuals from undetectable values seems unavoidable when 
relatively simple methods such as imputation of midpoints are used. Although this is 
unlikely to invalidate the estimates of the models’ parameters it may impact the 
associated standard errors and 95% confidence intervals, and the use of bootstrap 
methods to obtain confidence intervals for LME models where censoring is high, may 
be more appropriate (Ware 1985).
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A sensitivity analysis was carried out to assess the impact of imputing midpoints for 
undetectable measurements in the analysis of viral load in untreated women (Chapter 3). 
Using the conditional likelihood method to account for undetectable measurements and 
accounting for sampling period through a covariate term, a similar slope in pregnancy 
was revealed but with a considerably larger estimate for the mean HIV RNA at delivery 
intercept. This change in the intercept could be a direct result of either not accounting 
for the variability in sampling periods appropriately or using a more appropriate 
statistical method for the analysis of undetectable measurements (Jacqmin-Gadda et al. 
2000). These results suggested that although the slope estimate in this analysis was 
invariant to the imputation method, the mean estimate for the intercept was not and 
therefore caution should to be taken when interpreting the estimate for mean HIV RNA 
at delivery.
The decision to use a piecewise linear LME model for viral load and CD4 
measurements over pregnancy in treated women was based on the underlying pattern of 
the markers, and consideration of both minimisation of the AIC and ease of 
interpretation (Chapter 5). A limitation of this approach is that the chosen functional 
form may not have been fully representative of the markers on the introduction of 
explanatory variables, in particular with respect to the time of change-point. In addition, 
the median number of CD4 and HIV RNA measurements among this sample o f treated 
pregnant women was only three limiting any inferences that can be made on the 
underlying population trends in markers.
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The conditional likelihood method resulted in improved properties of the parameter 
estimates for viral load in women becoming pregnant while receiving HAART, 
although there was some evidence of non-normality in the tails of the residuals (Chapter 
5). However, after adjustment for CD4 count this was less evident.
The statistical method used to account for left-censoring among treated women was 
based on the assumption that the left-censored values are part of a Gaussian distribution, 
which estimates these viral load values by completing this distribution using the 
likelihood method (Thiebaut and Jacqmin-Gadda 2004). An asymmetrical distribution 
such as the gamma distribution may be more suitable for undetectable viral load values, 
however at present the approach using the NLMIXED procedure in SAS for left- 
censored values is not able to incorporate any other distributions and this modification 
was not investigated further.
A bivariate model was used to account for and to estimate the correlation between the 
markers in pregnancy but did not result in an improved model fit, while a bivariate 
model with the conditional likelihood approach could not be fitted (Chapter 5). A 
possible explanation for this is the small variation around the CD4 slope and intercept. 
The bivariate approach followed here takes into account the correlation between the two 
markers through the covariance matrix of their random effects, and insufficient 
variability around the random terms is likely to result in estimated covariances 
(correlations) close to zero, leading to unreliable and unstable parameter estimates and 
their standard errors (Everitt 1987;Goldstein 1989;SAS Institute Inc. 2004). Bivariate 
LME models with left-censoring have also been used to examine the changes in viral 
load and CD4 from baseline in non-pregnant adults from the APROCO Cohort and the
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CASCADE collaboration after initiation of treatment (Thiebaut et a l 2003;Thiebaut et 
al. 2006), using the CENSAD routine which requires the computation of a multiple 
integral over the number of censored measures per subject (Jacqmin-Gadda et a l 2000). 
The APROCO analysis included 929 patients with 4513 and 4491 CD4 count and viral 
load measurements followed for up to 12 months after initiation (Thiebaut et a l 2003), 
and the CASCADE analysis 943 patients with over 7000 viral load and CD4 
measurements and up to 24 months follow up after initiation (Thiebaut et a l 2006). No 
appreciable changes in parameter estimates from the use of a bivariate model over the 
univariate model were reported in these studies, but the correlations between the 
intercepts and slopes for both markers were adequately estimated. Several differences 
between these studies and the ECS analysis may explain why the random effects 
covariance could be properly estimated in these studies, but not in the ECS. The period 
of follow-up in these studies was considerably longer than in the ECS analysis which 
was restricted to the period of pregnancy and as a result the median number of 
measurements was only 3 in the ECS analysis, whereas the median number of 
measurements for viral load and CD4 counts was 5 in the APROCO study and 4 in the 
CASCADE study. Additionally, the statistical approach used in these two studies used 
the CENSAD routine, which uses a Marquadt algorithm to maximise the likelihood, a 
method that has been shown to be preferable when the number of random effects are 
large (>4 random effect terms) (Thiebaut and Jacqmin-Gadda 2004). However, in the 
ECS analysis the number of random effects was limited to 4 or less and the NLMIXED 
procedure has been shown to be reliable up to 4 random effects so the difference in 
statistical method is an unlikely explanation for why the random effects covariance 
could not be estimated for the ECS data (Thiebaut and Jacqmin-Gadda 2004). Although 
the possibility remains that the integration algorithm used in the CENSAD routine may
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have been more suitable for these data in estimating the random effects covariance 
matrix, the small amount of variation around the intercept and slopes for the women in 
these studies is a more likely explanation.
The bivariate random effects model, taking into account left-censoring with the 
conditional likelihood method is the preferable approach to the joint modelling of CD4 
and viral load as it allows for direct interpretation of the relationship between the two 
markers without assuming the dependence of one marker in relation to the other 
(Thiebaut et a l 2002). However as this model could not be estimated LME models of 
each marker as a function of the other marker were fitted instead. Given that HIV RNA 
directly targets CD4 cells leading to their decline, the LME model MODCD4-2, which 
modelled CD4 as a function of viral load may be biologically more credible (Chapter 5). 
However, during the period of pregnancy, the main focus of PMTCT is to ensure 
women have as low viral loads as possible throughout pregnancy and by the time of 
delivery (Mofenson et al. 1999;European Collaborative Study 1999;European 
Collaborative Study 2005b), and for this reason the LME model for viral load, 
MODVL-CL2, is the preferred model for informing clinical practice.
In the analysis of treated women, the repeated measures nature of the data was taken 
into account by assuming an unstructured covariance matrix for the random intercept 
and slope terms for all LME models (Chapter 5). The use of specific correlation 
structures to model the dependence among observations (through their within-group 
errors) was not feasible here as these methods require that the data are observed 
sequentially over time, i.e. at equally spaced time points (Pinheiro and Bates 2000). 
Compound symmetry and autoregressive LME models therefore could not be
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investigated. Further, the addition of stochastic terms to the LME models to allow for 
the correlation between measurements, using for example an Integrated Omstein 
Uhlenbeck (IOU) or Brownian motion term, was not feasible (Boscardin et al. 1998). 
Given sequentially observed data, Boscardin et al. also discuss the possibility of the 
joint modelling of two parameters by using a bivariate IOU process (Boscardin et al. 
1998). This bivariate stochastic model allows for the stochastic process in one marker to 
be influenced by the previous derivatives of the processes of both markers, while the 
process of the other marker is influenced only by its own process. This may be a 
suitable approach in the joint modelling of HIV RNA viral load and CD4, where the lag 
between measurements and the influence of previous measurements of each marker on 
subsequent CD4 and viral load measurements may be different for each marker. The 
bivariate stochastic model could allow for asymmetry in how one marker affects the 
other and also the lag between these measurements; whether this approach is suitable 
for the joint analysis of HIV RNA viral load and CD4 in pregnancy needs to be 
determined.
A limitation of the analysis of treated women in pregnancy (Chapter 5) was that it was 
carried out according to the intention-to-treat (or continue) principle and therefore did 
not take into account any treatment modifications or interruptions; the results therefore 
could be biased towards determining no effect (Pezzotti et al. 2001).
The LDM proved to be a useful tool in assessing the assumption of independence 
between residuals from the bivariate LME model (Chapter 5).
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As expected in an observational cohort study, treatment allocation was not randomised 
and viral load measurements occurred at various times after initiation of treatment 
depending on the frequency of clinic visits in pregnancy (Chapter 4). The non-standard 
measurement schedule and the interval censoring nature of the data required a 
parametric survival model to assess treatment differences (Griffin et al. 2006;Lindsey 
and Ryan 1998;Klein and Moeschberger 1997). Alternative parametric distributions, 
such as the log-logistic distribution or the piecewise exponential (Farrington 1996) have 
also been shown to be suitable for assessing treatment outcomes for data with this 
censoring structure (Griffin et al. 2006). However, investigation of the hazard rate here 
(Chapter 4) showed the Weibull model to be appropriate in modelling the hazard rates 
for the two treatment regimens, but with the advantage that the model estimates had a 
simpler interpretation through representation as an AFT or proportional hazards model 
(Klein and Moeschberger 1997).
The finding of an association between initiation of HAART in the third trimester and 
more rapid achievement of undetectable virus was a surprising finding. It is possible 
that this effect represents uncontrolled confounding or that this is an artefact of the time 
in the study for each woman related to the timing of viral load measurements that was 
not fully accounted for. The Weibull model used here also assumed that the viral load 
measurement times were independent of a woman’s treatment outcome, but it is feasible 
that the number of clinic visits for each woman was related to their current viral load, 
which will also have been dependent on the effectiveness of the treatment (Manavi et al. 
2007;Farrington and Gay 1999). Farrington et al. have proposed a statistical method to 
model interval-censored survival data with informative examination times, which 
involves modelling the hazard function by taking account of individual frailties related
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to the frequency of clinic measurements; the extent to which this would impact on 
estimated treatment differences in this setting, is not known (Farrington and Gay 1999).
Adjustment for the propensity score was used to create a quasi-randomised trial setting 
in the aim of reducing some of the bias associated with non-randomised treatment 
allocation but had a negligible effect on the treatment effect estimate (Chapter 4) 
(D'Agostino, Jr. 1998). However, propensity score methods assume that any differences 
in treatment allocation can be measured by the observed covariates, and biased 
treatment effect estimates may still result if this is not the case, which may explain why 
the propensity score correction made little difference in this analysis. Sturmer et al. have 
proposed a method called propensity score calibration, which addresses confounding by 
variables unobserved in the study, by using variables observed in a validation study 
(Sturmer et al. 2005). In the absence of an appropriate validation study for HIV-infected 
pregnant women, this is not a feasible approach at present.
An additional explanation for the negligible change in the treatment effect estimate after 
adjustment for the propensity score is that the logistic regression model, which predicts 
the propensity scores, may have been misspecified. Drake et al. carried out a simulation 
study of 1000 samples of size 100 to compare the propensity score model (stratification 
by quintiles of the propensity score) and prognostic model (adjusting for covariates 
only) in estimating treatment effects from observational studies (Drake 1993). After 
comparison of the resulting estimates, the author concluded that misspecification of the 
propensity score model resulted in smaller biases than misspecification of the 
prognostic model, however the bias associated with omitting a confounder was similar 
between both models. Given these results, it is unlikely that misspecification of the
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propensity score will have resulted in any treatment effect bias in the study presented 
here as all observed variables which were confounders were incorporated into the 
Weibull model.
There are currently few data on the ability of the propensity score to reduce treatment 
allocation bias in survival models. A recent study by Austin et al. used Monte Carlo 
simulations to examine the potential bias of different propensity score methods for 
estimating treatment effects through logistic, Poisson and Cox proportional hazards 
regression models (Austin et al 2007). They found that when either the odds ratio or the 
hazards ratio was used as the measure of treatment effect and when there was a true 
underlying treatment effect, conditioning on the propensity score resulted in biased 
estimation of the true treatment effect, towards that of no effect. This held true 
regardless of whether the scores were incorporated into the model through stratification, 
matching or covariate adjustment. However, they also found that for time-to-event 
outcomes, including only the true confounders in the regression model also resulted in a 
treatment effect bias; the model which adjusted for all variables, i.e. both those related 
to treatment outcome and those that are true confounders, resulted in no bias in the HR 
for the treatment effect (Austin et al. 2007). The propensity score model in the analysis 
of treatment effects on time to undetectable viral load presented here included only 
variables which were related to treatment effect, even if they were not related to the 
outcome of interest. This ensured that although the final Weibull model was not over 
parameterised, treatment assignment was balanced among women, given the observed 
covariates. However, given that the results from this study showed no changes in the 
treatment effect estimate, and based on the results from the study by Austin et al., 
propensity score adjustment seems to add little in terms of reducing bias in treatment
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effect estimates, and adjusting for confounders and variables which are related to the 
outcome appears to be the most appropriate approach.
Assessing the outcome of premature delivery in this cohort was complicated by the 
considerable use of elective CS (Chapter 6). These deliveries were viewed as right- 
censored outcomes, with a Cox-proportional hazards model used to assess the affect of 
type of HAART on the rate of delivery.
An important assumption made in statistical analysis is that any data which are missing 
are missing at random. In the analysis of prematurity between women receiving 
NNRTI-based vs. Pi-based HAART, there was some evidence of dependence between 
missing CD4 count and timing of treatment information and the type of HAART being 
received (Chapter 6). Therefore, this missing information and the mechanism of 
missingness was accounted for by weighting observations in the regression based on 
their likelihood of being incomplete, using inverse probability weights predicted from a 
propensity score model. The LME models used in the analysis of HIV RNA levels and 
CD4 cell counts in untreated and treated women also assume that the responses missing 
at any time point are missing at random. This assumption is important as although 
pregnant women in the ECS will have had a similar number of clinic visits as part of 
their routine antenatal care, not all women will have had an HIV RNA or CD4 cell 
measurement taken. However, if the measurements which were taken were not 
representative of the woman’s true trajectory or response to therapy, then a bias could 
be introduced. In the analysis of untreated women, HIV RNA levels among women with 
one measurement only were lower at delivery than women who had at least two 
measurements, and their inclusion in the model may lead to a possible bias. However, in
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a sensitivity analysis excluding women with only one measurement, the only change 
was in the estimate of mean HIV RNA at delivery, while the slope estimate was similar.
7.8 Recommendations and future research
There are several methodological aspects of this work which could be explored further 
but which was outside the scope of this thesis. Most HIV RNA assays used today are 
likely to be ultrasensitive, and the need for complicated methods to account for left- 
censoring in datasets where detection limits of assays are predominantly <50 copies/ml 
may not be as important as in the ECS datasets investigated here (Gray et al. 2004). 
Nevertheless, a clustering of measurements with the same undetectable value can lead 
to lack of homoscedasticity as observed here, and simple but effective methods to 
account for this need to be developed.
A limitation of the analyses of viral load and CD4 markers over pregnancy was that no 
preconception or postpartum data were available. Although, inferences on the effect of 
pregnancy are possible based on these data, prospective studies of women before, 
during and after pregnancy are needed to determine whether or not the changes 
observed here are due to pregnancy (either directly or indirectly).
There is an urgent need for further research in pharmacokinetics, efficacy and safety of 
antiretroviral drugs in pregnancy. Boosted PI regimens appear to offer superior 
virological suppression in ARV-naive adults compared to PI alone (Bartlett et al. 2006) 
and lopinavir/ritonavir is identified as a preferred PI for initial HAART in pregnancy in 
current US guidelines, albeit with limited pharmacokinetic and safety data (DHHS 
Panel on Antiretroviral Guidelines for Adults and Adolescents 2006;Stek et a l 2006).
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While only 17 women received boosted Pis in the ECS in 2005 (unpublished data), as 
more information becomes available, boosted Pis in initial HAART regimens in 
pregnancy may become increasingly common and the question of its equivalence to 
other HAART regimens warrants investigation. The UK CHIC study has reported a 
poor immunological and virological status in a small group of patients who have 
experienced failure of all three classes of ARVs and suggested the possibility of 
treatment exhaustion for these individuals (Sabin et al. 2005). Given the trend in 
increasing subsequent live births in infected women in Europe (European Collaborative 
Study 2005a) and the limited options for ARV treatment in pregnancy, research into 
newer agents such as integrase and fusion inhibitors with regards to both their safety 
and tolerability in pregnancy and their effectiveness for PMTCT need consideration.
248
R eference L ist
Abberger, K. (2002) Exploring local dependence. CoFE Discussion Paper 02-14,
Center of Finance and Econometrics, University of Konstanz.
AIDSinfo . AIDSinfo drug database, http://www.hivatis.org/. Accessed February 2007.
Akaike, H. (1974) A new look at the statistical model identification. IEEE 
Trans.Automat.Contr., AC-19, 716-23.
Anastos, K., Gange, S. J., Lau, B., Weiser, B., Detels, R., Giorgi, J. V., Margolick, J. B., 
Cohen, M., Phair, J., Melnick, S., Rinaldo, C. R., Kovacs, A., Levine, A., Landesman, 
S., Young, M., Munoz, A. and Greenblatt, R. M. (2000) Association of race and gender 
with HIV-1 RNA levels and immunologic progression. J.Acquir.Immune Defic.Syndr., 
24,218-226.
Antiretroviral Pregnancy Registry Steering Committee (2004). Antiretroviral Pregnancy 
Registry Interim Report for 1st January 1989 to 3 1st January 2003.
Anzala, A. O., Simonsen, J. N., Kimani, J., Ball, T. B., Nagelkerke, N. J., Rutherford, J., 
Ngugi, E. N., Bwayo, J. J. and Plummer, F. A. (2000) Acute sexually transmitted 
infections increase human immunodeficiency virus type 1 plasma viremia, increase 
plasma type 2 cytokines, and decrease CD4 cell counts. J.Infect.Dis., 182,459-466.
Austin, P. C., Grootendorst, P., Normand, S. L. and Anderson, G. M. (2007) 
Conditioning on the propensity score can result in biased estimation of common 
measures of treatment effect: a Monte Carlo study. Stat.Med., 26, 754-768.
249
Austin, P. C., Mamdani, M. M., Stukel, T. A., Anderson, G. M. and Tu, J. V. (2005)
The use of the propensity score for estimating treatment effects: administrative versus 
clinical data. Stat.Med, 24, 1563-1578.
Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., 
Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W. and 
Montagnier, L. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for 
acquired immune deficiency syndrome (AIDS). Science, 220, 868-871.
Bartlett, J. A., Fath, M. J., Demasi, R., Hermes, A., Quinn, J., Mondou, E. and 
Rousseau, F. (2006) An updated systematic overview of triple combination therapy in 
antiretroviral-naive HIV-infected adults. AIDS, 20, 2051-2064.
Baylor, M. S. and Johann-Liang, R. (2004) Hepatotoxicity associated with nevirapine 
use. J.Acquir.Immune Defic.Syndr., 35, 538-539.
Bersoff-Matcha, S. J., Miller, W. C., Aberg, J. A., van Der, H. C., Hamrick Jr, H. J., 
Powderly, W. G. and Mundy, L. M. (2001) Sex differences in nevirapine rash.
Clin.Infect.Dis., 32, 124-129.
Bessinger, R., Clark, R., Kissinger, P., Rice, J. and Coughlin, S. (1998) Pregnancy is not 
associated with the progression of HIV disease in women attending an HIV outpatient 
program. Am.J.Epidemiol., 147, 434-440.
Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Firtion, G., Ciraru-Vigneron, 
N., Lacroix, C., Rouzioux, C., Mandelbrot, L., Desguerre, I., Rotig, A., Mayaux, M. J. 
and Delfraissy, J. F. (1999) Persistent mitochondrial dysfunction and perinatal exposure 
to antiretroviral nucleoside analogues. Lancet, 354, 1084-1089.
Bocket, L., Cheret, A., Deuffic-Burban, S., Choisy, P., Gerard, Y., de, 1. T., X, Viget,
N., Ajana, F., Goffard, A., Barin, F., Mouton, Y. and Yazdanpanah, Y. (2005) Impact of
250
human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy 
effectiveness. Antivir.Ther., 10, 247-254.
Boer, K., Nellen, J. F., Patel, D., Timmermans, S., Tempelman, C., Wibaut, M., 
Sluman, M. A., van der Ende, M. E. and Godfried, M. H. (2007) The AmRo study: 
pregnancy outcome in HIV-1-infected women under effective highly active 
antiretroviral therapy and a policy of vaginal delivery. BJOG., 114, 148-155.
Boscardin, W. J., Taylor, J. M. and Law, N. (1998) Longitudinal models for AIDS 
marker data. Stat.Methods Med.Res., 7,13-27.
Brettle, R. P., Raab, G. M., Ross, A., Fielding, K. L., Gore, S. M. and Bird, A. G.
(1995) Hiv-Infection in Women - Immunological Markers and the Influence of 
Pregnancy. AIDS, 9, 1177-1184.
British HIV Association. Guidelines for the management of HIV infection in pregnant 
women and the prevention of mother-to-child transmission of HIV. 
http://www.bhiva.org/guidelines/2005/pregnancv/Pregnanev2005.doc Accessed March 
2007.
Brockmeyer, N. (1999) German-Austrian Guidelines for HIV-therapy during 
pregnancy-status: May/June 1998—common statement of the Deutsche AIDS- 
Gesellschaft (DAIG) and the Osterreichische AIDS-Gesellschaft (OAG). 
Eur.J.Med.Res., 4, 35-42.
Brumme, Z. L. and Harrigan, P. R. (2006) The impact of human genetic variation on 
HIV disease in the era of HAART. AIDS Rev., 8, 78-87.
Bryant, A. S., Leighty, R. M., Shen, X., Read, J. S., Brouwers, P., Turpin, D. B., 
Larussa, P. S., Pacheco-Acosta, E., Paul, M. E., Vajaranant, M. and Tuomala, R. E. 
(2007) Predictors of Repeat Pregnancy Among HIV-1-Infected Women.
J.Acquir.Immune Defic.Syndr., 44, 87-92.
251
Buckley, J. and James, I. (1979) Linear-Regression with Censored Data. Biometrika, 66, 
429-436.
Bunders, M., Lugada, E., Mermin, J., Downing, R., Were, W., Thome, C. and Newell, 
M. L. (2006) Within and between race differences in lymphocyte, CD4+, CD8+ and 
neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe 
and Uganda. Ann.Trop.Paediatr., 26, 169-179.
Bunders, M., Thome, C. and Newell, M. L. (2005) Maternal and infant factors and 
lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected 
mothers. AIDS, 19, 1071-1079.
Bums, D. N., Landesman, S., Minkoff, H., Wright, D. J., Waters, D., Mitchell, R. M., 
Rubinstein, A., Willoughby, A. and Goedert, J. J. (1998) The influence of pregnancy on 
human immunodeficiency vims type 1 infection: antepartum and postpartum changes in 
human immunodeficiency vims type 1 viral load. Am.J.Obstet.Gynecol, 178, 355-359.
Bums, D. N., Nourjah, P., Minkoff, H., Korelitz, J., Biggar, R. J., Landesman, S., 
Rubinstein, A., Wright, D. and Nugent, R. P. (1996) Changes in CD4+ and CD8+ cell 
levels during pregnancy and post partum in women seropositive and seronegative for 
human immunodeficiency vims- \ . Am.J.Obstet.Gynecol., 174, 1461-1468.
Cao, Y., Krogstad, P., Korber, B. T., Koup, R. A., Muldoon, M., Macken, C., Song, J. 
L., Jin, Z., Zhao, J. Q., Clapp, S., Chen, I. S., Ho, D. D. and Ammann, A. J. (1997) 
Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for 
the prevention of HIV transmission from mother to infant. Nat.Med., 3, 549-552.
Castilla, J. A., Rueda, R., Vargas, M. L., Gonzalez-Gomez, F. and Garcia-Olivares, E. 
(1989) Decreased levels of circulating CD4+ T lymphocytes during normal human 
pregnancy. JReprod.ImmunoL, 15, 103-111.
252
Centers for Disease Control (1981) Pneumocystis pneumonia—Los Angeles. MMWR 
Morb.Mortcd. Wkly.Rep., 30, 250-252.
Centers for Disease Control (1982) Unexplained immunodeficiency and opportunistic 
infections in infants—New York, New Jersey, California. MMWR 
Morb.Mortcd. Wkly.Rep., 31, 665-667.
Centers for Disease Control (1992) 1993 revised classification system for HIV infection 
and expanded surveillance case definition for AIDS among adolescents and adults. 
MMWR Recomm.Rep., 41,1-19.
Chalmers, T. C., Celano, P., Sacks, H. S. and Smith, H., Jr. (1983) Bias in treatment 
assignment in controlled clinical trials. N.Engl. J.Med, 309, 1358-1361.
Chirenda, J. (1999) Low CD4 count in HIV negative malaria cases and normal CD4 
count in HIV positive and malaria negative patients. Cent.Afr.J.Med., 45, 248.
Chou, R., Fu, R., Huffman, L. H. and Korthuis, P. T. (2006) Initial highly-active 
antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse 
transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet, 
368,1503-1515.
Coll O, Suy A and Martinez E . Increased risk of pre-eclampsia and fetal death in HIV- 
infected pregnant women receiving highly-active antiretroviral therapy. Proceedings 
and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections , San 
Francisco, CA, USA, 8-11 February 2004 (Abstract 921).
Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE 
EU Concerted Action (2000) Time from HIV-1 seroconversion to AIDS and death 
before widespread use of highly-active antiretroviral therapy: a collaborative re­
analysis. Lancet, 355, 1131-1137.
253
Collett, D. (1994) Modelling Survival Data in Medical Research. Chapman & Hall, 
London.
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, 
A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T.
C., Reichman, R. C., Hooper, C. and Corey, L. (1996) Treatment of human 
immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS 
Clinical Trials Group. N.Engl.J.Med., 334, 1011-1017.
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., 
VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L. and . (1994) Reduction of 
maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine 
treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
N.Engl.J.Med., 331, 1173-1180.
Conway, B. (2007) The role of adherence to antiretroviral therapy in the management of 
HIV infection. J.Acquir.Immune Defic.Syndr., 45 Suppl 1, S14-S18.
Coombs, R. W., Henrard, D. R., Mehaffey, W. F., Gibson, J., Eggert, E., Quinn, T. C. 
and Phillips, J. (1993) Cell-free plasma human immunodeficiency virus type 1 titer 
assessed by culture and immunocapture-reverse transcription-polymerase chain 
reaction. J.Clin.Microbiol., 31, 1980-1986.
Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C., Hayani, K., 
Handelsman, E., Smeriglio, V., Hoff, R. and Blattner, W. (2002) Combination 
antiretroviral strategies for the treatment of pregnant HIV-1-infected women and 
prevention of perinatal HIV-1 transmission. J.Acquir.Immune Defic.Syndr., 29,484- 
494.
Cooper, E. R., Nugent, R. P., Diaz, C., Pitt, J., Hanson, C., Kalish, L. A., Mendez, H., 
Zorrilla, C., Hershow, R., Moye, J., Smeriglio, V. and Fowler, M. G. (1996) After AIDS 
clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the 
subsequent reduction in the vertical transmission of human immunodeficiency virus in a
254
cohort of infected women and their infants. Women and Infants Transmission Study 
Group. J.Infect.Dis., 174, 1207-1211.
Cotter, A. M., Garcia, A. G., Duthely, M. L., Luke, B. and O'Sullivan, M. J. (2006) Is 
antiretroviral therapy during pregnancy associated with an increased risk of preterm 
delivery, low birth weight, or stillbirth? J.Infect.Dis., 193, 1195-1201.
Covington, D. L., Conner, S. D., Doi, P. A., Swinson, J. and Daniels, E. M. (2004) Risk 
of birth defects associated with nelfinavir exposure during pregnancy. Obstet.Gynecol, 
103,1181-1189.
Cox DR and Oakes D (1984) Analysis o f survival data. Chapman and Hall.
Cox, C., Chu, H., Schneider, M. F. and Munoz, A. (2007) Parametric survival analysis 
and taxonomy of hazard functions for the generalized gamma distribution. Stat.Med. 26, 
4352-4374.
Cox, D. R., Atkinson, A. C., Box, G. E. P., Darroch, J. N., Spjotvoll, E. and 
Wahrendorf, J. (1984) Interaction. International Statistical Review, 52, 1-31.
Cunningham, C. K., Balasubramanian, R., Delke, I., Maupin, R., Mofenson, L., 
Dorenbaum, A., Sullivan, J. L., Gonzalez-Garcia, A., Thorpe, E., Rathore, M. and 
Gelber, R. D. (2004) The impact of race/ethnicity on mother-to-child HIV transmission 
in the United States in Pediatric AIDS Clinical Trials Group Protocol 316.
J.Acquir.Immune Defic.Syndr., 36, 800-807.
D'Agostino, R. B., Jr. (1998) Propensity score methods for bias reduction in the 
comparison of a treatment to a non-randomized control group. Stat.Med., 17, 2265- 
2281.
Davison, A. C. and Hinkley, D. V. (1997) Bootstrap Methods and their Applications, 
Chapter 5. Cambridge University Press.
255
De Santis, M., Carducci, B., De Santis, L., Cavaliere, A. F. and Straface, G. (2002) 
Periconceptionai exposure to efavirenz and neural tube defects. Arch.Intern.Med., 162, 
355.
Delta Study (1996) Delta: a randomised double-blind controlled trial comparing 
combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in 
HIV-infected individuals. Delta Coordinating Committee. Lancet, 348,283-291.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for 
the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 
http://aidsinfo.nih.gov/ Accessed October 2006.
Dorenbaum, A., Cunningham, C. K., Gelber, R. D., Culnane, M., Mofenson, L., Britto, 
P., Rekacewicz, C., Newell, M. L., Delfraissy, J. F., Cunningham-Schrader, B., 
Mirochnick, M. and Sullivan, J. L. (2002) Two-dose intrapartum/newborn nevirapine 
and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized 
trial. JAMA, 288, 189-198.
Downs, A. M., Heisterkamp, S. H., Rava, L., Houweling, H., Jager, J. C. and Hamers, 
F. F. (2000) Back-calculation by birth cohort, incorporating age- specific disease 
progression, pre-AIDS mortality and change in European AIDS case definition. 
European Union Concerted Action on Multinational AIDS Scenarios. AIDS, 14, 2179- 
2189.
Drake, C. (1993) Effects of Misspecification of the Propensity Score on Estimators of 
Treatment Effect. Biometrics, 49, 1231.
Dunn, D. T., Newell, M. L., Ades, A. E. and Peckham, C. S. (1992) Risk of human 
immunodeficiency virus type 1 transmission through breastfeeding. Lancet, 340, 585- 
588.
256
ECS and Swiss Cohort and European Collaborative Study and the Swiss HIV 
Pregnancy Cohort (1997) Immunological markers in HIV-infected pregnant women. 
AIDS, 11, 1859-1865.
ECS and Swiss Cohort and European Collaborative Study and the Swiss HIV 
Pregnancy Cohort (2000) Combination antiretroviral therapy and duration of pregnancy. 
AIDS, 14,2913-2920.
Ekouevi, D., Inwoley, A., Tonwe-Gold, B., Danel, C., Becquet, R., N'dri-Yoman, T., 
ROuet, F., Leroy, V., Anglaret, X. and Dabis., F. Criteria for HAART Should Be 
Revisited in HIV-infected Pregnant Women in Resource-limited Settings. Poster at 13th 
Conference on Retroviruses and Opportunistic Infections (CROI2006). Abstract 704a .
EuroHIV . HIV / AIDS Surveillance in Europe: end year report 2003, No. 70. Institut de 
veille sanitaire, Saint-Maurice, France.
EuroHIV . HIV/AIDS Surveillance in Europe: mid-year report 2005, No. 72. 72. 2005. 
Saint-Maurice, France, Institut de Veille Sanitaire.
EuroHIV . HIV / AIDS Surveillance in Europe: end year report 2005, No. 73. Institut de 
veille sanitaire, Saint-Maurice, France. 2006.
European Collaborative Study (1988) Mother-to-child transmission of HIV infection. 
Lancet, 2, 1039-1043.
European Collaborative Study (1998) Therapeutic and other interventions to reduce the 
risk of mother-to-child transmission of HIV-1 in Europe. Br.J.Obstet.Gynaecol., 105, 
704-709.
European Collaborative Study (1999) Maternal viral load and vertical transmission of 
HIV-1: an important factor but not the only one. AIDS, 13, 1377-1385.
257
European Collaborative Study (2001) HIV-infected pregnant women and vertical 
transmission in Europe since 1986. AIDS, 15, 761-770.
European Collaborative Study (2002) Level and pattern of HIV-1-RNA viral load over 
age: differences between girls and boys? AIDS, 16,97-104.
European Collaborative Study (2003) Exposure to antiretroviral therapy in utero or 
early life: the health of uninfected children bom to HIV-infected women.
J.Acquir.Immune Defic.Syndr., 32, 380-387.
European Collaborative Study (2004) Increased risk of adverse pregnancy outcomes in 
HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS, 
18,2337-2339.
European Collaborative Study (2005a) Increasing likelihood of further live births in 
HIV-infected women in recent years. BJOG., 112, 881-888.
European Collaborative Study (2005b) Mother-to-child transmission of HIV infection in 
the era of highly active antiretroviral therapy. Clin.Infect.Dis., 40,458-465.
European Collaborative Study (2006) The mother-to-child HIV transmission epidemic 
in Europe: evolving in the East and established in the West. AIDS, 20, 1419-1427.
European Mode of Delivery Collaboration (1999) Elective caesarean-section versus 
vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical 
trial. Lancet, 353, 1035-1039.
Everitt, B. S. (1987) Introduction to Optimization Methods and their Application in 
Statistics. Chapman & Hall, London.
Farrington, C. P. (1996) Interval censored survival data: a generalized linear modelling 
approach. Stat.Med., 15,283-292.
258
Farrington, C. P. and Gay, N. J. (1999) Interval-censored survival data with informative 
examination times: parametric models and approximate inference. Stat.Med., 18, 1235- 
1248.
Fauci, A. S. (1996) Host factors and the pathogenesis of HIV-induced disease. Nature, 
384, 529-534.
Fiore, S., Newell, M. L., Trabattoni, D., Thome, C., Gray, L., Savasi, V., Tibaldi, C., 
Ferrazzi, E. and Clerici, M. (2006) Antiretroviral therapy-associated modulation of Thl 
and Th2 immune responses in HIV-infected pregnant women. J.Reprod.Immunol., 70, 
143-150.
Fischl, M. A., Richman, D. D., Causey, D. M., Grieco, M. H., Bryson, Y., Mildvan, D., 
Laskin, O. L., Groopman, J. E., Volberding, P. A., Schooley, R. T. and . (1989) 
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related 
complex. AZT Collaborative Working Group. JAMA, 262, 2405-2410.
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., 
Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T. and . 
(1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS 
and AIDS-related complex. A double-blind, placebo-controlled trial. N.Engl.J.Med., 
317, 185-191.
Fitzgerald, A. P., DeGruttola, V. G. and Vaida, F. (2002) Modelling HIV viral rebound 
using non-linear mixed effects models. Stat.Med., 21,2093-2108.
Food and drug administration . Important drug warning -  Zerit and Videx.
http://www.fda.gov/medwatcli/safetv/200 l/zerit&videx letter.htm 7 . Accessed 2005.
259
Frater, A. J., Dunn, D. T., Beardall, A. J., Ariyoshi, K., Clarke, J. R., McClure, M. O. 
and Weber, J. N. (2002) Comparative response of African HIV-1-infected individuals to 
highly active antiretroviral therapy. AIDS, 16, 1139-1146.
French, R. and Brocklehurst, P. (1998) The effect of pregnancy on survival in women 
infected with HIV: a systematic review of the literature and meta-analysis.
Br.J.Obstet.Gynaecol., 105, 827-835.
Friedman, J. H. (1984) A variable span scatterplot smoother. Laboratory fo r  
Computational Statistics, Stanford University Technical Report No. 5.
Gabiano, C., Tovo, P. A., de Martino, M., Galli, L., Giaquinto, C., Loy, A., Schoeller, 
M. C., Giovannini, M., Ferranti, G., Rancilio, L. and . (1992) Mother-to-child 
transmission of human immunodeficiency virus type 1: risk of infection and correlates 
of transmission. Pediatrics, 90, 369-374.
Gallant, A. R. (1987) Nonlinear statistical models. Wiley and Sons.
Gazzard, B., Bernard, A. J., Boffito, M., Churchill, D., Edwards, S., Fisher, N., Geretti, 
A. M., Johnson, M., Leen, C., Peters, B., Pozniak, A., Ross, J., Walsh, J., Wilkins, E. 
and Youle, M. (2006) British HIV Association (BHIVA) guidelines for the treatment of 
HIV-infected adults with antiretroviral therapy (2006). HIV.Med., 7,487-503.
Geretti, A. M. (2006) HIV-1 subtypes: epidemiology and significance for HIV 
management. Curr.Opin.Infect.Dis., 19, 1-7.
Ghani, A. C., Henley, W. E., Donnelly, C. A., Mayer, S. and Anderson, R. M. (2001) 
Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor- 
containing and protease inhibitor-containing regimens using observational databases. 
AIDS, 15, 1133-1142.
260
Giolo, S. R. (2004) Turnbull's nonparametric estimator for interval-censored data. 
Technical Report., Dept, of Statistics, Federal Univesrity of Parana, Parana, Brazil.
Giuliano, M., Guidotti, G., Andreotti, M., Liotta, G., Cusato, M., Cristina Marazzi, M., 
Loureiro, S., Regazzi, M., Palombi, L. and Vella, S. Triple antiretroviral therapy 
administered during pregnancy and after delivery significantly reduces breast milk viral 
load. Poster at 13th Conference on Retroviruses and Opportunistic Infections (CROI 
2006). Abstract 727.
Goldstein, H. (1989) Efficient prediction models for adult height. Auxology 88: 
Perspectives in the science o f growth and development, Smith-Gordon, London., ed. 
Tanner, J.M.
Grambsch, P. M. and Themeau, T. M. (1994) Proportional Hazards Tests and 
Diagnostics Based on Weighted Residuals. Biometrika, 81, 515-526.
Gray, L., Cortina-Borja, M. and Newell, M. L. (2004) Modelling HIV-RNA viral load 
in vertically infected children. Stat.Med., 23, 769-781.
Greenberg, M., Jacobziner, H., Pakter, J. and Weisl, B. A. G. (1958) Maternal Mortality 
in the Epidemic of Asian Influenza, New-York-City, 1957. American Journal o f  
Obstetrics and Gynecology, 76, 897-902.
Griffin, J. T., Fraser, C., Gras, L., de Wolf, F. and Ghani, A. C. (2006) The effect on 
treatment comparisons of different measurement frequencies in human 
immunodeficiency virus observational databases. Am.J.Epidemiol., 163, 676-683.
Gurrin, L. C., Scurrah, K. J. and Hazelton, M. L. (2005) Tutorial in biostatistics: spline 
smoothing with linear mixed models. Stat.Med., 24, 3361-3381.
261
Hamers, F. F. and Downs, A. M. (2004) The changing face of the HIV epidemic in 
western Europe: what are the implications for public health policies? Lancet, 364, 83- 
94.
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., 
Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, ML, Hirsch, M. S. 
and Merigan, T. C. (1996) A trial comparing nucleoside monotherapy with combination 
therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic 
millimeter. AIDS Clinical Trials Group Study 175 Study Team. N.Engl.J.Med, 335, 
1081-1090.
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S., Schooley, R. T., Jacobsen,
D. M., Thompson, M. A., Carpenter, C. C., Fischl, M. A., Gazzard, B. G., Gatell, J. M., 
Hirsch, M. S., Katzenstein, D. A., Richman, D. D., Vella, S., Yeni, P. G. and 
Volberding, P. A. (2006) Treatment for adult HIV infection: 2006 recommendations of 
the International AIDS Society-USA panel. JAMA, 296, 827-843.
Health Protection Agency . A complex picture: HIV and other sexually transmitted 
infections in the United Kingdom: 2006. Health Protection Agency, London.
Hitti, J., Frenkel, L. M., Stek, A. M., Nachman, S. A., Baker, D., Gonzalez-Garcia, A., 
Provisor, A., Thorpe, E. M., Paul, M. E., Foca, M., Gandia, J., Huang, S., Wei, L. J., 
Stevens, L. M., Watts, D. H. and McNamara, J. (2004) Maternal toxicity with 
continuous nevirapine in pregnancy: results from PACTG 1022. J.Acquir.Immune 
Defic.Syndr., 36, 772-776.
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. and Markowitz, 
M. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. 
Nature, 373, 123-126.
Holland, P. W. and Wang, Y. J. (1987) Dependence Function for Continuous Bivariate 
Densities. Communications in Statistics-Theory and Methods, 16, 863-876.
262
Hughes, J. P. (1999) Mixed effects models with censored data with application to HIV 
RNA levels. Biometrics, 55, 625-629.
Hytten, F. (1985) Blood volume changes in normal pregnancy. Clin.Haematol., 14, 601- 
612.
Ibrahim, T., Moodley, J. and Doorasamy, T. (2004) Lymphocyte changes in pregnancy: 
a comparison of the human immunodeficiency virus infected and non-infected women. 
J.Obstet.Gynaecol., 24,498-503.
Ickovics, J. R., Wilson, T. E., Royce, R. A., Minkoff, H. L., Fernandez, M. I., Fox- 
Tiemey, R. and Koenig, L. J. (2002) Prenatal and postpartum zidovudine adherence 
among pregnant women with HIV: results of a MEMS substudy from the Perinatal 
Guidelines Evaluation Project. J.Acquir.Immune Defic.Syndr., 30, 311-315.
International Perinatal HIV Group (2001) Duration of ruptured membranes and vertical 
transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS, 15, 
357-368.
Ioannidis, J. P., Abrams, E. J., Ammann, A., Bulterys, M., Goedert, J. J., Gray, L., 
Korber, B. T., Mayaux, M. J., Mofenson, L. M., Newell, M. L., Shapiro, D. E., Teglas,
J. P. and Wilfert, C. M. (2001) Perinatal transmission of human immunodeficiency virus 
type 1 by pregnant women with RNA virus loads <1000 copies/ml. J.Infect.Dis., 183, 
539-545.
Iribarren, J. A., Ramos, J. T., Guerra, L., Coll, O., de Jose, M. I., Domingo, P., Fortuny,
C., Miralles, P., Parras, F., Pena, J. M., Rodrigo, C. and Vidal, R. (2001) [Prevention of 
vertical transmission and treatment of infection caused by the human immunodeficiency 
virus in the pregnant woman. Recommendations of the Study Group for AIDS,
Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Association, the 
National AIDS Plan and the Spanish Gynecology and Obstetrics Society].
Enferm. Infecc. Microbiol. Cl in., 19, 314-335.
263
Italian Register for Human Immunodeficiency Virus Infection in Children (2002) 
Determinants of mother-to-infant human immunodeficiency virus 1 transmission before 
and after the introduction of zidovudine prophylaxis. Arch.Pediatr.Adolesc.Med156, 
915-921.
Jacqmin-Gadda, H., Thiebaut, R., Chene, G. and Commenges, D. (2000) Analysis of 
left-censored longitudinal data with application to viral load in HIV infection. 
Biostatistics, 1, 355-368.
Johnstone, F. D., Thong, K. J., Bird, A. G. and Whitelaw, J. (1994) Lymphocyte 
subpopulations in early human pregnancy. Obstet.Gynecol., 83, 941-946.
Jones, M. C. (1996) The local dependence function. Biometrika, 83, 899-904.
Jones, M. C. and Koch, I. (2003) Dependence maps: Local dependence in practice. 
Statistics and Computing, 13, 241-255.
Jungmann, E. M., Mercey, D., DeRuiter, A., Edwards, S., Donoghue, S., Booth, T., 
Mohan, D., Lyall, H. and Taylor, G. P. (2001) Is first trimester exposure to the 
combination of antiretroviral therapy and folate antagonists a risk factor for congenital 
abnormalities? Sex Transm.Infect., 77, 441-443.
Kaplan, E. L. and Meier, P. (1958) Nonparametric-Estimation from Incomplete 
Observations. Journal o f the American Statistical Association, 53,457-481.
Kidd, P. (2003) Thl/Th2 balance: the hypothesis, its limitations, and implications for 
health and disease. Altem.Med.Rev., 8, 223-246.
Kirkwood, B. R. and Sterne, J. A. C. (2003) Medical Statistics. Blackwell Publishing.
Klein, J. P. and Moeschberger, M. L. (1997) Survival Analysis. Springer-Verlag New 
York, Inc..
264
Kourtis, A. P., Schmid, C. H., Jamieson, D. J. and Lau, J. (2007) Use of antiretroviral 
therapy in pregnant HIV-infected women and the risk of premature delivery: a meta­
analysis. AIDS, 21, 607-615.
Laine, C., Newschaffer, C. J., Zhang, D., Cosier, L., Hauck, W. W. and Turner, B. J. 
(2000) Adherence to antiretroviral therapy by pregnant women infected with human 
immunodeficiency virus: a pharmacy claims-based analysis. Obstet.Gynecol., 95, 167- 
173.
Laird, N. M. and Ware, J. H. (1982) Random-effects models for longitudinal data. 
Biometrics, 38, 963-974.
Landes, M., Thome, C. and Newell, M.-L. Sexually transmitted infections in HIV-1- 
infected pregnant women: Prevalence and risk factors in a European population. Poster 
at XVI International AIDS Conference, 2006.Abstract no. TUPE0279 .
Le Chenadec, J., Mayaux, M. J., Guihenneuc-Jouyaux, C. and Blanche, S. (2003) 
Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS, 
17,2053-2061.
Lepage, P., Van de, P. P., Msellati, P., Hitimana, D. G., Simonon, A., Van Goethem, C., 
Mukamabano, B., Karita, E., Stevens, A. M., Mathieu, G. and . (1993) Mother-to-child 
transmission of human immunodeficiency vims type 1 (HIV-1) and its determinants: a 
cohort study in Kigali, Rwanda. Am. J.Epidemiol., 137, 589-599.
Leyland, A. H. and Goldstein, H. (2001) Multilevel Modelling o f Health Statistics. John 
Wiley & Sons, LTD.
Lindsey, J. C. and Ryan, L. M. (1998) Tutorial in biostatistics methods for interval- 
censored data. Stat.Med., 17,219-238.
265
Loader, C. (1999) Local Regression and Likelihood. Springer-Verlag New York, Inc.
Lorenzi, P., Spicher, V. M., Laubereau, B., Hirschel, B., Kind, C., Rudin, C., Irion, O. 
and Kaiser, L. (1998) Antiretroviral therapies in pregnancy: maternal, fetal and neonatal 
effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, 
and the Swiss Neonatal HIV Study. AIDS, 12, F241-F247.
Lowe, S. H., Prins, J. M. and Lange, J. M. (2004) Antiretroviral therapy in previously 
untreated adults infected with the human immunodeficiency virus type I: established 
and potential determinants of virological outcome. NethJ.Med., 62,424-440.
Lucas, G. M., Cheever, L. W., Chaisson, R. E. and Moore, R. D. (2001) Detrimental 
effects of continued illicit drug use on the treatment of HIV-1 infection.
J.Acquir.Immune Defic.Syndr., 27, 251-259.
Lucas, G. M., Mullen, B. A., Weidle, P. J., Hader, S., McCaul, M. E. and Moore, R. D. 
(2006) Directly administered antiretroviral therapy in methadone clinics is associated 
with improved HIV treatment outcomes, compared with outcomes among concurrent 
comparison groups. Clin.Infect.Dis., 42, 1628-1635.
Luzzi, G. A., Peto, T. E. A., Weiss, R. A. and Conlon, C. P. (2003) HIV and AIDS. In 
Oxford Textbook o f Medicine. Oxford University Press.
Lyles, C. M., Dorrucci, M., Vlahov, D., Pezzotti, P., Angarano, G., Sinicco, A., 
Alberici, F., Alcorn, T. M., Vella, S. and Rezza, G. (1999) Longitudinal human 
immunodeficiency virus type 1 load in the italian seroconversion study: correlates and 
temporal trends of virus load. J.Infect.Dis., 180,1018-1024.
Lynch M. and Walsh B. (1998) Genetics and Analysis o f Quantitative Traits. Sinauer 
Assocs Inc., Sunderland, MA.
266
Lyons, F. E., Coughlan, S., Byme, C. M., Hopkins, S. M., Hall, W. W. and Mulcahy, F. 
M. (2005) Emergence of antiretroviral resistance in HIV-positive women receiving 
combination antiretroviral therapy in pregnancy. AIDS, 19, 63-67.
Manavi, K., McDonald, A. and Al Sharqui, A. (2007) Plasma lopinavir trough levels in 
a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS, 
21,643-645.
Mandelbrot, L., Kermarrec, N., Marcollet, A., Lafanechere, A., Longuet, P., Chosidow,
D. and Saada, M. (2003) Case report: nucleoside analogue-induced lactic acidosis in the 
third trimester of pregnancy. AIDS, 17, 272-273.
Mandelbrot, L., Landreau-Mascaro, A., Rekacewicz, C., Berrebi, A., Benifla, J. L., 
Burgard, M., Lachassine, E., Barret, B., Chaix, M. L., Bongain, A., Ciraru-Vigneron, 
N., Crenn-Hebert, C., Delffaissy, J. F., Rouzioux, C., Mayaux, M. J. and Blanche, S. 
(2001a) Lamivudine-zidovudine combination for prevention of maternal-infant 
transmission of HIV-1. JAMA, 285,2083-2093.
Mandelbrot, L., Mayaux, M. J., Bongain, A., Berrebi, A., Moudoub-Jeanpetit, Y., 
Benifla, J. L., Ciraru-Vigneron, N., Le Chenadec, J., Blanche, S. and Delfraissy, J. F.
(1996) Obstetric factors and mother-to-child transmission of human immunodeficiency 
virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection 
Study Group. Am.J.Obstet.Gynecol., 175, 661-667.
Mandelbrot, L., Peytavin, G., Firtion, G. and Farinotti, R. (2001b) Maternal-fetal 
transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency 
virus-infected pregnant women. Am. J.Obstet.Gynecol., 184, 153-158.
Manfredi, R. and Calza, L. (2006) Nevirapine versus efavirenz in 742 patients: no link 
of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 
cells/microl. AIDS, 20,2233-2236.
267
Manffedi, R., Calza, L. and Chiodo, F. (2005) Prospective, open-label comparative 
study of liver toxicity in an unselected population of HIV-infected patients treated for 
the first time with efavirenz or nevirapine. HIVClin. Trials, 6,302-311.
Marcollet, A., Goffinet, F., Firtion, G., Pannier, E., Le Bret, T., Brival, M. L. and 
Mandelbrot, L. (2002) Differences in postpartum morbidity in women who are infected 
with the human immunodeficiency virus after elective cesarean delivery, emergency 
cesarean delivery, or vaginal delivery. Am.J.Obstet.Gynecol, 186, 784-789.
Matthews, G. V., Sabin, C. A., Mandalia, S., Lampe, F., Phillips, A. N., Nelson, M. R., 
Bower, M., Johnson, M. A. and Gazzard, B. G. (2002) Virological suppression at 6 
months is related to choice of initial regimen in antiretroviral-naive patients: a cohort 
study. AIDS, 16, 53-61.
Mayaux, M. J., Dussaix, E., Isopet, J., Rekacewicz, C., Mandelbrot, L., Ciraru- 
Vigneron, N., Allemon, M. C., Chambrin, V., Katlama, C., Delffaissy, J. F. and Puel, J. 
(1997a) Maternal virus load during pregnancy and mother-to-child transmission of 
human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST 
Cohort Group. J.Infect.Dis., 175, 172-175.
Mayaux, M. J., Teglas, J. P. and Blanche, S. (2003) Characteristics of HIV-infected 
women who do not receive preventive antiretroviral therapy in the French Perinatal 
Cohort. J.Acquir.Immune Defic.Syndr., 34, 338-343.
Mayaux, M. J., Teglas, J. P., Mandelbrot, L., Berrebi, A., Gallais, H., Matheron, S., 
Ciraru-Vigneron, N., Pamet-Mathieu, F., Bongain, A., Rouzioux, C., Delffaissy, J. F. 
and Blanche, S. (1997b) Acceptability and impact of zidovudine for prevention of 
mother-to-child human immunodeficiency virus-1 transmission in France. J.Pediatr., 
131,857-862.
Mazhude, C., Jones, S., Murad, S., Taylor, C. and Easterbrook, P. (2002) Female sex 
but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor- 
induced rash. AIDS, 16, 1566-1568.
268
McCullagh, P. and Nelder, J. A. (1983) Generalized Linear Models. Chapman and Hall.
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., 
Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P. and Rinaldo, C. R., Jr.
(1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 
infection. Ann.Intern.Med., 126, 946-954.
Melvin, A. J., Burchett, S. K., Watts, D. H., Hitti, J., Hughes, J. P., McLellan, C. L., 
King, P. D., Johnson, E. J., Williams, B. L., Frenkel, L. M. and Coombs, R. W. (1997) 
Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. 
J.Acquir.Immune Defic.Syndr.Hum.Retrovirol., 14, 232-236.
Mirochnick, M. (2000) Antiretroviral pharmacology in pregnant women and their 
newborns. Ann.N.Y.Acad.Sci., 918, 287-297.
Mirochnick, M. and Capparelli, E. (2004) Pharmacokinetics of antiretrovirals in 
pregnant women. Clin.Pharmacokinet., 43, 1071-1087.
Mocroft, Horban, Clumeck, Stellbrink, Monforte, A., Zilmer, Kirk, Gatell, Phillips and 
Lundgren (2006a) Comparison of single and boosted protease inhibitor versus 
nonnucleoside reverse transcriptase inhibitor-containing cART regimens in 
antiretroviral-naive patients starting cART after January 1, 2000. HIV.Clin.Trials, 7, 
271-284.
Mocroft, A., Gill, M. J., Davidson, W. and Phillips, A. N. (1998) Predictors of a viral 
response and subsequent virological treatment failure in patients with HIV starting a 
protease inhibitor. AIDS, 12, 2161-2167.
Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., d'Arminio, M. A., Knysz,
B., Dietrich, M., Phillips, A. N. and Lundgren, J. D. (2003) Decline in the AIDS and 
death rates in the EuroSIDA study: an observational study. Lancet, 362,22-29.
269
Mocroft, A., Phillips, A. N., Ledergerber, B., Katlama, C., Chiesi, A., Goebel, F. D., 
Knysz, B., Antunes, F., Reiss, P. and Lundgren, J. D. (2006b) Relationship between 
antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients 
with suppressed viremia. AIDS, 20, 1141-1150.
Mocroft, A., Youle, M., Morcinek, J., Sabin, C. A., Gazzard, B., Johnson, M. A. and 
Phillips, A. N. (1997) Survival after diagnosis of AIDS: a prospective observational 
study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative 
Group. BMJ, 3 1 4 ,409-413.
Mofenson, L. M., Lambert, J. S., Stiehm, E. R., Bethel, J., Meyer, W. A., Ill, 
Whitehouse, J., Moye, J., Jr., Reichelderfer, P., Harris, D. R., Fowler, M. G., Mathieson,
B. J. and Nemo, G. J. (1999) Risk factors for perinatal transmission of human 
immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS 
Clinical Trials Group Study 185 Team. N.Engl.J.Med., 3 4 1 ,385-393.
Montaner, L. J., Griffin, P. and Gordon, S. (1994) Interleukin-10 inhibits initial reverse 
transcription of human immunodeficiency virus type 1 and mediates a virostatic latent 
state in primary blood-derived human macrophages in vitro. J.Gen. Virol., 75 ( P t 12), 
3393-3400.
Moore, D. M., Hogg, R. S., Yip, B., Wood, E., Tyndall, M., Braitstein, P. and 
Montaner, J. S. (2005) Discordant immunologic and virologic responses to highly active 
antiretroviral therapy are associated with increased mortality and poor adherence to 
therapy. J.Acquir.Immune Defic.Syndr., 40, 288-293.
Mucahy, F., Wallace, E., Woods, S., Hanlon, M., Clarke, S., Bergin, C. and Jackson, J. 
CD4 Counts in Pregnancy Do not Accurately Reflect the Need for Long-term HAART. 
Poster at 13th Conference on Retroviruses and Opportunistic Infections (CROI 2006). 
Abstract 704b.
270
Munoz, A., Gange, S. J. and Jacobson, L. P. (2000) Distinguishing efficacy, individual 
effectiveness and population effectiveness of therapies. AIDS, 14, 754-756.
Mwanyumba, F., Gaillard, P., Inion, I., Verhofstede, C., Claeys, P., Chohan, V., 
Vansteelandt, S., Mandaliya, K., Praet, M. and Temmerman, M. (2002) Placental 
inflammation and perinatal transmission of HIV-1. J.Acquir.Immune Defic.Syndr., 29, 
262-269.
Naumova, E. N., Must, A. and Laird, N. M. (2001) Tutorial in Biostatistics: Evaluating 
the impact of'critical periods' in longitudinal studies of growth using piecewise mixed 
effects models. Int.J.Epidemiol., 30, 1332-1341.
Nellen, J. F., Schillevoort, I., Wit, F. W., Bergshoeff, A. S., Godfried, M. H., Boer, K., 
Lange, J. M., Burger, D. M. and Prins, J. M. (2004) Nelfinavir plasma concentrations 
are low during pregnancy. Clin.Infect.Dis., 39, 736-740.
Newell, M. L., Rogers, M., Coll, O., Fiore, S., Floridia, M., Giaquinto, C., Grosch- 
Womer, I., Guiliano, M., Lindgren, S., Lyall, H., Mandelbrot, L .,., Peckham, C., Rudin,
C., Semprini, A. E., Taylor, G., Thome, C. and Tovo, P. A. (2002) Pregnancy and HIV 
infection: A european consensus on management. AIDS, 16 Suppl 2, S I-18.
Nightingale, S. L. (1998) From the Food and Drug Administration. JAMA, 280, 1472.
O'Shea, S., Newell, M. L., Dunn, D. T., Garcia-Rodriguez, M. C., Bates, I., Mullen, J., 
Rostron, T., Corbett, K., Aiyer, S., Butler, K., Smith, R. and Banatvala, J. E. (1998) 
Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J.Med. Virol., 
54,113-117.
Odell, P. M., Anderson, K. M. and D'Agostino, R. B. (1992) Maximum likelihood 
estimation for interval-censored data using a Weibull-based accelerated failure time 
model. Biometrics, 48, 951-959.
271
Overton, E. T., Sungkanuparph, S., Nurutdinova, D. and Powderly, W. G. (2005) 
Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral 
experience from previous pregnancy. AIDS, 19, 1439-1440.
Ozkan, H., Olgun, N., Sasmaz, E., Abacioglu, H., Okuyan, M. and Cevik, N. (1993) 
Nutrition, immunity and infections: T lymphocyte subpopulations in protein—energy 
malnutrition. J.Trop.Pediatr., 39, 257-260.
Palepu, A., Tyndall, M., Yip, B., O’Shaughnessy, M. V., Hogg, R. S. and Montaner, J.
S. (2003) Impaired virologic response to highly active antiretroviral therapy associated 
with ongoing injection drug use. J.Acquir.Immune Defic.Syndr., 32, 522-526.
Patel, R. R., Steer, P., Doyle, P., Little, M. P. and Elliott, P. (2004) Does gestation vary 
by ethnic group? A London-based study of over 122,000 pregnancies with spontaneous 
onset of labour. Int. J.Epidemiol, 33, 107-113.
Perrin, L., Kaiser, L. and Yerly, S. (2003) Travel and the spread of HIV-1 genetic 
variants. Lancet Infect. Dis., 3,22-27.
Pezzotti, P., Pappagallo, M., Phillips, A. N., Boros, S., Valdarchi, C., Sinicco, A., 
Zaccarelli, M. and Rezza, G. (2001) Response to highly active antiretroviral therapy 
according to duration of HIV infection. J.Acquir.Immune Defic.Syndr., 26,473-479.
Phillips, A. N., Grabar, S., Tassie, J. M., Costagliola, D., Lundgren, J. D. and Egger, M. 
(1999) Use of observational databases to evaluate the effectiveness of antiretroviral 
therapy for HIV infection: comparison of cohort studies with randomized trials. 
EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study 
Groups. AIDS, 13,2075-2082.
Phillips, A. N., Staszewski, S., Weber, R., Kirk, O., Francioli, P., Miller, V., Vemazza, 
P., Lundgren, J. D. and Ledergerber, B. (2001) HIV viral load response to antiretroviral 
therapy according to the baseline CD4 cell count and viral load. JAMA, 286, 2560-2567.
272
Pickard, R. E. (1968) Varicella Pneumonia in Pregnancy. American Journal o f 
Obstetrics and Gynecology, 101, 504-508.
Pinheiro, J. C. and Bates, D. M. (2000) Mixed-Effects Models in S  andS-PLUS.
Springer-Verlag New York, Inc.
Podzamczer, D., Ferrer, E., Consiglio, E., Gatell, J. M., Perez, P., Perez, J. L., Luna, E., 
Gonzalez, A., Pedrol, E., Lozano, L., Ocana, I., Llibre, J. M., Casiro, A., Aranda, M., 
Barrufet, P., Martinez-Lacasa, J., Miro, J. M., Badia, X., Casado, A., Lupo, S., Cahn, P., 
Manos, M. and Estela, J. (2002) A randomized clinical trial comparing nelfinavir or 
nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the 
Combine Study). Antivir. Ther., 7, 81-90.
Porter, K., Babiker, A., Bhaskaran, K., Darbyshire, J., Pezzotti, P., Porter, K. and 
Walker, A. S. (2003) Determinants of survival following HIV-1 seroconversion after the 
introduction of HAART. Lancet, 362, 1267-1274.
Powderly, W. G., Saag, M. S., Chapman, S., Yu, G., Quart, B. and Clendeninn, N. J. 
(1999) Predictors of optimal virological response to potent antiretroviral therapy. AIDS, 
1 3 ,1873-1880.
Public Health Service Taskforce (2006a) Recommendations for use of antiretroviral 
drugs in pregnant HIV-1 infected women for maternal health and interventions to 
reduce perinatal HIV-1 transmission in the United States.
httv://aidsinfo.nih.£ov/Content Files/PerinatalGL.pdf. Accessed January 2007.
Public Health Service Taskforce (2006b). Safety and Toxicity of Individual 
Antiretroviral Agents in Pregnancy. Accessed February 2007.
273
Pugh, M., Robbins, J., Lipsitz, S. and Harrington, D. (1992) Inference in the Cox 
proportional hazards model with missing covariates. Department o f Biostatistics, 
Harvard School o/Publich Health,Boston, Technical Report 75 8Z.
R Development Core Team . R: A language and environment for statistical computing. 
R Foundation for Statistical Computing.Vienna, Austria, 2006.
Read, J. S., Tuomala, R., Kpamegan, E., Zorrilla, C., Landesman, S., Brown, G., 
Vajaranant, M., Hammill, H. and Thompson, B. (2001a) Mode of delivery and 
postpartum morbidity among HIV-infected women: the women and infants transmission 
study. J.Acquir.Immme Defic.Syndr., 26,236-245.
Read, J. S., Tuomala, R., Kpamegan, E., Zorrilla, C., Landesman, S., Brown, G., 
Vajaranant, M., Hammill, H. and Thompson, B. (2001b) Mode of delivery and 
postpartum morbidity among HIV-infected women: the women and infants transmission 
study. J.Acquir.Immune Defic.Syndr., 26, 236-245.
Repik, A., Richards, K. H. and Clapham, P. R. (2007) The promise of CCR5 antagonists 
as new therapies for HIV-1. Curr.Opin.Investig.Drugs, 8, 130-139.
Rich, K. C., Siegel, J. N., Jennings, C., Rydman, R. J. and Landay, A. L. (1995) Cd4(+) 
Lymphocytes in Perinatal Human-Immunodeficiency-Virus (Hiv) Infection - Evidence 
for Pregnancy-Induced Immune Depression in Uninfected and Hiv-Infected Women. 
Journal o f Infectious Diseases, 172,1221-1227.
Ronsmans, C., Khlat, M., Kodio, B., Ba, M., De Bemis, L. and Etard, J. (2001)
Evidence for a 'healthy pregnant woman effect' in Niakhar, Senegal? Int.J.Epidemiol, 
30,467-473.
Rosenbaum, P. R. and Rubin, D. B. (1983) The Central Role of the Propensity Score in 
Observational Studies for Causal Effects. Biometrika, 70,41-55.
274
Saada, M., Le Chenadec, J., Berrebi, A., Bongain, A., Delfraissy, J. F., Mayaux, M. J. 
and Meyer, L. (2000) Pregnancy and progression to AIDS: results of the French 
prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS, 14,2355-2360.
Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coombs, R., Poscher, M.
E., Jacobsen, D. M., Shaw, G. M., Richman, D. D. and Volberding, P. A. (1996) HIV 
viral load markers in clinical practice. Nat.Med, 2, 625-629.
Sabin, C. A. (2004) Pitfalls of assessing hepatotoxicity in trials and observational 
cohorts. Clin.Infect.Dis., 38 Suppl 2, S56-S64.
Sabin, C. A., Devereux, H., Phillips, A. N., Hill, A., Janossy, G., Lee, C. A. and 
Loveday, C. (2000) Course of viral load throughout HIV-1 infection. J.Acquir.Immune 
Defic.Syndr., 23, 172-177.
Sabin, C. A., Hill, T., Lampe, F., Matthias, R., Bhagani, S., Gilson, R., Youle, M. S., 
Johnson, M. A., Fisher, M., Scullard, G., Easterbrook, P., Gazzard, B. and Phillips, A.
N. (2005) Treatment exhaustion of highly active antiretroviral therapy (HAART) among 
individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ, 
330,695.
Sabin, C. A. and Phillips, A. N. (2001) Treatment comparisons in HIV infection: the 
benefits and limitations of observational cohort studies. J.Antimicrob.Chemother., 47, 
371-375.
Samer, L. and Fakoya, A. (2002) Acute onset lactic acidosis and pancreatitis in the third 
trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex 
Transm.Infect., 78, 58-59.
SAS Institute Inc. (2004) SAS OnlineDoc® 9.1.3. SAS Institute Inc., Cary, NC.
275
Saul, J., Erwin, J., Sabin, C. A., Kulasegaram, R. and Peters, B. S. (2001) The 
relationships between ethnicity, sex, risk group, and virus load in human 
immunodeficiency virus type 1 antiretroviral-naive patients. J.Infect.Dis., 183, 1518- 
1521.
Schmee, J. and Hahn, G. J. (1979) Simple Method for Regression-Analysis with 
Censored Data. Technometrics, 21,417-432.
Schulte, J., Dominguez, K., Sukalac, T., Bohannon, B. and Fowler, M. G. (2007) 
Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Bom to 
HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: 
Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics, 119, e900-e904.
Shapiro, R. L., Thior, I., Gilbert, P. B., Lockman, S., Wester, C., Smeaton, L. M., 
Stevens, L., Heymann, S. J., Ndung'u, T., Gaseitsiwe, S., Novitsky, V., Makhema, J., 
Lagakos, S. and Essex, M. (2006) Maternal single-dose nevirapine versus placebo as 
part of an antiretroviral strategy to prevent mother-to-child HIV transmission in 
Botswana. AIDS, 20, 1281-1288.
Silverman, B. W. (1986) Density Estimation. Chapman and Hall.
Slattery, M. M. and Morrison, J. J. (2002) Preterm delivery. Lancet, 360, 1489-1497.
Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F. and Moatti, J. P. (2002) 
Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: 
from a predictive to a dynamic approach. Soc.Sci.Med., 54, 1481-1496.
Stebbing, J. and Bower, M. (2006) Comparative pharmacogenomics of antiretroviral 
and cytotoxic treatments. Lancet Oncol., 7, 61-68.
276
Stek, A. M., Mirochnick, M., Capparelli, E., Best, B. M., Hu, C., Burchett, S. K., Elgie,
C., Holland, D. T., Smith, E., Tuomala, R., Cotter, A. and Read, J. S. (2006) Reduced 
lopinavir exposure during pregnancy. AIDS, 20, 1931-1939.
Sterling, T. R., Vlahov, D., Astemborski, J., Hoover, D. R., Margolick, J. B. and Quinn, 
T. C. (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and 
men. N.Engl.J.Med., 344, 720-725.
Stem, J. O., Robinson, P. A., Love, J., Lanes, S., Imperiale, M. S. and Mayers, D. L. 
(2003) A comprehensive hepatic safety analysis of nevirapine in different populations 
of HIV infected patients. J.Acquir.Immune Defic.Syndr., 34 Suppl 1, S21-S33.
Sturmer, T., Schneeweiss, S., Avom, J. and Glynn, R. J. (2005) Adjusting effect 
estimates for unmeasured confounding with validation data using propensity score 
calibration. Am. J. Epidemiol., 162,279-289.
Szyld, E. G., Warley, E. M., Freimanis, L., Gonin, R., Cahn, P. E., Calvet, G. A., 
Duarte, G., Melo, V. H. and Read, J. S. (2006) Maternal antiretroviral drugs during 
pregnancy and infant low birth weight and preterm birth. AIDS, 20, 2345-2353.
Taha, T. E., Brown, E. R., Hoffman, I. F., Fawzi, W., Read, J. S., Sinkala, M., 
Martinson, F. E., Kafulafula, G., Msamanga, G., Emel, L., Adeniyi-Jones, S. and 
Goldenberg, R. (2006) A phase III clinical trial of antibiotics to reduce 
chorioamnionitis-related perinatal HIV-1 transmission. AIDS, 20, 1313-1321.
The American College of Obstetricians and Gynecologists (2000) ACOG committee 
opinion 234. Washington DC, ACOG.
The Antiretroviral Therapy Cohort Collaboration (2006) Rates of disease progression 
according to initial highly active antiretroviral therapy regimen: a collaborative analysis 
of 12 prospective cohort studies. J.Infect.Dis., 194, 612-622.
277
The European Collaborative Study (1996) Vertical transmission of HIV-1: maternal 
immune status and obstetric factors. AIDS, 10, 1675-1681.
The Working Group on Mother-To-Child Transmission of HIV (1995) Rates of mother- 
to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 
perinatal studies. J.Acquir.Immune Defic.Syndr.Hum.Retrovirol., 8, 506-510.
Themeau, T. M. and Grambsch, T. M. (2000) Modeling Survival Data. Springer-Verlag 
New York, Inc.
Thiebaut, R. and Jacqmin-Gadda, H. (2004) Mixed models for longitudinal left- 
censored repeated measures. Comput.Methods Programs Biomed., 74, 255-260.
Thiebaut, R., Jacqmin-Gadda, H., Babiker, A. and Commenges, D. (2005) Joint 
modelling of bivariate longitudinal data with informative dropout and left-censoring, 
with application to the evolution of CD4+ cell count and HIV RNA viral load in 
response to treatment of HIV infection. Stat.Med., 24, 65-82.
Thiebaut, R., Jacqmin-Gadda, H., Chene, G., Leport, C. and Commenges, D. (2002) 
Bivariate linear mixed models using SAS proc MIXED. Comput.Methods Programs 
Biomed., 69, 249-256.
Thiebaut, R., Jacqmin-Gadda, H., Leport, C., Katlama, C., Costagliola, D., Le, M., V, 
Morlat, P. and Chene, G. (2003) Bivariate longitudinal model for the analysis of the 
evolution of HIV RNA and CD4 cell count in HIV infection taking into account left 
censoring of HIV RNA measures. J.Biopharm.Stat., 13,271-282.
Thiebaut, R., Jacqmin-Gadda, H., Walker, S., Sabin, C., Prins, M., Del Amo, J., Porter, 
K., Dabis, F. and Chene, G. (2006) Determinants of response to first HAART regimen 
in antiretroviral-naive patients with an estimated time since HIV seroconversion.
HIV.Med., 7, 1-9.
278
Thomson, M. M., Perez-Alvarez, L. and Najera, R. (2002) Molecular epidemiology of 
HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet 
Infect.Dis., 2,461-471.
Thome, C., Fiore, S. and Rudin, C. (2003) Antiretroviral therapy during pregnancy and 
the risk of an adverse outcome. N. Engl. J. Med., 348,471-472.
Thome, C., Newell, M. L., Dunn, D. and Peckham, C. (1995) The European 
Collaborative Study: clinical and immunological characteristics of HIV 1-infected 
pregnant women. Br.J.Obstet.Gynaecol., 102, 869-875.
Thorpe, L. E., Frederick, M., Pitt, J., Cheng, I., Watts, D. H., Buschur, S., Green, K., 
Zorrilla, C., Landesman, S. H. and Hershow, R. C. (2004) Effect of hard-drug use on 
CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events 
among HIV-infected women. J.Acquir.Immune Defic.Syndr., 37, 1423-1430.
Tincani, A., Balestrieri, G., Faden, D. and DiMario, C. (1991) Systemic lupus 
erythematosus in pregnancy. Lancet, 338, 756-757.
Touloumi, G., Pantazis, N., Babiker, A. G., Walker, S. A., Katsarou, O., Karafoulidou, 
A., Hatzakis, A. and Porter, K. (2004) Differences in HIV RNA levels before the 
initiation of antiretroviral therapy among 1864 individuals with known HIV-1 
seroconversion dates. AIDS, 18,1697-1705.
Townsend, C. L., Cortina-Borja, M., Peckham, C. and Tookey, P. (2007a) Mother-to- 
child-transmission of HIV in the UK and Ireland, 1990-2004. Poster at 14th Conference 
on Retroviruses and Opportunistic Infections (CROI2007).Abstract 761 .
Townsend, C. L., Cortina-Borja, M., Peckham, C. S. and Tookey, P. A. (2007b) 
Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the 
United Kingdom and Ireland. AIDS, 21, 1019-1026.
279
Townsend, C. L., Tookey, P. A., Cortina-Borja, M. and Peckham, C. S. (2006) 
Antiretroviral therapy and congenital abnormalities in infants bom to HIV-1-infected 
women in the United Kingdom and Ireland, 1990 to 2003. J.Acquir.Immune 
Defic.Syndr., 42, 91-94.
Tuomala, R. E., O'Driscoll, P. T., Bremer, J. W., Jennings, C., Xu, C., Read, J. S., 
Matzen, E., Landay, A., Zorrilla, C., Blattner, W., Charurat, M. and Anderson, D. J. 
(2003) Cell-associated genital tract vims and vertical transmission of human 
immunodeficiency vims type 1 in antiretroviral-experienced women. J.Infect.Dis., 187, 
375-384.
Tuomala, R. E., Shapiro, D. E., Mofenson, L. M., Bryson, Y., Culnane, M., Hughes, M.
D., O'Sullivan, M. J., Scott, G., Stek, A. M., Wara, D. and Bulterys, M. (2002) 
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. 
N.Engl.J.Med., 346, 1863-1870.
Tuomala, R. E., Watts, D. H., Li, D., Vajaranant, M., Pitt, J., Hammill, H., Landesman,
S., Zorrilla, C. and Thompson, B. (2005) Improved obstetric outcomes and few maternal 
toxicities are associated with antiretroviral therapy, including highly active antiretroviral 
therapy during pregnancy. J.Acquir.Immune Defic.Syndr., 38,449-473.
Turnbull, B. W. (1976) Empirical Distribution Function with Arbitrarily Grouped, 
Censored and Truncated Data. Journal o f the Royal Statistical Society Series B- 
Methodological, 38, 290-295.
UNAIDS 2006 Report on the Global AIDS Epidemic.
van Benthem, B. H., Vemazza, P., Coutinho, R. A. and Prins, M. (2005) Impact of 
pregnancy and menopause on CD4 cell counts. J.Acquir.Immune Defic.Syndr., 38 
Suppl 1, S22.
280
van Heeswijk, R. P., Khaliq, Y., Gallicano, K. D., Bourbeau, M., Seguin, I., Phillips, E. 
J. and Cameron, D. W. (2004) The pharmacokinetics of nelfinavir and M8 during 
pregnancy and post partum. Clin.Pharmacol. Ther., 76, 588-597.
Vaz, M. J., Barros, S. M., Palacios, R., Senise, J. F., Lunardi, L., Amed, A. M. and 
Castelo, A. (2007) HIV-infected pregnant women have greater adherence with 
antiretroviral drugs than non-pregnant women. Int. J.STD AIDS, 18,28-32.
Venables, W. N. and Ripley, B. D. (1997) Modern Applied Statistics with S-PLUS. 
Springer-Verlag New York, Inc.
Villani, P., Floridia, M., Pirillo, M. F., Cusato, M., Tamburrini, E., Cavaliere, A. F., 
Guaraldi, G., Vanzini, C., Molinari, A., degli, A. A. and Regazzi, M. (2006) 
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. 
Br.JClin.Pharmacol., 62, 309-315.
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., 
Johnson, D., Lalonde, R., Japour, A., Brun, S. and Sun, E. (2002) Lopinavir-ritonavir 
versus nelfinavir for the initial treatment of HIV infection. N.Engl.J.Med., 346, 2039- 
2046.
Ware, J. H. (1985) Linear-Models for the Analysis of Longitudinal-Studies. American 
Statistician, 39, 95-101.
Watts, D. H., Balasubramanian, R., Maupin, R. T., Jr., Delke, I., Dorenbaum, A., Fiore,
S., Newell, M. L., Delffaissy, J. F., Gelber, R. D., Mofenson, L. M., Culnane, M. and 
Cunningham, C. K. (2004a) Maternal toxicity and pregnancy complications in human 
immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. 
Am.J. Obstet. Gynecol., 190, 506-516.
Watts, D. H., Covington, D. L., Beckerman, K., Garcia, P., Scheuerle, A., Dominguez, 
K., Ross, B., Sacks, S., Chavers, S. and Tilson, H. (2004b) Assessing the risk of birth
281
defects associated with antiretroviral exposure during pregnancy. Am.J.Obstet.Gynecol., 
191,985-992.
Watts, D. H., Lambert, J., Stiehm, E. R., Harris, D. R., Bethel, J., Mofenson, L., Meyer, 
W. A., Ill, Mathieson, B., Fowler, M. G. and Nemo, G. (2003) Progression of HIV 
disease among women following delivery. J.Acquir.Immune Defic.Syndr., 33, 585-593.
Wegmann, T. G., Lin, H., Guilbert, L. and Mosmann, T. R. (1993) Bidirectional 
Cytokine Interactions in the Maternal-Fetal Relationship - Is Successful Pregnancy A 
Th2 Phenomenon. Immunology Today, 14, 353-356.
Weinberg, E. D. (1984) Pregnancy-associated depression of cell-mediated immunity. 
Rev.Infect.Dis., 6, 814-831.
Weisser, M., Rudin, C., Battegay, M., Pfluger, D., Kully, C. and Egger, M. (1998) Does 
pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort 
studies. J.Acquir.Immune Defic.Syndr.Hum.Retrovirol., 17, 404-410.
Wimalasundera, R. C., Larbalestier, N., Smith, J. H., de Ruiter, A., McG Thom, S. A., 
Hughes, A. D., Poulter, N., Regan, L. and Taylor, G. P. (2002) Pre-eclampsia, 
antiretroviral therapy, and immune reconstitution. Lancet, 360, 1152-1154.
Wood, E., Hogg, R. S., Heath, K. V., de la, R. R., Lee, N., Yip, B., O'Shaughnessy, M. 
V. and Montaner, J. S. (2003) Provider bias in the selection of non-nucleoside reverse 
transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy 
and HIV treatment outcomes in observational studies. AIDS, 17, 2629-2634.
Wood, E., Hogg, R. S., Yip, B., Harrigan, P. R., O'Shaughnessy, M. V. and Montaner, J. 
S. (2004) The impact of adherence on CD4 cell count responses among HIV-infected 
patients. J.Acquir.Immune Defic.Syndr., 35, 261-268.
282
World Health Organisation (2004) HIV transmission through breastfeeding. A review of 
available evidence. WHO, Geneva, Switzerland..
World Health Organisation (2006) Antiretroviral therapy for HIV infection in adults and 
adolescents in resource-limited settings: towards universal access. WHO, Geneva, 
Switzerland..
Yamashita, T. E., Modjarrad, K. and Munoz, A. (2003) Variability of HIV-1 £NA 
before AIDS and highly active antiretroviral therapy. AIDS, 17, 1264-1266.
Ziegler, J. B., Cooper, D. A., Johnson, R. O. and Gold, J. (1985) Postnatal transmission 
of AIDS-associated retrovirus from mother to infant. Lancet, 1, 896-898.
283
Appendix A European Collaborative Study data collection forms 
MATERNAL INFORMATION AT DELIVERY
MATERNAL LABORATORY INVESTIGATIONS DURING PREGNANCY 
AND AT DELIVERY
PERINATAL INFORMATION
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ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MATERNAL INFORMATION AT DELIVERY
Centre
Mothers Study Number 
Child Study Number
Mother’s date of birth (day, month, year)
Country of b irth .........................................................................................................................
Marital Status
Single (1), Married (2), Divorced, Separated, Widowed (3), Cohabiting (4)
Ethnic Group
Asian (1), White (2), Black (3), Oriental (4), Other (5)
Age when leaving full-time education, years..............................................................................
Obstetric History
Number of previous livebirths ..................................................................................................
Number of previous stillbirths ..................................................................................................
Number of previous miscarriages..............................................................................................
Number of previous terminations..............................................................................................
Mothers Risk Group
History of intravenous Drug Abuse (Y/N)
Trimester of last use: pre-conception (0), 1st (1), 2nd (2), 3rd (3), unknown (9)
Needle sharing? never (1) past (2) present (3) unknown (9)
Sexual partner of Bisexual (Y/N)
Sexual partner of Haemophiliac (Y/N)
Sexual partner of Intravenous Drug Abuser (Y/N)
Sexual partner of Other high risk group (Y/N)
(Specify) ...................................................................................................................................
O ther.........................................................................................................................................
Mothers HIV History
Date of first HIV+ test (day, month, year)
Current clinical sta tus
Current HTV staging (CD C).......................................................................................................
Specify symptoms .....................................................................................................................
Date of onset .............................................................................................................................
Details of treatm ent during pregnancy
Has the woman received any antiretroviral therapy at any time during this pregnancy? Y/N 
Please give details of both ART and other prophylaxis (eg. TMP-SMX)
Drug Date started Date stopped Currently taken? 
(yes/no)
285
ECS 3
PR O SPEC TIV E STUDY O F CH ILDREN BORN TO HIV PO SITIV E M O TH ERS
y  Page 2
M ATERNAL INFORM ATION
L aboratory  investigations during  pregnancy and a t delivery:
Centre Number 
Mothers Study Number 
Child Study Number
1-2
6
3-5
Virology
Date: Date: Date:
HIV-DNA PCR Pos / Neg Pos / Neg Pos / Neg
HIV-RNA PCR copies/ml copies/ml copies/ml
Sample type Plasma / Serum Plasma / Serum Plasma / Serum
Assay used
O ther laboratory  investigations
Date: Date: Date:
Total lymphocytes
CD4 (109/litre)
CD8 (109/litre)
IgG (gm/litre)
IgA (gm/litre)
IgM (gm/litre)
p24 Ag
HIV Elisa
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ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
PERINATAL INFORMATION Centre
Mothers Study Number 
Child Study Number 
Child’s date of birth (day, month, year)
Sex (M, F) 
Gestational age (weeks) 
Birthweight (gm) 
OFC (cm
Hospital where delivery took place  ............................................................
Obstetrician (initals)..................................................................................
Antiretroviral therapy during labour/delivery Y/N
If yes, which drug?.......................................................... Orally / IV?
Delivery
Caesarean Section: Elective (1), Emergency (2)
If Caesarean Section, reason.....................................................................
Vaginal: Spontaneous (3), vacuum (4), forceps (5)
Presentation: breech (Y/N)
Duration of labour 1st stage (if known)........................................................
Duration of labour 2nd stage (if known)......................................................
Time from rupture of membranes to delivery (if known)................................
Scalp Electrodes (Y/N)
Episiotomy or vulvovaginal tear (Y/N)
Perinatal Problems (Y/N). Specify Details:
Hepatomegaly ..........................................................................................
Splenomegaly...........................................................................................
Drug Withdrawal Symptoms....................... ..............................................
Thrombocytopenic Purpura.......................................................................
Infection: suspected (1) confirmed (2 )........................................................
Transfusion...........................................................     *
Congenital Abnormalities........................................................................... *
Other.......................................................................................................
Disposition
with parents (1) fostered (2) adopted (3)
remained in hospital (4) other (5)..................................................... *
if remained in hospital, say why: ..................................................
Feeding: breast (1) bottle (2) breast and bottle (3)
was breast feeding tried and abandoned? Y/N
Died? Y/N
Date of death: (day/month/year)
Postmortem results, if available........................................................ *
EE U
n
Take sample required; Please record laboratory results on yellow form
Appendix B European Collaborative Study Collaborators
Dr C Giaquinto, Dr O Rampon, Dr R D'Elia and Prof A De Rossi (Universita degli 
Studi di Padova, Italy); Prof I Grosch-Womer (Charite Virchow-Klinikum, Berlin, 
Germany); Dr J Mok (Royal Hospital for Sick Children, Edinburgh); Dr I de Jose, Dra 
Laaru, Dr I Bates, Dra Salas, Dr J Ma Pena, Dr J Gonzalez Garcia, Dr JR Arribas Lopez 
and Dr MC Garcia-Rodriguez (Hospital Infantil La Paz, Madrid); Prof F Asensi-Botet, 
Dr MC Otero, Dr D Perez-Tamarit (Hospital La Fe, Valencia, Spain); Dr H J 
Scherpbier, M Kreyenbroek, Dr MH Godfried, Dr FJB Nellen and Dr K Boer 
(Academisch Medisch Centrum, Amsterdam, The Netherlands); Dr AB Bohlin, Dr S 
Lindgren, Dr B Anzen, Dr K Lidman, Dr K Elfgren, Dr K Gyllensten and Dr PO 
Pehrson (Karolinska University Hospital, Huddinge and Solna, Sweden); Prof J Levy, 
Dr P Barlow, Dr Y Manigart, Dr M Hainaut, Dr A Peltier and Dr T Goetghebuer 
(Hospital St Pierre, Brussels, Belgium); Dr A Ferrazin (Infectious Diseases Clinic, 
University of Genoa, Italy); Prof A De Maria (Department of Internal Medicine, 
University of Genoa, Italy) Prof G Bentivoglio, Dr S Ferrero, Dr C Gotta (Department 
of Obstetrics and Gynecology-Neonatology Unit, University of Genoa, Italy); Prof A 
Mur, Dr A Paya, Dr MA Lopez-Vilchez, Dr R Carreras (Hospital del Mar, Universidad 
Autonoma, Barcelona, Spain); Dr N H Valerius, Dr V Rosenfeldt (Hvidovre Hospital, 
Denmark); Dr J Jimenez (Hospital 12 De Octubre, Madrid, Spain); Dr O Coll, Dr A Suy 
and Dr J M Perez ( Hospital Clinic, Barcelona, Spain); Dr C Fortuny, Dr J Boguna 
(Hospital Sant Joan de Deu, Barcelona, Spain); Dr M Casellas Caro (Hospital Vail 
D'Hebron, Barcelona, Spain); Dr Y Canet (Hospital Parc Tauli de Sabadell, Barcelona, 
Spain); Prof G Pardi, Dr M Ravizza (Ospedale San Paolo, Milano, Italy); Dr B Guerra, 
Dr M Lanari, Dr S Bianchi, Dr L Bovicelli (Policlinico S Orsola, Bologna, Italy); Dr E
Prati, Prof. M. Duse (Universita di Brescia, Brescia, Italy); Dr G Scaravelli, Dr M 
Stegagno (Universita La Sapienza, Roma, Italy); Dr M De Santis (Universita Cattolica, 
Roma, Italy); Dr V Savasi, Dr S Fiore, Dr M Crivelli, Prof E Ferrazzi (Ospedale L. 
Sacco, Milan, Italy); Dr A Vigano, Dr V Giacomet, Dr D Frasca and Prof G Zuccotti 
(Department of Pediatrics, L. Sacco Hospital, University of Milan); Dr F Ravagni 
Probizer, Prof A Maccabruni (Policlinico S Matteo, Pavia, Italy); Dr A Bucceri, Dr L 
Rancilio (Clinica Mangiagalli and Clinica De Marchi, Milano, Italy); Dr S.Alberico, 
Dr M Rabusin, M Bemardon (IRCCS Burlo Garofolo, Trieste, Italy); Dr G P Taylor, Dr 
EGH Lyall (St Mary’s Hospital, London); Ms Z Penn (Chelsea and Westminster 
Hospital, London); Drssa W. Buffolano, Dr R Tiseo, (Pediatric Dept, Federico II 
University, Naples), Prof P Martinelli, Drssa M Sansone, Dr G Maruotti, Dr A Agangi 
(Obstetric Dept, Federico II University, Naples, Italy); Dr C Tibaldi, Dr S Marini, Dr G 
Masuelli, Prof C Benedetto (University di Torino, Italy); Dr T Niemie9  (National 
Research Institute of Mother & Child, Warsaw, Poland), Prof M Marczynska, Dr S 
Dobosz, Dr J Popielska, Dr A Oldakowska (Medical University of Warsaw, Infectious 
Diseases Hospital, Warsaw, Poland); Dr R Malyuta, Dr I Semenenko, T Pilipenko (ECS 
Ukraine coordinating centre), Dr S Posokhova, Dr T Kaleeva, (Odessa), Dr A Stelmah, 
Dr G Kiseleva (Simferopol).
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Appendix C Publications arising from this research
Chapter 4:
European Collaborative Study, prepared by Patel, D., Cortina-Borja, M., Thome, C., 
Newell ML. Time to undetectable viral load after HAART initiation in HIV-1 infected 
pregnant women. Clinical Infectious Diseases, 2007;44:1647-56
Chapter 6:
European Collaborative Study, prepared by Patel, D., Thome, C., Fiore, S., Newell, ML. 
Does Highly Active Antiretroviral Therapy Increase the Risk of Congenital 
Abnormalities in HIV-Infected Women?. J.Acquir.Immune Defic.Syndr, 40; 116-118
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Appendix D R code for nonparametric interval-censored survival
estimation (Giolo 2004)
cria.tau <- function(data){
1 <- data$left 
r <- data$right
tau <- sort(unique(c(1,r[is.finite(r)]))) 
return(tau)
}
S.ini <- function(tau){ 
m<-length(tau)
ekm<-survfit(Surv(tau[1:m-l],rep(l,m-l)))
So<-c(1,ekm$surv) 
p <- -diff(So) 
return(p)
}
cria.A <- function(data,tau){
taul2 <- cbind(tau[-length(tau)],tau[-1])
interv <- function(x,inf,sup) ifelse(x(Wimalasundera et a l . 2002)>=inf 
& x(Mandelbrot et a l .  2001a)<=sup,1,0)
A <- apply(taul2f1,interv,inf=data$left,sup=data$right) 
id.lin.zero <- which(apply(A==0, 1, all)) 
if(length(id.lin.zero)>0) A <- A[-id.lin.zero, ] 
return(A)
}
Turnbull <- function(p, A, data, eps=le-3, iter.max=200, 
verbose=FALSE){ 
n<-nrow(A) 
m<-ncol(A)
Q<-matrix(l,m) 
iter <- 0 
repeat {
iter <- iter + 1 
diff<- (Q-p)
maxdiff<-max(abs(as.vector(diff))) 
if (verbose) 
print(maxdiff)
if (maxdiff<eps I iter>=iter.max)
break
Q<-p
C<-A%*%p
p<-p*((t(A)%*%(l/C))/n)
}
cat("Iterations = ", iter,"\n")
cat("Max difference = ", maxdiff,"\n")
cat("Convergence criteria: Max difference < le-3","\n")
dimnames(p)<-list(NULL,c("P Estimate"))
survc-round(c(1,l-cumsum(p)),digits=5)
right <- data$right
if(any(!(is.finite(right)))){
t <- max(right[is.finite(right)])
return(list(time=tau[tau<t],surv=surv[tau<t]))
}
else
return(list(time=tau,surv=surv))
}
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A ppend ix  E A ssessing  b ivariate relationships
The dependence between two measures such as HIV RNA viral load and CD4 counts 
can be explored with a scalar dependence such as a correlation, but may not be adequate 
in summarising the complex structure between the two.
An important assumption made in a bivariate LME model is that the within-group 
residuals from each response variable are independent. Assessment of the residuals with 
a plot is a useful tool in assessing any dependence, and may be further aided with a test 
o f statistical significance. The Pearson correlation coefficient, and other scalar 
dependence measures, used to assess this relationship may be unreliable as the 
dependence will be averaged out over the range of the residuals. The local dependence 
map (Jones and Koch 2003), an extension of the local dependence function (Holland 
and Wang 1987) may be a useful alternative in exploring the dependence between viral 
load and CD4 and bivariate residuals, which may exhibit non-constant dependence.
Statistical methods
Local dependence function and local dependence maps
The local dependence function (LDF) (Holland and Wang 1987) allows for a more 
complex understanding of the nature of the dependence between two random variables, 
X  and Y. The LDF is the mixed partial derivative of the log density function and extends 
the scalar association measure such as the correlation coefficient to one of local 
dependence (Jones 1996).
Take/ to be the density function, such that
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n u  \ Sf ( x>y)
Consider now discretising the plane by overlaying it with a grid to produce a 
contingency table with ordered marginal categories, so any point in the grid is now 
surrounded by a 2 * 2 table made up of the four cells nearest to it. The natural measure 
of dependence in this local 2 x 2  table is its log-odds ratio. Assuming that the mixed 
partial derivative of /  (x, y )  exists and that /  is defined on a Cartesian product set,
Holland and Wang showed the natural continuous analogue of the collection of the log- 
odds ratios which characterise the dependency structure of this bivariate discrete data 
(Jones 1996) to be
/ \ d2\ o g f ( x , y )
r(*>y)  = — -z -z — -  0 ) -
o x o y
Jones showed that the global measure of dependence, the Pearson correlation coefficient 
p , could be ‘localised’ by introducing a kernel function into any integrals involved 
with this definition and letting the bandwidths of the kernel tend to zero, also resulting 
in y ( x , y )  (Jones 1996;Jones and Koch 2003). As a result of these derivations, positive 
and negative values of y  corresponding to positive and negative dependence can be 
interpreted in the same way as positive and negative values of the correlation coefficient 
and log odds ratio. Important properties of the LDF include:
a) it is finite everywhere
b) it is zero if and only if X  and Y  are independent
c) it is constant if/  is the bivariate normal density, and takes the value P/
elsewhere, where p  is the Pearson correlation coefficient.
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y  can then be estimated with kernel methods using
x  \  fxr (x>yY' h  (x -y)  ( 2 )  
fay)
where,
f z  (x,y)  = n - ' f l Z,Kti ( X . - x ) ^  ( Y , - y )  (3),
;=1
fxr  in (2) is equation (3) with X tY, replacing Z ,, while /  is with 1 replacing Z,
and is the usual kernel estimator of/ ,  = 1 , is the dataset, \  and are
bandwidths associated with the kernel controlling the amount of smoothing in the x  and 
y  directions, respectively. The bivariate kernel K is taken to be the product of symmetric
univariate densities, where Kh(u) = h~{K{h~xu} is a kernel function with bandwidth h
and k2 = ^u2K {u ) du , is the variance of the kernel function since it has mean zero 
(Silverman 1986).
The LDF can be graphed using a contour plot, however the results o f the plots are hard 
to interpret, and was the motivation behind developing the local dependence maps 
(LDM) (Jones and Koch 2003). The construction of the local dependence map can be 
summarised as follows. The first step is to estimate the density /  using the kernel 
density estimator defined in (3), as a product of biweight univariate densities
M “ ) = ( % ) O - " 2)2’ m2^ ’ (4)
with the bandwidths }\ and chosen as
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where Sj is the sample standard deviation and r is the sample correlation. Point at which 
/  appear to be small are then excluded from the LDM, as the estimation of the second 
derivative, y  will be extremely unreliable there (Jones and Koch 2003). The next step is
to carry out a local permutation test of the null hypothesis that y(*7 , yy ) = 0, i.e. a test
of local independence. This step reveals the importance of using the biweight kernel 
over a Gaussian kernel and also highlights why the LDM cannot be extended to the left- 
censoring case. A regular grid is now placed across each gridpoint, for example at 
(jcy, y}) say, as depicted by the red point shown in Figure A6.1.
Figure A6.1 Exam ple of gridpoint used in perm uation testing in LDMs
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At this gridpoint, can be calculated using equation (2) and the bandwidths
\  and ^  • Using the data within the grid point, samples satisfying the null hypothesis 
can be generated by randomly permuting the F s  to break their ties with the JTs (with X  
fixed). This is done P times and f p calculated for each permuted dataset p =  1 ,..., P. 
Now the local dependence map value is defined to be “positive” if the observed value of 
f ( xj , y j )  is in the highest ( a t  2)%  of the simulated f p s,  “negative” if  the observed
value is in the lowest ( a t 2)%  o f simulated f p s and set to be “0” otherwise. The 
recommended value o f ^=499 was used here with the tests carried out at the 5% 
significance level (a  = 0.025).
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Localisation of the permutation test is crucial and is performed in the same way as 
localisation of the estimators, i.e. the local subset of the data associated with ) is
those datapoints within the scaled kernel centred on (the red point marked in
Figure 6.11), using the same bandwidths of and 4 .  The choice of a kernel with finite
support, such as the biweight kernel (4) is paramount here as it ensures that the local 
neighbourhood of the gridpoint is a rectangle centred on the point with sides of length
2 \  and 2h, . The use of a Gaussian kernel for example would not be possible here, as
does not have finite support, i.e. it is not restricted to be <1 like the biweight kernel. 
Extending this method for use of left-censored data then involves the use of a kernel 
which has finite support and also takes account of the censoring. An approach to fit the 
LDM using local regression density estimation has been suggested using a tricube 
kernel which also has finite support (Abberger 2002;Loader 1999). Local regression 
density estimation methods have been extended to include censoring, but do not have 
the properties of finite support and therefore this approach was not suitable here (Loader 
1999;Schmee and Hahn 1979;Buckley and James 1979).
Implementation
The local dependence maps were implemented in R 2.4.1 (R Development Core Team 
2006) with the use of a program written by Mario Cortina-Borja (Personal 
communication).
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